EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2014. Scientific Opinion on the essential composition of infant and follow-on formulae

EFSA Publication; Tetens, Inge

Link to article, DOI: 10.2903/j.efsa.2014.3760

Publication date: 2014

Document Version
Publisher’s PDF, also known as Version of record

SCIENTIFIC OPINION

Scientific Opinion on the essential composition of infant and follow-on formulae

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)2,3

European Food Safety Authority (EFSA), Parma, Italy

This scientific output, published on 05 August 2014, replaces the earlier version published on 24 July 2014*

ABSTRACT

Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver a scientific opinion on the essential composition of infant and follow-on formula. This opinion reviews the opinion provided by the Scientific Committee on Food in 2003 on the essential requirements of infant and follow-on formulae in light of more recent evidence and by considering the Panel’s opinion of October 2013 on nutrient requirements and dietary intakes of infants and young children in the European Union. The minimum content of a nutrient in formula proposed in this opinion is derived from the intake levels the Panel had considered adequate for the majority of infants in the first six months of life in its previous opinion and an average amount of formula consumed during this period. From a nutritional point of view, the minimum contents of nutrients in infant and follow-on formula proposed by the Panel cover the nutritional needs of virtually all healthy infants born at term and there is no need to exceed these amounts in formulae, as nutrients which are not used or stored have to be excreted and this may put a burden on the infant’s metabolism. Therefore, the Panel emphasises that maximum amounts should be interpreted not as target values but rather as upper limits of a range which should not be exceeded.

© European Food Safety Authority, 2014

KEY WORDS

infant formula, follow-on formula, composition

---

1 On request from the European Commission, Question No EFSA-Q-2013-00264, adopted on 26 June 2014.
2 Panel members: Carlo Agostoni, Roberto Berni Canani, Susan Fairweather-Tait, Marina Heinonen, Hannu Korhonen, Sébastien La Vieille, Rosangela Marchelli, Ambroise Martin, Androniki Naska, Monika Neuhäuser-Berthold, Grażyna Nowicka, Yolanda Sanz, Alfonso Siani, Anders Sjödin, Martin Stern, Sean (J.J.) Strain, Inge Tetens, Daniel Tomé, Dominique Turck and Hans Verhagen. Correspondence: nda@efsa.europa.eu
3 Acknowledgement: The Panel wishes to thank the members of the Working Group on Dietetic Products: Carlo Agostoni, Roberto Berni Canani, TamásDecsi, MaryFewtrell, Lotte Lauritzen, Hildegard Przyrembel, Yolanda Sanz, Inga Thorsdottir, Daniel Tomé and Dominique Turck for the preparatory work on this Scientific Opinion.
4 An editorial amendment was carried out that does not materially affect the contents or outcome of this opinion. To avoid confusion, the original version has been removed from the EFSA Journal, but is available on request, as is a version showing all the changes made.


Available online: www.efsa.europa.eu/efsajournal

© European Food Safety Authority, 2014
SUMMARY

Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver a scientific opinion on the essential composition of infant and follow-on formula. This opinion reviews the opinion provided by the Scientific Committee on Food (SCF) in 2003 on the essential requirements of infant and follow-on formulae in the light of more recent evidence and by considering the Panel’s opinion of October 2013 on nutrient requirements and dietary intakes of infants and young children in the European Union.

There is scientific consensus that breast milk is the preferred food for all healthy infants and provides an adequate supply of all nutrients to support growth and development (with the exception of vitamin K during the first weeks of life and of vitamin D). Whereas the composition of infant formula remains stable over time, breast milk composition changes continuously and therefore infant formula cannot imitate breast milk.

All formulae intended for infants must be safe and suitable to meet the nutritional requirements and promote growth and development of infants born at term when used as a sole source of nutrition during the first months of life, and when used as the principal liquid element in a progressively diversified diet after the introduction of appropriate complementary feeding. Nutrients and substances should be added to formulae for infants only in amounts that serve a nutritional or other benefit. The addition in amounts higher than those serving a benefit or the inclusion of unnecessary substances in formulae may put a burden on the infant’s metabolism and/or on other physiological functions, as substances which are not used or stored have to be excreted.

The minimum content of a nutrient in formula proposed in this opinion is derived from the intake levels the Panel had considered adequate for the majority of infants in the first half of the first year of life in its previous opinion and an average amount of daily energy intake from formula during this period (500 kcal/day). These minimum amounts should be understood as target values which cover the nutritional needs of virtually all infants born at term for optimal growth and development, whereas maximum amounts are driven by safety aspects and also taking into account technological considerations and should not be interpreted as target values but rather as upper limits of a range, which should not be exceeded.

Specifications for the currently permitted maximum amounts of micronutrients in formulae were mostly calculated as three to five times the minimum amounts established at the time and took into account the established history of apparent safe use (Codex Stan 72-1981, Codex Stan 156-1987, the Directive 2006/141/EC, and the SCF) and were not based on scientific evidence for adverse effects owing to the lack of such evidence for most nutrients.

There are no reports on any adverse effects associated with the use of formulae complying with the current specifications for micronutrients as laid down in Directive 2006/141/EC, although there are no studies available which were designed to investigate the short- or long-term health consequences of consumption of formulae containing the currently permitted maximum amounts of micronutrients in infant or follow-on formula. Assuming an energy intake from formula of 500 kcal/day (average of the average requirement for energy of boys and girls aged three to four months), regular consumption of a formula by an infant containing the currently permitted maximum amounts of zinc, iodine, vitamin A and folate (if the whole amount is provided in the form of folic acid) would imply that the Tolerable Upper Intake Levels (ULs) are exceeded for these nutrients. When assuming an energy intake from formula of 700 kcal/day (highest observed mean energy intakes in infants below six months of age), also intakes of selenium would exceed the UL. The Panel acknowledges that the ULs used in this estimation were those derived for young children and there is uncertainty with respect to their extrapolation to infants.

Cow’s milk, goat’s milk and isolated soy protein are safe and suitable protein sources for use in infant and follow-on formulae based on intact protein. The use of other protein sources in infant and follow-
on formulae and/or the introduction of new technologies need clinical evaluation and their safety and suitability should be established in the target population prior to their general use in infant and follow-on formulae.

Formulae containing protein hydrolysates are insufficiently characterised by the declared protein content even though they fulfil regulatory criteria concerning amino acid patterns; therefore, the safety and suitability of each specific infant and follow-on formula containing protein hydrolysates have to be established by clinical evaluation in the target population.

The use of a default conversion factor of 6.25 is proposed to calculate the protein content from the total nitrogen content, irrespective of the protein source.

Infant and follow-on formulae should provide on an energy basis indispensable and conditionally indispensable amino acids in amounts at least equal to the reference protein (i.e. breast milk), irrespective of the protein source.

There is no necessity to add arachidonic acid, eicosapentaenoic acid, non-digestible oligosaccharides, “probiotics” or “synbiotics”, chromium, fluoride, taurine and nucleotides to infant and follow-on formulae. There is also no necessity to use phospholipids as a source of long-chain polyunsaturated fatty acids instead of triacylglycerols in infant and follow-on formulae or to use triacylglycerols with palmitic acid predominantly esterified in the sn-2 position in infant and follow-on formulae instead of triacylglycerols from other fat sources. For follow-on formulae, in contrast to infant formulae, the addition of L-carnitine, inositol and choline is not necessary.

The Panel did not consider it necessary to propose specific compositional criteria for formulae consumed after one year of age, as formulae consumed during the first year of life can continue to be used by young children.
TABLE OF CONTENTS

Abstract .................................................................................................................. 1
Summary ................................................................................................................ 2
Table of contents .................................................................................................. 4
Background as provided by the European Commission ........................................ 6
Terms of reference as provided by the European Commission ............................... 7
Assessment .......................................................................................................... 8
1. Introduction ...................................................................................................... 8
2. Definitions ....................................................................................................... 9
3. General aspects of infant feeding .................................................................. 10
4. Methodological considerations .................................................................... 10
   4.1. Minimum content of nutrients and other substances in IF and FOF .......... 11
   4.2. Maximum content of nutrients and other substances in IF and FOF ...... 11
5. Minimum and maximum content of energy and macronutrients in IF and FOF .......................................................... 12
   5.1. Energy .................................................................................................... 12
   5.2. Protein ................................................................................................... 14
   5.3. Fat ......................................................................................................... 21
   5.4. Carbohydrates ....................................................................................... 31
6. Minimum content of micronutrients in IF and FOF ........................................ 39
   6.1. Calcium ................................................................................................. 39
   6.2. Phosphorus ............................................................................................ 41
   6.3. Magnesium ............................................................................................ 42
   6.4. Sodium .................................................................................................. 43
   6.5. Chloride ................................................................................................ 44
   6.6. Potassium .............................................................................................. 44
   6.7. Iron ........................................................................................................ 45
   6.8. Zinc ......................................................................................................... 49
   6.9. Copper ................................................................................................... 51
   6.10. Selenium ............................................................................................... 51
   6.11. Iodine ................................................................................................... 52
   6.12. Chromium ............................................................................................ 53
   6.13. Molybdenum ....................................................................................... 54
   6.15. Fluoride ............................................................................................... 56
   6.16. Vitamin A ............................................................................................ 56
   6.17. Vitamin D ............................................................................................. 58
   6.18. Vitamin E ............................................................................................. 59
   6.19. Vitamin K ............................................................................................. 60
   6.20. Thiamin (vitamin B1) ............................................................................ 61
   6.21. Riboflavin (vitamin B2) ........................................................................ 61
   6.22. Niacin ................................................................................................... 62
   6.23. Pantothenic acid .................................................................................. 63
   6.24. Vitamin B6 ........................................................................................... 64
   6.25. Biotin .................................................................................................... 65
   6.26. Folate .................................................................................................... 66
   6.27. Cobalamin (vitamin B12) ..................................................................... 67
   6.28. Vitamin C ............................................................................................. 68
7. Maximum content of micronutrients in IF and FOF ...................................... 69
8. Specifications for other ingredients in IF and FOF ......................................... 70
   8.1. Choline ................................................................................................. 70
   8.2. Inositol .................................................................................................. 71
   8.3. Taurine ................................................................................................... 71
   8.4. L-Carnitine ............................................................................................ 71
   8.5. Nucleotides and nucleosides ................................................................. 72
8.6. “Probiotics” and “synbiotics” ................................................................. 73
9. Use of formulae by young children ............................................................ 74
10. Recommendations for further research ...................................................... 75
Conclusions .................................................................................................. 75
Documentation provided to EFSA ................................................................. 78
References .................................................................................................... 78
Abbreviations ............................................................................................... 104
BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION

Directive 2009/39/EC on foodstuffs intended for particular nutritional uses lays down general rules on the composition of such foods that are specially designed to meet the particular nutritional requirements of the persons to whom they are intended, including infants and young children in good health.


The Directive defines ‘infants’ as “children under the age of 12 months” and ‘young children’ as “children aged between one and three years”.

The Directive also defines ‘infant formulae’ as “foodstuffs for particular nutritional use by infants during the first months of life and satisfying by themselves the nutritional requirements of such infants until the introduction of appropriate complementary feeding” and ‘follow-on formulae’ as “foodstuffs intended for particular nutritional use by infants when appropriate complementary feeding is introduced and constituting the principal liquid element in a progressively diversified diet of such infants”.

The Directive sets essential requirements for the composition of infant formula and follow-on formula, which are based on a number of opinions of the Scientific Committee on Food, the latest one being the “Report of the Scientific Committee on Food on the Revision of Essential Requirements of Infant Formulae and Follow-on Formulae”, adopted on 4 April 2003. In the last ten years, scientific and technological developments on the essential composition of these products have progressed and there are increasing calls for a review of the legislation to reflect such developments.

The Commission’s proposal for a Regulation of the European Parliament and the Council on foods intended for infants and young children and on food for special medical purposes aims at revising the legal framework applicable to food for particular nutritional uses and, among others, at repealing Directive 2009/39/EC. Negotiations on the proposal are reaching their conclusion and it is expected that such Regulation will be adopted in the next months.

Once the new Regulation is adopted, the Commission will need to adopt delegated acts setting specific rules for the categories of food covered by the Regulation, including infant formulae and follow-on formulae.

In the last years, increasing numbers of milk-based drinks and similar products are marketed in different Member States with the denomination of ‘growing-up milks’ or ‘toddlers’ milks’ or with similar terminology. The composition of these products varies with respect to the protein origin (they can be derived from protein of animal or vegetable origin such as cows’ milk, goats’ milk, soy or rice) and other ingredients. They are promoted as being particularly suitable for young children and, as such, under the current rules, may be considered as foodstuffs for particular nutritional uses. However, no composition requirements for these products are set in EU legislation.

Different views exist in the scientific community and among stakeholders on whether these products are necessary to satisfy the nutritional requirements of young children or have any nutritional benefits when compared to other foods that can constitute the normal diet of young children. In this context,

7 COM (2011) 353.
some would argue that, given the potential variability of weaning diets that may result in different nutrient intakes for this group of the population, these products are convenient, as a liquid element in the diet of young children, in contributing to meeting their nutritional requirements. Taking all these elements into account, the European Parliament and the Council agreed that these products should be subject of a specific reflection. Therefore, in the abovementioned revision of the legal framework, the Commission will be requested, after consulting the European Food Safety Authority, to draft a report on the necessity, if any, of special provisions for milk-based drinks and similar products intended for young children (hereinafter ‘growing-up milks’).

In the meantime, at international level, the Codex Committee on Nutrition and Food for Special Dietary Uses (CCNFSDU) agreed at its 34th session in December 2012 to revise their existing standard for follow-up formulae\(^8\), which dates back to 1987 and applies to food intended for use as a liquid part of the weaning diet for the infant from the 6th month on and for young children up to three years of age. Such review will cover all aspects of the existing standard and will include consideration of issues such as technological and scientific developments in follow-up formula production and composition over the past 25 years, the age range of the intended population, product definition and the role of such products in the diet of infants and young children. Furthermore, following comments by WHO and some Codex Member Countries and observers, the review may also consider whether this standard is still necessary at all. The first discussion on this subject has taken place at the session of the CCNFSDU held on 4-8 November 2013.

Taking into account the developments described above, it is considered necessary to request the EFSA to provide a scientific opinion on all milk-based drinks and similar products intended for infants and young children.

**TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION**

In accordance with Article 29(1) (a) of Regulation (EC) No 178/2002\(^9\), the European Commission asks EFSA to:

- Provide advice on the nutritional requirements of infants and young children and, in particular, on those requirements that may be satisfied by breast milk, milk-based drinks and similar products. In this context it will also be important to provide advice to the Commission on how these nutritional requirements evolve during the age period 0-3 years.

- Provide advice on the essential composition requirements of infant formulae and follow-on formulae by updating the relevant opinions of the SCF on the matter.

- Provide advice on the importance of the role that ‘growing-up milks’ may have as a liquid element in the diet of young children, with respect to elements such as the pattern of consumption, the nutritional intake and any other relevant aspect related to exposure to substances that may be present in their diet. In this context it would be useful to take into account that different products are on the market which may have a considerably varied composition.

- Provide advice on whether ‘growing-up milks’ are necessary to satisfy the nutritional requirements of young children or have any nutritional benefits when compared to other foods that may be included in the normal diet of young children (such as breast milk, infant formulae, follow-on formulae, cows’ milk and other similar products).

- If considered appropriate, advise the Commission with respect to the appropriate age range and the essential composition of ‘growing-up milks’.

\(^{8}\) CODEX STAN 156-1987.

ASSESSMENT

1. Introduction

The period of infancy is characterised by special needs in nutrition, with respect to requirements for energy and for nutrient amounts per kilogram body mass, which must not only maintain the body but also support a rapid growth rate and the appropriate synthesis and deposition of body tissue. A special feature of young infancy is that, as a rule, one liquid food is the sole source of nutrition and must supply appropriate amounts of energy, water and nutrients.

Comparative studies in affluent countries have indicated important health advantages of breast-feeding over formula-feeding for the recipient infants, such as lower incidence of gastrointestinal and respiratory tract infections (Ip et al., 2007; Agostoni et al., 2009; Hörnell et al., 2013b) and of otitis media (Hörnell et al., 2013b) and a lower risk of overweight and obesity (von Kries et al., 1999; Toschke et al., 2002; Owen et al., 2005; Hörnell et al., 2013b).

Infant formulae (IF) and follow-on formulae (FOF) have been regulated as foods for particular nutritional uses under Directive 2009/39/EC\(^{10}\) and its implementing Directive 2006/141/EC\(^{11}\) based upon a series of reports from the Scientific Committee on Food (SCF, 1983, 1989, 1991, 1993a, 1995, 2003b) and EFSA (EFSA, 2005f; EFSA NDA Panel, 2012a). No revision of the SCF reports in the light of new available evidence has been undertaken since then, and such review in the context of the revision of the implementation of Regulation (EU) No 609/2013\(^{12}\) is part of the present Terms of Reference (ToR).

Owing to the limited time frame given, the Panel has decided, in agreement with the European Commission, to produce two separate opinions. Of the five parts of the ToR:

- nutritional requirements of infants and young children and their coverage by human milk and milk-based products,
- advice on the essential composition requirements of IF and FOF by updating the relevant opinions of the SCF on the matter,
- the potential role of milk-based drinks designed, manufactured and advertised to be used in the diets of infants and young children other than IF and FOF,
- a comparison of the nutritional role of such other milk-based drinks in the diet of young children with other formulae, human milk or cow’s milk,
- eventually advice on the essential composition of such other milk-based drinks and their target groups,

the Panel will provide in this second opinion

1) advice on the essential composition requirements of IF and FOF by updating the relevant opinions of the SCF on the matter, and

---


2) advice on the appropriateness to propose compositional requirements for formulae consumed after one year of life.

Advice on the dietary requirements of infants and young children, an evaluation of dietary intakes of infants and young children living in Europe in comparison with requirements and advice on the potential role of milk-based drinks designed, manufactured and advertised to be used in the diets of infants and young children, including an evaluation whether they have any nutritional benefits when compared with other foods (such as breast milk, IF, FOF and cow’s milk) that may be included in the normal diet of infants and young children, has been given by the Panel in a previous opinion (EFSA NDA Panel, 2013a).

This opinion will not address compositional requirements of formulae intended for pre-term infants, for very low- or low-birth-weight infants or for infants with specific nutritional requirements. Also, the dietary management of cow’s milk allergy in infants is outside the scope of this opinion.

However, the general considerations and the specifications with respect to nutrients or other ingredients proposed in the present opinion may serve as a basis for defining compositional requirements for foods for special medical purposes for infants, unless the disease conditions for which such foods are to be used necessitate other compositional aspects.

2. Definitions

For this opinion the following definitions apply:

- Infants means children under the age of 12 months (Article 2(2)(a) of Regulation (EU) No 609/2013).

- Young children means children aged between one and three years (36 months) (Article 2(2)(b) of Regulation (EU) No 609/2013).

- IF means food intended for use by infants during the first months of life and satisfying by itself the nutritional requirements of such infants until the introduction of appropriate complementary feeding (Article 2(2)(c) of Regulation (EU) No 609/2013 and Codex Stan 72-1981).\(^{13}\)

- FOF means food intended for use by infants when appropriate complementary feeding is introduced and which constitutes the principal liquid element in a progressively diversified diet of such infants (Article 2(2)(d) of Regulation (EU) No 609/2013).

- “Growing-up milk” or “toddlers’ milk” are formulae intended specifically for young children. No compositional criteria have been laid down in EU legislation. They may or may not be based on milk. In the latter case they would have to contain other animal or plant protein. The Panel proposes not to use the term “growing-up milk” because this would imply a particular effect on growth. The Panel will also not use the term “toddlers’ milk” because it considers that a “young child” is better defined by age. Young-child formula is the term proposed by the Panel for formulae intended for young children. This term includes also formulae based on protein sources other than cow’s milk.

- Complementary feeding, as defined by the World Health Organization (WHO) in 2002, is “the process starting when breast milk alone is no longer sufficient to meet the nutritional requirements of infants” so that “other foods and liquids are needed, along with breast milk” (WHO, 2002). In the Panel’s opinion on the appropriate age for the introduction of complementary food (EFSA NDA Panel, 2009) “complementary feeding” means the period,

when complementary foods are given together with either human milk or a breast milk substitute. The Panel notes that this definition differs from the definition of “complementary feeding” provided by WHO.

- Complementary food in this opinion comprises, therefore, all liquid, semisolid and solid foods other than breast milk and IF or FOF that are fed to infants. Complementary food can be beverages, spoon-fed foods or finger food (EFSA NDA Panel, 2009). Cereal-based foods and baby foods are regulated in Directive 2006/125/EC.14

3. General aspects of infant feeding

There is scientific consensus that breast milk is the preferred food for all healthy infants and provides an adequate supply of all nutrients to support growth and development (with the exception of vitamin K, during the first weeks of life, and of vitamin D), besides providing protection against infection and immunostimulatory components (EFSA NDA Panel, 2013a). When complementary food is introduced into the infant’s diet, breast milk remains the most appropriate liquid part of a progressively diversified diet (EFSA NDA Panel, 2009, 2013a).

4. Methodological considerations

All formulae intended for infants must be safe and suitable to meet the nutritional requirements and promote growth and development of infants born at term when used as a sole source of nutrition during the first months of life, and when used as the principal liquid element in a progressively diversified diet after the introduction of appropriate complementary feeding. The safety and suitability of such formulae should be demonstrated by generally accepted scientific evidence.

Even though human milk composition of healthy, well-nourished mothers can provide guidance for the composition of formulae intended for infants, compositional similarity to human milk is not the only appropriate determinant or indicator of safety and nutritional suitability of such formulae. The mere presence of a substance in human milk does not necessarily indicate a specific benefit of this substance for the infant, nor do the concentrations of nutrients in human milk necessarily reflect infants’ dietary requirements because they may mirror maternal intakes rather than infants’ needs or because absorption efficiency of certain nutrients differ between breast milk and formula. A more suitable approach to evaluate the compositional suitability of formulae intended for infants is to relate health outcomes, including physiological parameters (including growth and development) and biochemical parameters, in formula-fed infants to those of healthy term infants who have been exclusively breast fed for four to six months. The Panel also notes that nutrients and substances should be added to formulae for infants only in amounts that serve a nutritional or other benefit. The addition in amounts higher than those serving a nutritional or other benefit or the inclusion of unnecessary substances in formulae may put a burden on the infant’s metabolism or on other physiological functions, as substances which are not used or stored have to be excreted.

The compositional requirements of IF and FOF as laid down by Directive 2006/141/EC have been set by specifying the minimum and maximum content of nutrients and other substances in formulae as ready for consumption, including the contribution of water used to reconstitute powdered formulae. The Panel notes that, whereas minimum amounts should be understood as target values which cover the nutritional needs of the majority of infants born at term for optimal growth and development, maximum amounts are driven by safety aspects while also taking into account technological considerations and should not be interpreted as target values but rather as upper limits of a range which should not be exceeded.

---

4.1. Minimum content of nutrients and other substances in IF and FOF

Minimum amounts of nutrients in formulae should be based on generally accepted scientific evidence which establishes the nutrient requirements of virtually all infants in the target population. The Panel considers that the minimum content of a nutrient in formula can be derived from the intake levels the Panel had considered adequate for the majority of infants in the first half of the first year of life (EFSA NDA Panel, 2013a) and an average amount of formula consumed during this period. The average amount of formula consumed in the first six months of life is taken to be equivalent to 500 kcal/day by averaging the Average Requirements (ARs) for energy of boys and girls aged three to less than four months (i.e. 479 kcal/day) (EFSA NDA Panel, 2013a) and rounding up. The Panel notes that observed mean energy intakes at this age are generally above the AR. Therefore, the Panel considers observed mean energy intakes not to be a suitable basis for deriving the minimum content of nutrients in formulae. Bearing in mind that the levels the Panel had considered adequate for the majority of infants in the first half of the first year of life take into account inter-individual variability in nutrient requirements and are designed to cover the dietary requirements of at least 97.5% of infants and that observed formula intakes are generally above the intakes assumed by the Panel, the minimum content derived on that basis can be assumed to be adequate for virtually all infants below six months of age and there is no necessity to provide nutrients in amounts higher than the amounts proposed by the Panel.

The Panel notes that the intake levels of micronutrients the Panel had considered adequate for the majority of infants in the first six months of life were mostly derived from observed mean nutrient intakes from breast milk. These Adequate Intakes (AIs) are less precise estimators of recommended intakes than an AR or a Population Reference Intake (PRI). AIs are used when available data are insufficient to derive an AR and a subsequent PRI. For other substances with a physiological role, which can be synthesised endogenously, a temporarily insufficient synthesising capacity of the infant needs to be taken into account when proposing minimum contents of these substances in IF or FOF. As data are sparse, especially in the very young infant, the evidence for the estimate of the adequate amount of those substances to be supplied to infants in formula is less strong than for essential nutrients. Whenever a recommendation of the Panel is made purely on the basis of expert judgement, this is stated in the appropriate section.

The Panel also notes that while for a food which is the sole source of energy and nutrients, such as IF, compositional requirements can be based on energy and nutrient needs of the targeted population, the evidence for proposing compositional requirements for foods which are not the sole source of energy and nutrients, such as FOF, is less strong, as other foods contribute to nutrient and energy intakes in variable amounts. For the present opinion, the Panel assumes that energy and nutrient intakes from complementary foods will compensate for the higher requirements of infants and for the potentially lower feeding volume of formulae in infants receiving complementary foods, unless otherwise specified in the appropriate section.

4.2. Maximum content of nutrients and other substances in IF and FOF

As the different protein and fat sources used in the manufacture of formula and the water used to reconstitute powdered formula contribute to the total nutrient content of a formula in varying amounts, maximum contents of nutrients have been established in order to ensure the safe use of formulae while limiting technological alterations of the initial nutrient contents of food constituents used in the production of formulae.

The Panel notes that specifications for the currently permitted maximum amounts of micronutrients in formulae were mostly calculated as three to five times the minimum amounts established at the time and took into account the established history of apparent safe use (Codex Stan 72-1981, Codex Stan 156-1987, the Directive 2006/141/EC, and the SCF (2003b)) and were not based on scientific evidence for adverse effects owing to the lack of such evidence for most nutrients.
The Panel acknowledges that scientific data available to derive Upper Tolerable Intake Levels (UL) for infants remain scarce for most micronutrients, and there are no reports on any adverse effects associated with the use of formulae complying with the current specifications as laid down in Directive 2006/141/EC. However, there is a lack of studies designed to investigate the short- or long-term health consequences of consumption of formulae containing the currently permitted maximum amounts of nutrients in IF or FOF. Whenever a UL has been established for a specific nutrient for infants or young children, the Panel will note if the continuous consumption of formulae containing the currently permitted maximum amount of that micronutrient could lead to intakes exceeding the UL.

5. **Minimum and maximum content of energy and macronutrients in IF and FOF**

5.1. **Energy**

5.1.1. **Current compositional requirements of IF and FOF**

Based on the opinion of SCF (2003b), Directive 2006/141/EC lays down a minimum energy content of 60 kcal/100 mL and a maximum energy content of 70 kcal/100 mL. These minimum and maximum values apply both to IF and to FOF and were based on the energy content of breast milk.

5.1.2. **Energy density of human milk**

The average energy density of human milk has been shown by Butte et al. (2001) to be about 65 kcal/100 mL.

Since then, this value has been confirmed by several recent studies on donor breast milk or own mother’s milk (mean ± standard deviation (SD)): 65 ± 11 kcal/100 mL for donor breast milk (Wojcik et al., 2009); 67.3 ± 6.5 kcal/100 mL for own mother’s milk, 64.1 ± 5.9 kcal/100 mL for single-donor pooled breast milk, 63.6 ± 4.5 kcal/100 mL for multiple-donor pooled breast milk (de Halleux and Rigo, 2013); 62 ± 9.6 kcal/100 mL to 65 ± 9.1 kcal/100 mL for own mother’s milk (Nielsen et al., 2011) and 66 ± 12 kcal/100 mL for donor breast milk (Cooper et al., 2013).

5.1.3. **Energy requirements of infants**

The energy content of human milk can provide some guidance for the composition of IF and FOF. However, the energy content of human milk changes within one feed. Because the lipid content increases markedly with emptying of the breast, hindmilk has a significantly higher energy content than foremilk (Stam et al., 2013), while formula is of stable composition. Therefore, the knowledge of energy requirements of infants is a key factor to determine the optimal composition of IF and FOF. Energy requirement is the amount of food energy needed to balance energy expenditure in order to maintain body mass, body composition and a level of physical activity consistent with long-term good health. This requirement includes the energy needed for growth and development. Dietary Reference Values (DRVs) for energy are provided as ARs (EFSA NDA Panel, 2013d). Table 1 summarises the energy intakes considered adequate for infants in the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a).
These ARs are generally lower than the ones used by the SCF (2003b), with the exception of those for male infants at the age of one month (+1.9 %) and two months (+4.7 %) and for female infants at the age of two months (+4.7 %). From three months of age onwards, the differences range between -6.2 % and -3.2 %. This is a result of more refined equations used to calculate total energy expenditure, different assumptions made with respect to energy needs for growth and the use of updated reference body weights.

5.1.4. Energy intakes of infants

Data on energy intakes were available from four surveys for mostly formula-fed infants aged from zero to less than six months (Hilbig, 2005; Noble and Emmett, 2006; Fantino and Gourmet, 2008; Lennox et al., 2013) in which mean/median energy intakes of about 550-700 kcal/day were reported. In exclusively breast-fed infants, mean energy intakes at 15 and 25 weeks of age were reported to be 590 kcal/day and 620 kcal/day, respectively (Nielsen et al., 2011). For infants in the second half of the first year of life mean/median energy intakes in the range of 650-980 kcal/day were observed (Lagström et al., 1997; Noble and Emmett, 2001; Hilbig, 2005; de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008; Marriott et al., 2008; Thorsdottir et al., 2008; Lennox et al., 2013).

Only one study from a representative sample of French infants (Fantino and Gourmet, 2008) reported on the contribution of formula to energy intakes in formula-fed infants over the first year of life. Energy from formula intakes represented the following percentages of the total energy intakes (E %): 95.5 E % at one to three months; 91.0 E % at four months; 77.8 E % at five months; 63.8 E % at six months; 58.6 E % at seven months; 54 E % at eight to nine months; and 36.7 E % at 10-12 months of age.

5.1.5. Health consequences

Several studies have observed slight differences in growth patterns of formula-fed infants compared with breast-fed infants, with formula-fed infants growing at a faster rate over the first year of life (Koletzko et al., 2009a; Hörnell et al., 2013a). The higher energy and protein content of IF compared with breast milk has been suggested as an explanation for these differences. A number of studies have found associations between a high growth velocity during the first months of life and an increased risk of non-communicable diseases later in life. Systematic reviews found that upwards percentile crossing for weight and length in infancy was associated with a higher risk of later obesity (Baird et al., 2005; Monteiro and Victora, 2005).

The Panel notes that the composition of IF has evolved over the last decade, and the energy and protein contents of current IF resemble more closely those of human milk. It should also be noted,
however, that, whereas composition of IF remains stable over time, breast milk composition changes continuously, and therefore IF cannot imitate breast milk with respect to its energy and protein content.

5.1.6. Recommendations

IF and FOF should ensure that the growth and development of infants fed IF are similar to those of infants who are exclusively breast fed during the first four to six months of life, and that the growth and development of infants fed FOF in association with appropriate complementary feeding are similar to those of infants who continue to be breast fed while complementary food is introduced into their diet. Since IF and FOF can be used instead of breast milk, there is no reason to set different minimum and maximum energy contents for IF and FOF.

There is no scientific evidence suggesting that the mean energy content of breast milk or the energy requirements of infants up to the age of one year are markedly different from the values used by the SCF (2003b) to determine the minimum and maximum energy content of IF and FOF. An energy density of IF and FOF considerably higher than that of human milk may increase total energy intakes beyond the energy intakes considered adequate for infants and may play a role in the development of a higher than desirable weight gain.

The Panel therefore proposes a minimum energy content of IF and FOF of 60 kcal (250 kJ)/100 mL and a maximum energy content of 70 kcal (293 kJ)/100 mL. However, the Panel considers it desirable if IF and FOF are designed in a way that their energy content tends towards the lower bound of the range provided that infants are fed *ad libitum*.

5.2. Protein

5.2.1. Current compositional requirements of IF and FOF

Permitted sources of protein in IF and FOF as laid down in Directive 2006/141/EC include cow’s milk protein, goat’s milk protein, isolated soy protein (ISP) and protein hydrolysates of unspecified origin and unspecified degree of hydrolysis. Currently permitted minimum and maximum amounts of protein in IF and FOF as laid down in Directive 2006/141/EC and compared with the recommendations by the SCF (2003b) are shown in Table 2.

<table>
<thead>
<tr>
<th>Formula with</th>
<th>IF</th>
<th>FOF</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>min</td>
<td>max</td>
</tr>
<tr>
<td>Cow’s milk protein</td>
<td>1.80(\textsuperscript{a})</td>
<td>3.00</td>
</tr>
<tr>
<td>Goat’s milk protein</td>
<td>1.80(\textsuperscript{a})</td>
<td>3.00</td>
</tr>
<tr>
<td>Protein hydrolysates</td>
<td>1.80(\textsuperscript{b})</td>
<td>3.00</td>
</tr>
<tr>
<td>ISP</td>
<td>2.25</td>
<td>3.00</td>
</tr>
</tbody>
</table>

(a): Formulae with a protein content between 1.80 and 2.00 g per 100 kcal currently require that their safety and suitability is demonstrated by clinical evaluation.

(b): Formulae with a protein content between 1.80 and 2.25 g per 100 kcal currently require that their safety and suitability is demonstrated by clinical evaluation. To date, only one specific formulation of whey protein hydrolysates that provides 1.86 g protein per 100 kcal is authorised for use in IF and FOF following an evaluation by the Panel (EFSA, 2005f).

(c): EFSA NDA Panel (2012a).

5.2.2. Protein content of human milk

Protein concentrations in human milk change during the first days of life. In a meta-analysis of 21 studies reporting on energy and macronutrient composition of breast milk from mothers of healthy
singleton infants born at term and who were exclusively breast fed at the time of breast milk sampling (Hester et al., 2012), crude protein content expressed as mean (range) was reported as follows: for colostrum (1-5 days), 2.5 (1.4-6.5) g/100 mL (3.8 (2.2-10.0) g/100 kcal, n = 433); for transitional milk (6-14 days), 1.7 (1.3-2.5) g/100 mL (2.6 (2.0-3.8) g/100 kcal, n = 308); and, for mature human milk (> 14 days), 1.3 (0.8-2.1) g/100 mL (2.0 (1.2-3.2) g/100 kcal, n = 415). Protein accounts for around 17 E% in colostrum and 7 E% in mature human milk (Räihä, 1994). The concentrations of different proteins also change with duration of lactation. Casein is low or absent in early lactation, then increases rapidly and subsequently decreases. The concentration of whey proteins decreases from early lactation and continues to fall. These changes result in a whey protein–casein ratio of about 90:10 in the first three to four days post partum, 55:45 in mature milk and 50:50 in late lactation (at around six months) (Kunz and LönnérDAL, 1992).

5.2.3. Protein requirements of infants

Estimating true protein intakes from breast milk is difficult because of the non-protein nitrogen (NPN) fraction, which represents about 25% of total nitrogen and is made up of urea (up to 50% of NPN), free amino acids and other nitrogenous compounds. How and how much of NPN is utilised by the body is not entirely understood (WHO/FAO/UNU, 2007). Moreover, the composition of the protein fraction of breast milk changes with time, and no data are available on the true digestibility of the different fractions. Therefore, in previous opinions (EFSA NDA Panel, 2012c, 2013a) the Panel decided to derive an AR and subsequently a PRI for protein for infants based on a factorial approach as the sum of the requirement for maintenance and the requirement for growth adjusted for efficiency of dietary protein utilisation.

Table 3 summarises the protein intakes considered adequate for the majority of infants in the Panel’s previous opinion on nutrient requirements and dietary intakes in infants and young children in the European Union (EFSA NDA Panel, 2013a).

Table 3: Intakes of protein considered adequate for the majority of infants (EFSA NDA Panel, 2013a)

<table>
<thead>
<tr>
<th>Age (months)</th>
<th>PRI (g/kg body weight per day)</th>
<th>Body weight (kg)(a)</th>
<th>PRI (g/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Boys</td>
<td>Girls</td>
</tr>
<tr>
<td>1 to &lt; 2</td>
<td>1.77</td>
<td>4.5</td>
<td>4.2</td>
</tr>
<tr>
<td>2 to &lt; 3</td>
<td>1.50</td>
<td>5.6</td>
<td>5.1</td>
</tr>
<tr>
<td>3 to &lt; 4</td>
<td>1.36</td>
<td>6.4</td>
<td>5.8</td>
</tr>
<tr>
<td>4 to &lt; 5</td>
<td>1.27</td>
<td>7.0</td>
<td>6.4</td>
</tr>
<tr>
<td>5 to &lt; 6</td>
<td>1.21</td>
<td>7.5</td>
<td>6.9</td>
</tr>
<tr>
<td>6 to &lt; 7</td>
<td>1.15</td>
<td>7.9</td>
<td>7.3</td>
</tr>
<tr>
<td>7 to &lt; 8</td>
<td>1.27</td>
<td>8.3</td>
<td>7.6</td>
</tr>
<tr>
<td>8 to &lt; 9</td>
<td>1.23</td>
<td>8.6</td>
<td>7.9</td>
</tr>
<tr>
<td>9 to &lt; 10</td>
<td>1.19</td>
<td>8.9</td>
<td>8.2</td>
</tr>
<tr>
<td>10 to &lt; 11</td>
<td>1.16</td>
<td>9.2</td>
<td>8.5</td>
</tr>
<tr>
<td>11 to &lt; 12</td>
<td>1.14</td>
<td>9.4</td>
<td>8.7</td>
</tr>
</tbody>
</table>

(a): 50th percentile of WHO Growth Standards.

No PRI has been proposed by the Panel for the age group zero to less than one month owing to the lack of data for the first month of life. However, the Panel considers it safe to assume that requirements for protein intakes in the first month of life do not differ significantly from those of the second month of life.

5.2.4. Protein intakes of infants

Protein intakes in mostly formula-fed infants in Europe have been reported to be around 9-10 E% in infants less than six months of age (Hilbig, 2005; Noble and Emmett, 2006; Fantino and Gourmet,
2008; Lennox et al., 2013) and around 10-15 E % in infants in the second half of the first year of life (Lagström et al., 1997; Noble and Emmett, 2001; Hilbig, 2005; de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008; Marriott et al., 2008; Thorsdottir et al., 2008; Lennox et al., 2013).

5.2.5. Health consequences

5.2.5.1. Protein intakes to ensure adequate growth and development

Several studies which investigated the safety and suitability of IF based on intact cow’s milk protein with protein contents of 1.8-1.9 g/100 kcal have been reviewed by the Panel previously (EFSA, 2005f). These studies have generally shown that protein concentrations in formula of 1.8-1.9 g/100 kcal when derived from intact milk protein are adequate to promote normal growth when these formulae are fed ad libitum. In a study of infants (Koletzko et al., 2009b) consuming a low protein IF with 1.77 g protein per 100 kcal and subsequently FOF providing 2.2 g protein per 100 kcal for the first year of life and who were followed up until 24 months of age, no statistically significant differences between the group consuming low-protein formula and the breast-fed reference group with respect to weight-for-length and body mass index (BMI) were found at 24 months of follow-up. Another study (Trabulsi et al., 2011) investigated the effect on infant growth of an IF with a protein content of 1.9 g/100 kcal compared with an IF with a protein content of 2.2 g/100 kcal which was consumed for four months. There were no statistically significant differences between the two formula groups with respect to weight gain, length gain and head circumference at the end of the study at four months of age.

No studies which evaluated the safety and suitability of lower than currently permitted (i.e. 2.25 g/100 kcal) protein contents in formulae containing ISP were published after the report by the SCF (2003b). Also, no evidence is available to suggest that this protein content would be inadequate to ensure adequate growth and development.

The Panel considers that, based on the available evidence, a minimum protein intake of 1.8 g/100 kcal from IF and FOF based on intact milk protein and of 2.25 g/100 kcal from formula containing ISP is sufficient to ensure adequate growth and development. Adequate minimum protein intakes from IF and FOF containing protein hydrolysates need to be established for each specific IF or FOF containing hydrolysed proteins following clinical evaluation, as outlined in section 5.2.5.4.

5.2.5.2. High protein intakes

In infants, a very high protein intake (around 20 E %) can impair the water balance, particularly when no other liquids are consumed and/or extrarenal water losses are increased (EFSA NDA Panel, 2012c). It has been suggested that high protein intakes contribute to higher insulin secretion, and to a higher release of insulin-like growth factor (IGF)-1 and IGF-binding protein (IGFBP)-1 (Axelsson, 2006). It has also been suggested to be associated with increased growth (Koletzko et al., 2009b; EFSA NDA Panel, 2012c; Hörnell et al., 2013a) and a higher BMI in childhood (Hörnell et al., 2013a; Thorsdottir et al., 2013; Weber et al., 2014). Whether protein plays a role in the observed increased growth rate and higher BMI in childhood is still matter of debate and requires more research.

5.2.5.3. Plant proteins as protein sources for IF and FOF

Some plant proteins are deficient in certain indispensable amino acids and the digestibility of plant proteins can be less than that of milk proteins. Therefore, a higher minimum protein content is usually recommended for formulae with intact proteins other than milk proteins. Also, when setting minimum amounts for the contents of certain minerals in IF and FOF based on plant proteins, the increased content of phytic acid, which can reduce the availability of minerals, has to be taken into account (SCF, 2003b).

Currently, for formulae containing intact proteins, the only permitted source of plant proteins is ISP. ISP is low in sulphur-containing amino acids. It contains around 1-2 % phytate and is rich in nucleotides and isoflavones (SCF, 2003b). Soy protein also contains trypsin inhibitors and lectins.
(Bhatia et al., 2008). Reducing phytic acid content in formulae by about a half, from around 600 mg/kg to around 270 mg/kg, or completely compared with around 250-400 mg/kg ready-to-feed formula, has been shown to improve zinc absorption and also, to a lesser extent, iron absorption (Lönnerdal et al., 1984; Davidsson et al., 1994; Davidsson et al., 2004). Concerns have been raised with respect to potential negative effects of soy isoflavones on sexual, reproductive and neurobehavioural development, immune function and thyroid function. The American Academy of Pediatrics (AAP) Committee on Nutrition concluded in its review that the evidence for adverse effects of dietary soy isoflavones on human development, reproduction or endocrine function is not conclusive (Bhatia et al., 2008). The European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) Committee on Nutrition acknowledged the lack of evidence from human studies, but recommended the reduction of soy isoflavones in soy-based formulae as a precautionary approach (ESPGHAN Committee on Nutrition et al., 2006). Trypsin inhibitors and lectins may interfere with protein digestion and nutrient absorption. Enzyme inhibitors and lectins are inactivated under heat treatment, although some residual activity can be found when proper heating is not achieved (Lajolo and Genovese, 2002). It is technologically possible to remove isoflavones, trypsin inhibitors, lectins and phytic acid from formulae.

The Panel considers that concentrations of isoflavones, trypsin inhibitors, lectins and phytic acid in IF and FOF should be kept as low as is feasible.

The Panel notes that the main indications for the use of formulae exclusively based on ISP in place of milk-based formulae are congenital lactase deficiency and galactosaemia, provided the formula is lactose free according to the criteria laid down in Directive 2006/141/EC (i.e. 0.01 g/100 kcal) (EFSA NDA Panel, 2010a), and infants for whom caregivers chose a vegan diet.

5.2.5.4. Protein hydrolysates as protein sources for IF and FOF

According to Directive 2006/141/EC, formulae containing hydrolysed protein may be produced from any suitable protein source and by different enzymatic or chemical means provided that the compositional criteria laid down by the Directive are met. In its opinion, the SCF (2003b) concluded that there is a need for clinical evaluation of formulae containing protein hydrolysates with respect to their safety and suitability.

The Panel emphasises that the safety and suitability of each specific formula containing protein hydrolysates has to be established by clinical studies. Information on protein sources and the technological processes applied should also be provided. In this context, the Panel notes that one particular formula containing partially hydrolysed whey protein has been evaluated for its safety and suitability by the Panel (EFSA, 2005f) and has been authorised for use by Directive 2006/141/EC.

Directive 2006/141/EC specifies criteria that formulae containing protein hydrolysates must meet if they are to be allowed to be marketed as reducing the risk of developing allergy to milk proteins. Attempts have been made to classify formulae containing hydrolysed protein into partially and extensively hydrolysed protein formulae according to the degree of protein fragmentation, but there is no agreement on the criteria on which to base this classification (Greer et al., 2008), and no regulatory definition exists as to what would constitute a partially or extensively hydrolysed protein formula. Formulae containing hydrolysed protein have been studied with respect to their potential to reduce the risk of developing allergic manifestations in at-risk infants who are not exclusively breast fed (Osborn and Sinn, 2006; Szajewska and Horvath, 2010; von Berg et al., 2013; de Silva et al., 2014). These studies indicate that the characterisation of a formula by molecular weight of protein cannot predict their potential to reduce the risk of developing allergic manifestations in genetically predisposed infants in the general population.

The Panel considers that the criteria given in Directive 2006/141/EC alone are not sufficient to predict the potential of a formula to reduce the risk of developing allergy to milk proteins. Clinical studies are necessary to demonstrate if and to what extent a particular formula reduces the risk of developing
short- and long-term clinical manifestations of allergy in at-risk infants who are not exclusively breast fed.

5.2.5.5. Protein quality

Amino acid reference patterns can be used in the assessment of protein quality by comparing the amino acid composition of a food with an amino acid reference pattern. Given that intakes of breast milk from a healthy, well-nourished mother are considered to satisfy the amino acid requirements for the first six months of life, the Panel considers the amino acid pattern of breast milk to be the best reference pattern for a product substituting for breast milk in infants.

The SCF (2003b) determined the amount of indispensable and conditionally indispensable amino acids per energy value in IF and FOF based on six studies on the amino acid content of human milk (Bindels and Harzer, 1985; Lönnertal and Forsum, 1985; Janas et al., 1987; Darrough and Moughan, 1998; Villalpando et al., 1998; Räihä et al., 2002). A recent meta-analysis of 26 studies (Zhang et al., 2013) which investigated the total amino acid profile in human milk closely corroborated the amounts of indispensable and conditionally indispensable amino acids in human milk determined by the SCF (2003b) and which are also in line with the values proposed by the Codex Alimentarius in Codex Stan 72-1981 and by an ESPGHAN coordinated international expert group (Koletzko et al., 2005). The Panel, therefore, considers that the available evidence supports the amino acid pattern of human milk proposed by the SCF (2003b).

Based upon results indicating a lower formation of cysteine from cystathionine in the transsulphuration pathway, it has been considered that L-cysteine is a conditionally indispensable amino acid for neonates and that methionine cannot substitute for cysteine completely (White et al., 1994; Vina et al., 1995). These results were not confirmed in recent studies in parenterally fed infants (Courtney-Martin et al., 2008; Thomas et al., 2008; Courtney-Martin et al., 2010). However, as there is marked individual variability in the rate of transsulphuration, the Panel considers that it is appropriate to provide both cysteine and methionine in IF and FOF, and the ratio of methionine to cysteine in IF shall not exceed 2 unless the safety and suitability of the formula has been demonstrated by clinical evaluation.

Tyrosine is synthesised by the hydroxylation of phenylalanine, via phenylalanine hydroxylase in the liver. Studies in human neonates have reported a substantial ability to hydroxylate phenylalanine (the first step in phenylalanine oxidation) (van Toledo-Eppinga et al., 1996; House et al., 1998). However, the extent to which neonates can accommodate high phenylalanine and low tyrosine intakes via phenylalanine hydroxylation remains unknown. Infants may require a pre-formed dietary source of tyrosine because the activity of phenylalanine hydroxylase in some neonates can be low, and hyperphenylalaninaemia tends to occur, whereas tyrosine tends to be deficient in these infants. Therefore, the Panel considers that it is appropriate to provide both tyrosine and phenylalanine in IF and FOF, but the ratio of tyrosine and phenylalanine in IF shall not exceed 2 unless the safety and suitability of the formula has been demonstrated by clinical evaluation.

5.2.5.6. Effects of processing on nutritional value of protein

The nutritional value of protein is influenced by its amino acid composition and by protein hydrolysis, but also by heat treatment, especially in the presence of iron, vitamin C and lactose in these products. Heat processing is essential for the preservation of IF and FOF but induces a number of degradation reactions in milk, including Maillard reactions between lactose and protein and advanced glycation end products, as well as other direct modification reactions, which reduce the nutritional value of protein and could produce potentially active derivatives (Pischetsrieder and Henle, 2012). Among the Maillard reaction products, the most important is lactulosyllysine, the reaction product of lactose and lysine side chains of the milk proteins (Fritsch and Klostermeyer, 1981; Langhendries et al., 1992; Henle et al., 1993). The presence of lactose is also an important prerequisite for extensive protein oxidation during the thermal treatment of milk (Meltretter et al., 2007) as the oxidation of other amino acid side chains can be promoted by reactive oxygen species, which are formed in the course of the
Maillard reaction (Mossine et al., 1999). As a consequence of their specific formulation and processing, IF and FOF can show higher content of glycation markers than regular milk products. Liquid formulae contain around twice as much advanced Maillard reaction products as formulae in powdered form (SCF, 2003b).

The Panel considers that the contents of Maillard reaction products and protein degradation products in IF and FOF should be kept as low as technologically possible owing to their potentially untoward effects on the nutritional value of protein.

5.2.6. Recommendations

5.2.6.1. Calculation of protein content

The SCF (2003b) proposed to use a default conversion factor of 6.25 to calculate the protein content from the total nitrogen content, irrespective of the protein source. The Panel is aware of the discussions with respect to the use of different conversion factors for different protein sources in order to reflect variations in the nitrogen content of different proteins (EFSA NDA Panel, 2012c). The Panel, however, proposes to retain the conversion factor of 6.25 mainly for practical considerations.

5.2.6.2. Protein sources

The Panel considers that cow’s milk protein, goat’s milk protein and ISP are safe and suitable protein sources for use in IF and FOF based on intact protein. The use of other protein sources in IF and FOF and/or the introduction of new technologies need clinical evaluation and their safety and suitability should be established in the target population prior to their general use in IF and FOF.

With respect to formulae containing protein hydrolysates, the Panel reiterates the conclusions of the SCF (2003b) that those formulae are insufficiently characterised by the declared protein content even if they fulfil regulatory criteria concerning amino acid patterns and contents and that the safety and suitability of each specific IF or FOF containing protein hydrolysates has to be established by clinical evaluation.

The Panel notes that the characterisation of protein hydrolysates by molecular weight of the protein cannot predict their potential to reduce the risk of developing allergic manifestations in genetically predisposed infants. Therefore, the Panel considers that the criteria given in Directive 2006/141/EC are not sufficient to predict the potential of a formula to reduce the risk of developing allergy to milk proteins.

5.2.6.3. Minimum and maximum protein content of IF and FOF

Human milk is a food of changing composition during the lactational period, during 24 hours and during one feed, whereas an IF is a product of constant composition and, therefore, must be a compromise on the safe side, both as to the amount and as to the quality of the protein.

Based on the studies which investigated the adequacy of IF containing around 1.8 g protein per 100 kcal, the Panel considers that a minimum protein content in IF and FOF of 1.8 g/100 kcal (0.43 g/100 kJ) for cow’s and goat’s milk-based formulae is suitable to satisfy the nutritional requirements of infants. For IF and FOF containing ISP, the Panel proposes a minimum protein content of 2.25 g/100 kcal (0.54 g/100 kJ). A minimum protein content for IF and FOF containing protein hydrolysates cannot be proposed and the adequacy of protein content of a specific IF or FOF containing hydrolysed proteins needs to be established based on clinical evaluation.

There is no evidence of a physiological need for protein intakes at amounts of 3.0 g/100 kcal in infancy, which is the currently permitted maximum content of protein in IF. In addition, protein intakes of infants are generally well above the requirements, so the protein content of IF and FOF could be decreased. Therefore, the Panel proposes to reduce the currently permitted maximum protein content to 2.5 g/100 kcal (0.60 g/100 kJ) for IF and FOF based on cow’s milk and goat’s milk protein.
and to 2.8 g/100 kcal (0.67 g/100 kJ) for IF and FOF containing ISP and IF and FOF containing protein hydrolysates. The Panel, however, acknowledges that there are no scientific data available which allow the establishment of precise cut-off values for the maximum protein content in IF and FOF and the proposed values are based on expert judgement of what would constitute an upper bound of the adequate range of intake. Table 4 gives an overview of the proposed minimum and maximum amounts of protein in IF and FOF.

Table 4: Proposed minimum and maximum content of protein in IF and FOF

<table>
<thead>
<tr>
<th>Formulae with minimum content</th>
<th>Minimum content g/100 kcal</th>
<th>Maximum content g/100 kcal</th>
<th>Minimum content g/100 kJ</th>
<th>Maximum content g/100 kJ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cow’s milk protein</td>
<td>1.80</td>
<td>2.50</td>
<td>0.43</td>
<td>0.60</td>
</tr>
<tr>
<td>Goat’s milk protein</td>
<td>1.80</td>
<td>2.50</td>
<td>0.43</td>
<td>0.60</td>
</tr>
<tr>
<td>ISP</td>
<td>2.25</td>
<td>2.80</td>
<td>0.54</td>
<td>0.67</td>
</tr>
<tr>
<td>Protein hydrolysates (a)</td>
<td>–</td>
<td>2.80</td>
<td>–</td>
<td>0.67</td>
</tr>
</tbody>
</table>

(a): The safety and suitability of formulae containing protein hydrolysates, including their minimum protein content, should be established based on clinical evaluation.

5.2.6.4. Amino acid reference pattern

As IF are considered breast milk substitutes and FOF can be used as the principal liquid element of a progressively diversified diet of infants in place of breast milk, the Panel considers that IF and FOF should provide indispensable and conditionally indispensable amino acids in amounts on an energy basis at least equal to the reference protein (i.e. breast milk), irrespective of the protein source.

Given that a recent meta-analysis (Zhang et al., 2013) closely corroborated the findings of the SCF (2003b) with respect to the total amino acid content of human milk, the Panel proposes to base the amino acid reference pattern for IF and FOF on the analysis of indispensable and conditionally indispensable amino acids in human milk by the SCF (2003b). The proposed reference pattern is depicted in Table 5.

Table 5: Proposed amino acid reference pattern for human milk protein using a conversion factor of 6.25

<table>
<thead>
<tr>
<th>Amino acid</th>
<th>g/100 g protein</th>
<th>mg/100 kcal</th>
<th>mg/100 kJ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cysteine</td>
<td>2.1</td>
<td>38</td>
<td>9</td>
</tr>
<tr>
<td>Histidine</td>
<td>2.2</td>
<td>40</td>
<td>10</td>
</tr>
<tr>
<td>Isoleucine</td>
<td>5.0</td>
<td>90</td>
<td>22</td>
</tr>
<tr>
<td>Leucine</td>
<td>9.2</td>
<td>166</td>
<td>40</td>
</tr>
<tr>
<td>Lysine</td>
<td>6.3</td>
<td>113</td>
<td>27</td>
</tr>
<tr>
<td>Methionine</td>
<td>1.3</td>
<td>23</td>
<td>5</td>
</tr>
<tr>
<td>Phenylalanine</td>
<td>4.6</td>
<td>83</td>
<td>20</td>
</tr>
<tr>
<td>Threonine</td>
<td>4.3</td>
<td>77</td>
<td>18</td>
</tr>
<tr>
<td>Tryptophan</td>
<td>1.8</td>
<td>32</td>
<td>8</td>
</tr>
<tr>
<td>Tyrosine</td>
<td>4.2</td>
<td>76</td>
<td>18</td>
</tr>
<tr>
<td>Valine</td>
<td>4.9</td>
<td>88</td>
<td>21</td>
</tr>
</tbody>
</table>

The sum of methionine and cysteine and the sum of tyrosine and phenylalanine in IF may be used for calculation purposes. If the ratio of methionine to cysteine and/or the ratio of tyrosine and phenylalanine, exceeds 2, this must be justified by clinical evaluation. For FOF, the Panel considers that no restrictions with respect to amino acid ratios need to apply, because complementary foods will contribute to amino acid intakes and the metabolism of older infants is more mature with respect to the capacity to convert methionine to cysteine and phenylalanine to tyrosine.
5.3. Fat

5.3.1. Current compositional requirements of IF and FOF

Current compositional requirements of IF and FOF with respect to total fat, fatty acids and phospholipids as laid down by Directive 2006/141/EC are depicted in Table 6. These compositional requirements differ from the opinion of the SCF (2003b) with respect to the minimum content of alpha-linolenic acid (ALA, 18:3, n-3) and the maximum content of phospholipids (PLs) in IF and FOF. These differences are highlighted in Table 6 as footnotes.

Table 6: Current compositional requirements of IF and FOF with respect to total fat, fatty acids and PLs as laid down by Directive 2006/141/EC

<table>
<thead>
<tr>
<th>Compulsory composition</th>
<th>IF g per 100 kcal</th>
<th>FOFO g per 100 kcal</th>
<th>Voluntary addition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total fat</td>
<td>Min 4.40 (a) Max 6.00 (b)</td>
<td>Min 4.00 (c) Max 6.00 (b)</td>
<td></td>
</tr>
<tr>
<td>Trans-fatty acids</td>
<td>3.0 Max 3.0</td>
<td></td>
<td>Total n-3 LCPUFAs</td>
</tr>
<tr>
<td>Lauric acid + myristic acid</td>
<td>20.0 Max 20.0</td>
<td></td>
<td>Total n-6 LCPUFAs</td>
</tr>
<tr>
<td>Erucic acid</td>
<td>1.0 Max 1.0</td>
<td></td>
<td>ARA (20:4, n-6)</td>
</tr>
<tr>
<td>LA (18:2, n-6)</td>
<td>0.30 1.20</td>
<td></td>
<td>DHA (22:6, n-3)</td>
</tr>
<tr>
<td>ALA (18:3, n-3)</td>
<td>0.05 0.24 (f)</td>
<td></td>
<td>EPA (20:5, n-3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Phospholipids</td>
</tr>
</tbody>
</table>

(a): 40 E %.  
(b): 55 E %.  
(c): 35 E %.  
(d): With a ratio of LA to ALA of ≥ 5 and ≤ 15.  
(e): The SCF (2003b) proposed a minimum content of 0.05 mg/100 kcal for formulae supplemented with ARA and DHA and 0.10 mg/100 kcal for formulae not supplemented with ARA and DHA.  
(f): Calculated from the lowest permitted LA:ALA ratio of 5 and the highest permitted LA concentration.  
(g): The SCF (2003b) proposed a maximum content of 1 g/L.  

Conjugated-linoleic acid (CLA) is currently not permitted to be added to formulae in addition to the CLA naturally present in the fat ingredients, and it is considered to be a novel food ingredient in this context. Also, the use of sesame oil and cottonseed oil is not permitted in IF and FOF.

5.3.2. Fat composition of human milk

Breast milk has an average total fat content of 24-59 g/L (3.7-9.1 g/100 kcal, around 50 E %), but the fat content varies markedly with pregnancy weight gain and during the feed as the fat content increases as the breast is emptied (Michaelsen et al., 1994). Most of the fat in breast milk is triacylglycerol (TAG, > 98 %), but it also contains some cholesterol (around 0.25 g/L) and PLs (around 0.24 g/L), predominantly sphingomyelin, phosphatidylethanolamine and phosphatidylcholine (Abrahamse et al., 2012; Giuffrida et al., 2013).

The main saturated fatty acid (SFA) in human milk is palmitic acid (16:0), which accounts for around 26 % of total fatty acids (FA %), and the main monounsaturated fatty acid (MUFA) is oleic acid (18:1,
n-9), which typically accounts for approximately 35 FA % (Abrahamse et al., 2012). The composition of polyunsaturated fatty acids (PUFAs) in human milk varies depending on the dietary intake of the mother, with milk from vegans having the highest content of linoleic acid (LA, 18:2, n-6) and ALA (Sanders and Reddy, 1992; Davis and Kris-Etherton, 2003). Inuit and other populations with a high intake of marine animals have the highest breast milk content of docosahexaenoic acid (DHA, 22:6n-3). The concentrations of DHA in breast milk, however, are also influenced by polymorphisms in the fatty acid desaturase (FADS) gene cluster (Moltó-Puigmarti et al., 2010). In general, DHA concentrations are the most variable of all fatty acid concentrations in human milk, while the content of arachidonic acid (ARA, 20:4, n-6) is much more stable (Brenna et al., 2007). Breast milk usually has a low content of trans-fatty acids (TFAs), around 2-5 FA % (Rist et al., 2001), and CLA, 0.2-0.6 FA % (Rist et al., 2007), but the content of these fatty acids varies depending on the maternal diet (Rist et al., 2001; Rist et al., 2007).

Human milk contains only small amounts of short-chain SFAs (SCFAs, with a carbon chain length < 6), but usually contains 8-10 FA % as medium-chain SFAs (MCFAs, usually defined as fatty acids with a carbon length of 6-10) (EFSA NDA Panel, 2010c). TAGs containing SCFAs, MCFAs and to some extent also lauric acid, with 12 carbon atoms, are more rapidly hydrolysed by gastrointestinal lipases and the hydrolysis products are more easily absorbed and are taken to the liver directly via the portal vein (Novak and Innis, 2011). The ingestion of these fatty acids, therefore, could provide some benefit under conditions where fat absorption is a limiting factor. The MCFA content of human milk varies and is increased by a high carbohydrate and low fat intake of the mother (Koletzko et al., 1992; Sauerwald et al., 2001; Novak and Innis, 2011).

About 70 % of the palmitic acid in human milk is esterified to the sn-2 position of the milk TAG (Innis, 2011) and, as the endogenous lipases hydrolyse dietary TAG mainly at the sn-1,3 position, palmitic acid may be absorbed in part as glycerol-palmitate. It has been proposed that the absorption of unesterified palmitic acid is limited.

### 5.3.3. Requirement for total fat and essential fatty acids and Adequate Intakes (AIs) of long-chain (LC) PUFAs

In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded on levels of intakes of fats, essential fatty acids and LCPUFAs (unsaturated fatty acids with 20 or more carbon atoms) considered adequate for the majority of infants. These are shown in Table 7.

**Table 7:** Intakes of fat, essential fatty acids and DHA considered adequate for the majority of infants (EFSA NDA Panel, 2013a)

<table>
<thead>
<tr>
<th>Age</th>
<th>RI total fat</th>
<th>AI LA</th>
<th>AI ALA</th>
<th>RI DHA</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 to &lt; 6 months</td>
<td>50–55</td>
<td>4</td>
<td>0.5</td>
<td>100</td>
</tr>
<tr>
<td>6 to &lt; 12 months</td>
<td>40</td>
<td>4</td>
<td>0.5</td>
<td>100</td>
</tr>
</tbody>
</table>

RI, Reference Intake range for macronutrients.

### 5.3.4. Total fat and fatty acid intakes of infants

Mean total fat intakes in mostly formula-fed European infants below the age of six months were available from four studies (Hilbig, 2005; Noble and Emmett, 2006; Fantino and Gourmet, 2008; Lennox et al., 2013) and were between 42 and 46 E %. Intakes of SFAs, MUFAs and PUFAs were reported to be around 16-22 E %, 15-17 E % and 6.7-7.0 E %, respectively (Hilbig, 2005; Noble and Emmett, 2006; Lennox et al., 2013). Intakes of LA were 3.6-4.2 g/day (around 6-7 E %), of ALA 0.41-0.48 g/day (around 0.7-0.8 E %) and of DHA 57 mg/day (Fantino and Gourmet, 2008; Schwartz et al., 2010). Total fat intake usually decreases once breast-feeding or formula-feeding ceases (Niinikoski et al., 2007). In infants aged between 6 and < 12 months, mean total fat intakes were reported to be between 26 and 40 E % (Lagström et al., 1997; Noble and Emmett, 2001; Hilbig, 2005;
de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008; Marriott et al., 2008; Thorsdottir et al., 2008; Lennox et al., 2013). Intakes of SFAs, MUFA and PUFAs were around 12-16 E %, 9-14 E % and 4.6-7.0 E %, respectively (Lagström et al., 1997; Noble and Emmett, 2001; Hilbig, 2005; de Boer et al., 2006; DGE, 2008). Intakes of LA were 3.4-6.8 g/day (around 3.4-4.4 E %), of ALA 0.40-0.65 g/day (around 0.5-0.9 E %) and of DHA 28-47 mg/day (Lagström et al., 1997; de Boer et al., 2006; Fantino and Gourmet, 2008; Schwartz et al., 2010). The Panel, however, notes the skewed distribution of LA, ALA and DHA intakes and that in the absence of information on median intakes the given values cannot be interpreted.

5.3.5. Fat sources for IF and FOF

The obvious and previously used staple sources of fat for use in the production of IF and FOF are cow’s milk, to a certain extent goat’s milk and different types of vegetable oils. Like human milk, the lipids in bovine milk are mainly present in globules as an oil-in-water emulsion. Most of the fat is saturated, and around 11 % of the fatty acids are SCFAs, almost half of which is butyric acid (4:0) (Månsson, 2008). The SCFAs are esterified almost entirely at the sn-3 position of the TAG molecules, but, similar to human milk, cow’s milk usually has palmitic acid and MCFAs preferentially esterified at positions sn-2 and sn-1 and oleic acid in positions sn-1,3. Owing to the hydrogenation of PUFAs catalysed by rumen bacteria, cow’s milk has a relatively high content of TFA, typically 2.6-3.9 FA %, of which cis-9,11-trans-CLA and 11-trans-vaccenic acid (18:1t) are the major ones, accounting for 0.3-0.5 FA % and 2-3.3 FA %, respectively, and a low content of PUFAs (Slots et al., 2009).

The average total fat content in goat’s milk is similar to that found in other ruminant species and ranges from 3 to 6 % (Chilliard and Ferlay, 2004). The fatty acids are arranged in TAG in accordance with the milk pattern of other ruminants and the percentage of unsaturated fatty acids does not differ from that found in cow’s milk. The major difference between caprine and bovine milk fat is the distribution among specific SFAs, as goat’s milk has a lower content of SCFAs and more MCFAs, specifically a higher content of capric acid (10:0) and caprylic acid (8:0) (Strzałkowska et al., 2009).

There are many different vegetable oils that could be used in the production of IF, but most of the vegetable oils that are used have a high content of PUFAs and a lower content of SFAs. Furthermore, the TAG positioning of SFAs in vegetable oils differs from that in breast milk, as vegetable oils will usually have more unsaturated fatty acids in the sn-2 position and the SFAs in position sn-1,3. An overview about the typical fatty acid composition of human milk and other potential fat sources for IF and FOF is given in Table 8.

Table 8: Typical fatty acid composition of breast milk and potential sources of fat other than sources of LCPUFAs for IF and FOF

<table>
<thead>
<tr>
<th>Fatty acid</th>
<th>Human milk(a) FA %</th>
<th>Cow’s milk(b) FA %</th>
<th>Goat’s milk(c) FA %</th>
<th>Soybean oil(d) FA %</th>
<th>Canola oil(d) FA %</th>
<th>Sunflower oil(d) FA %</th>
<th>Palm oil(d) FA %</th>
</tr>
</thead>
<tbody>
<tr>
<td>SFA</td>
<td>45–46</td>
<td>53–84</td>
<td>62–79</td>
<td>16</td>
<td>7</td>
<td>10</td>
<td>49</td>
</tr>
<tr>
<td>MUFA</td>
<td>35–40</td>
<td>13–42</td>
<td>17–29</td>
<td>23</td>
<td>63</td>
<td>20–45</td>
<td>37</td>
</tr>
<tr>
<td>PUFA</td>
<td>14–19</td>
<td>2–4</td>
<td>3–6</td>
<td>58</td>
<td>28</td>
<td>40–66</td>
<td>9</td>
</tr>
<tr>
<td>LA</td>
<td>10–15</td>
<td>1–2</td>
<td>1.5–4</td>
<td>50</td>
<td>18</td>
<td>40–66</td>
<td>9</td>
</tr>
<tr>
<td>ARA</td>
<td>0.7–1.1</td>
<td>0.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALA</td>
<td>0.1–2.0</td>
<td>0.2–1.3</td>
<td>0.25–1.3</td>
<td>7</td>
<td>9</td>
<td>0–0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>DHA</td>
<td>0.2–0.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(a): From Greek and Finnish mothers (Antonakou et al., 2013; Mäkelä et al., 2013).
(b): Klem et al. (2013); Ferrand-Calmels et al. (2014).
(c): Ferrand-Calmels et al. (2014).
(d): USDA (online).

As neither cow’s milk nor vegetable oils contain LCPUFAs, oil sources other than those discussed above are needed to supply LCPUFAs. LCPUFA sources currently used in IF and FOF are fish oil,
DHA-rich algal oil from *Cryptocodinium cohnii*, ARA-rich fungal oil from *Mortierella alpina* and egg PL (lecithin/phosphatidylcholine from egg yolk).

5.3.6. Health consequences

5.3.6.1. Overall fat intake

The content of fat in IF and FOF is determined by the need for energy for growth and for the supply of essential fatty acids. Moreover, fat facilitates the absorption of the fat-soluble vitamins. TAGs are the predominant source of energy for breast-fed and formula-fed infants. Major changes in body size and composition take place during early life, and the early growth pattern may have both beneficial and adverse long-term effects on health and obesity risk. The concern about excessive weight gain in infancy has increased as childhood obesity becomes increasingly more prevalent. The role of high or low fat intakes as determinants of adiposity in infancy and childhood has been poorly studied and results are inconclusive (Macé et al., 2006; Agostoni and Caroli, 2012; Rolland-Cachera et al., 2013).

5.3.6.2. Fatty acid composition

The background for the concern about the use of myristic and lauric acid in IF and FOF expressed by the SCF (2003b) is their cholesterol-increasing effects in adults. However, palmitic acid is by far the most dominant SFA in breast milk and also increases cholesterol. Furthermore, plasma cholesterol is higher in breast-fed than in formula-fed infants, and there is no evidence that this has any long-term adverse health effects (Owen et al., 2008; Owen et al., 2011). With respect to MCFAs, the SCF (2003b) concluded that there was no necessity to add MCFAs to IF or FOF. The main purpose of adding MCFAs would be to increase fat absorption (as would lauric acid), but healthy infants do not appear to have any limitations with respect to fat absorption. Furthermore, MCFAs may have potential negative health effects, as high MCFAs intakes may lead to diarrhea and dicarboxylic aciduria (Borum, 1992; Tserrng et al., 1996; Odle, 1997). In infants, TFAs may interfere with PUFA metabolism (Larqué et al., 2001), but no studies have been able to link intake of TFAs with adverse effects on growth or developmental outcomes in infants. CLA, evaluated in the form of CLA-rich oils (cis-9,trans-11 and trans-10,cis-12 in a mixture 1:1), has been suggested to have negative health effects (EFSA NDA Panel, 2010e, 2010d). Both TFA and cis-9,trans-11-CLA are present in milk and therefore are contained in formula in which milk fat has been used as a fat source and are not of safety concern in the amounts which are naturally introduced to formula from milk fat.

ALA is essential in human nutrition as a precursor for n-3 LCPUFAs. LA, when incorporated into skin ceramides, is essential for maintaining the water permeability barrier of the skin and thereby avoiding excessive transepidermal water loss and the accompanying energy loss from water evaporation. A meta-analysis of the effect of ALA on growth and development of pre-term and term infants (Udell et al., 2005) concluded that ALA supplementation had a statistically significant effect on plasma and erythrocyte PL DHA concentrations but that there was a lack of convincing evidence for the effects of ALA supplementation of formula on infant growth and development. The meta-analysis did not find any effects of ALA on growth of pre-term infants and the small differences in weight and length between term infants fed ALA-enriched formula and controls which were observed at 12 months of age were not sustained at 24 months of age. There was a transient improvement in retinal function in pre-term but not in term infants and no effect on any of the other developmental indices.

Eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and, to a lesser degree, DHA are synthesised from ALA. DHA is a component of membrane structural lipids, especially of PL in nervous tissue and the retina. The developing brain accumulates large amounts of DHA both pre- and post-natally, particularly during the first two years of life. DHA is predominantly acquired from the mother via placental transfer and from breast milk or formula, although the capacity of the fetus and newborn to synthesise DHA increases with gestational age (EFSA NDA Panel, 2010c). Biochemical changes of n-3 PUFA deficiency include a decrease in plasma and tissue DHA concentrations. There is no accepted cut-off concentration of plasma or tissue DHA concentrations below which functions ascribed to n-3 PUFA such as visual or neurological functions are impaired (IoM, 2005a).
DHA is accreted in the brain during the first two years of life and data mainly from in vitro and animal studies have shown effects of DHA on neuronal cell growth, rhodopsin function and levels of neurotransmitters (Lauritzen and Carlson, 2011). Studies generally show that the most predictable way to increase tissue DHA is to supply DHA rather than ALA (Arterburn et al., 2006).

DHA has mainly been studied for its potential effect on neurodevelopment in infants and children.

Assessment of neurodevelopment in children is complex because of the broad range of developmental domains, which include neurological and brain function, cognition (memory, attention, learning, intelligence, language, problem solving), visual function, motor skills, temperament and mental health. Different assessments exist within each domain, and there is wide variation in performance measures and psychometric characteristics. For example, assessments of visual function include both behavioural and electrophysiological measures of acuity determined by discrimination of visual angle or stereocuity, as well as recordings of electrical responses in the retina and visual cortex.

Test characteristics vary considerably with children’s age. Standardised age-normed tests for assessing infant development (e.g. the Bayley Scales of Infant Development (BSID)) measure the timely achievement of developmental milestones, but provide only a crude and global assessment of development. Other infant tests measure specific abilities, such as speed of processing, attention, problem solving and working memory, but most are not standardised and age-normed, and for most there is no agreed procedure for administering the test. These factors make it difficult to interpret and compare the results from different studies, especially when assessments have been conducted at different ages.

The effect of addition of DHA and ARA, or DHA alone, to IF on performance on the Mental Developmental Index (MDI) and the Psychomotor Development Index (PDI) of the BSID has been investigated in several studies on term infants at different ages.

In these studies, no statistically significant differences between the intervention groups consuming IF with DHA and ARA and control groups in MDI scores were reported at three months of age (one study (Ben et al., 2004a)), six months of age (two studies (Auestad et al., 2001; Ben et al., 2004a)) and at one year of age (three studies (Scott et al., 1998; Makrides et al., 2000; Auestad et al., 2001)). At 18 months of age, one study (Birch et al., 2000) reported significant differences in MDI scores while three other studies reported in four publications did not report such differences at 18 months of age (Lucas et al., 1999; Bouwstra et al., 2005; Drover et al., 2011; Colombo et al., 2013). In addition, the studies which investigated this outcome at two years of age (Makrides et al., 2000) and six years of age (Colombo et al., 2013) did not report any significant differences in this outcome.

None of the studies investigating the effect of DHA alone on MDI scores reported any differences between intervention and control groups at one year of age (three studies (Scott et al., 1998; Makrides et al., 2000; Auestad et al., 2001)) and two years of age (one study (Makrides et al., 2000)), which were the only time points measured.

The same studies which investigated the impact of DHA and ARA added to IF on MDI scores also tested the effect on PDI scores. None of the studies reported an effect on this outcome at any tested age (3, 6, 12, 18 and 24 and 72 months). Similarly, this was the case for the three studies which investigated the effect of DHA alone at one and two years of age.

Two studies investigated the impact of DHA and ARA addition to IF on intelligence quotient (IQ) scores using the Wechsler Preschool and Primary Scale of Intelligence Revised (WPPSI-R) at four (Birch et al., 2007) and six (Willatts et al., 2013) years of age and one study the WPSSI, third edition (Colombo et al., 2013), also at six years of age. The study by Birch et al. (2007) also included a group who consumed formula with added DHA alone. None of the studies reported significant differences between the intervention and control groups for processing speed IQ (investigated only in the study by Colombo et al. (2013)), performance IQ, verbal IQ or full-scale IQ. In another study (de Jong et al.,
2012), the Wechsler Abbreviated Scale of Intelligence was used to investigate the effect of addition of DHA and ARA to IF on IQ at nine years of age. DHA and ARA addition to IF was reported to have been associated with statistically significantly higher verbal IQ scores in children whose mothers had smoked during pregnancy and with statistically significantly lower scores in children whose mothers had not smoked. No statistically significant effects on full-scale IQ or performance IQ were reported.

The Peabody Picture Vocabulary Test, 3rd edition (PPVT-III), was used in two studies to assess language comprehension at 2 years, 3.5 years (Drover et al., 2012) and 5 years (Colombo et al., 2013) of age and the PPVT, revised (PPVT-R), in one study (Auestad et al., 2003) at 39 months of age. The study by Colombo et al. (2013) comprised three intervention groups consuming DHA and ARA but with increasing amounts of DHA (i.e. 0.00 FA %, 0.32 FA %, 0.64 FA % and 0.96 FA %). Statistically significantly higher scores were reported in the intervention groups consuming the two intermediate doses of DHA but not in the group consuming the highest dose of DHA at five years of age. For the study by Drover et al. (2012), statistically significantly higher scores were reported at two years of age in the control group than in the intervention groups (consuming IF with added DHA and ARA) with no statistically significant differences at 3.5 years. In the study by Auestad et al. (2003), no statistically significant differences in this outcome were reported.

Other studies have investigated the impact of addition of DHA and ARA, or DHA alone, to IF on other tests of neurodevelopment, including the Knobloch, Passamanik, and Sherrards Development Screening Inventory (Lucas et al., 1999), the Brunet–Lézine developmental test (Agostoni et al., 1997), the Standford–Binet scales (Auestad et al., 2003), vocabulary and gesture communication scores from the MacArthur Communicative Development Inventories (Scott et al., 1998), the Fagan Infant Test of Development (Auestad et al., 2001), problem solving assessment (Willatts et al., 1998), the Behaviour Rating Scale (Drover et al., 2011), the Neurological Optimality Score (Bouwstra et al., 2005), the pair subtask of the Children’s Memory Scale (de Jong et al., 2012), A Developmental NEuroPSYchological Assessment (NEPSY) (de Jong et al., 2012), the Test of Everyday Attention for Children (de Jong et al., 2012), the Delayed Response Task (Colombo et al., 2013), the Bear-Dragon Go/No-Go Task (Colombo et al., 2013), the Dimensional Change Card Sort (Colombo et al., 2013), the Stroop task (Colombo et al., 2013), the Tower of Hanoi task (Colombo et al., 2013), the Day–Night test (Willatts et al., 2013), the matching family figures test (Willatts et al., 2013), the Bracken Basic Concept Scale Revised (Drover et al., 2012) and mean length of utterance (Auestad et al., 2003). Furthermore, the effects on brainstem auditory evoked potentials (Ünay et al., 2004), look duration and sustained attention (Colombo et al., 2011) were evaluated. However, all these studies were single studies only and, although a few studies reported statistically significant effects, these findings were not replicated in other studies.

Consumption of IF with added DHA has been associated with greater visual acuity at 12 months of age compared with consumption of control formula (EFSA, 2009). Only a few studies have investigated the persistence of the effect beyond infancy. The study by Birch et al. (2007), which used HOTV testing to assess visual acuity, reported statistically significantly higher right eye acuity in the group who had consumed formula with DHA than in the control formula group, but not when the group consuming DHA and ARA was compared with the control group at four years of age. No differences in visual acuity of the left eye were observed. The study by Singhal et al. (2007), which used the Sonksen–Silver Acuity System, and the study by Auestad et al. (2003), which used Teller acuity cards, did not report an effect of DHA on visual acuity at 39 months, and between 4 and 6 years of age. However, it has to be acknowledged that studies using Teller acuity cards also did not report any significant findings on visual acuity at 12 months of age (Carlson et al., 1996; Auestad et al., 1997; Auestad et al., 2001).

The effect of addition of DHA and ARA to IF on blood pressure at four, six and nine years of age was investigated in two studies (Forsyth et al., 2003; de Jong et al., 2011). None of the studies reported a significant effect on systolic blood pressure. In the study by Forsyth et al. (2003), a statistically significantly lower diastolic blood pressure was reported in the intervention group compared with the control formula group, while the study by de Jong et al. (2011) did not report such an effect.
The principal PUFA components of membrane PLs are DHA, ARA and LA. In the presence of adequate dietary intakes, DHA is preferentially incorporated into brain membranes and is favoured over ARA and LA (Makrides et al., 1994). Low dietary intakes of n-3 PUFA led to the replacement of DHA in brain membranes with the nearest n-6 PUFA equivalents in animal studies, but few changes were seen when n-6 PUFA intakes were low (Neuringer et al., 1986; Carrie et al., 2000). This is consistent with findings that brain DHA concentrations can be influenced by diet, whereas ARA levels are not (Hsieh and Brenna, 2009). The current requirement, established by Directive 2006/141/EC, to add n-6 LCPUFAs to IF and FOF in the presence of DHA in amounts which exceed those of DHA stems from a concern which was raised in one small randomised controlled trial (RCT) in pre-term infants (Carlson et al., 1993) in relation to potential adverse effects on growth of formulae containing DHA but no ARA. In this study, plasma phosphatidylcholine ARA concentrations were found to correlate with measures of normalised growth, which led the authors to hypothesise that ARA deficiency may contribute to decreased growth in pre-term infants over the first year of life. Earlier observational data have also shown a positive correlation between body weight and post-natal plasma triglyceride ARA (and total n-6 PUFAs) content and an inverse correlation with ALA (Koletzko and Braun, 1991). Since then, three RCTs investigated the effect on growth in term infants, comparing an IF containing added ARA and DHA with an IF containing DHA alone and with a control formula (Auestad et al., 1997; Birch et al., 1998; Makrides et al., 1999), and three studies (Makrides et al., 1995; Innis et al., 1996; Lapillonne et al., 2000) compared an IF containing added DHA with a control formula. None of these studies found any statistically significant differences in growth, although erythrocyte ARA concentrations were observed to be lower in the groups consuming IF with DHA alone than in the groups consuming the control formula. Only two RCTs (Scott et al., 1998; Makrides et al., 2000) allow the assessment of whether ARA would have an independent effect on cognitive function by comparing infants having been fed formula containing DHA and ARA and infants who have received formula containing DHA; however, there were no statistically significant differences between the two groups in BSID-MDI or PDI scores. In a previous opinion (EFSA, 2009), the Panel has already investigated the potential role of ARA in visual development and concluded that, on the basis of available data, a role of ARA in visual development cannot be established.

One meta-analysis concluded that post-natal n-3 LCPUFA intake (from fish, fish oil and breast milk) decreases childhood asthma (Yang et al., 2013), whereas a systematic review of RCTs found an effect on asthma and the response to skin prick test only after supplementation during pregnancy, and no significant effect was seen after post-natal intake (Klemens et al., 2011).

Studies have suggested that polymorphisms in the FADS gene cluster that determine the endogenous conversion of LA and ALA to LCPUFAs alter the effect of breast-feeding on cognitive outcomes (Caspi et al., 2007; Steer et al., 2010; Martin et al., 2011; Morales et al., 2011; Steer et al., 2013) and risk of atopy (Rzehak et al., 2010; Standl et al., 2011; Standl et al., 2012). Different FADS single-nucleotide polymorphisms (SNPs) may have different effects on LCPUFA synthesis, and these may vary with age (Harsløf et al., 2013). The presence of these polymorphisms could influence the effect of LCPUFA addition and thus further complicate the evaluation of the effects of addition of LCPUFAs to IF and FOF.

The Panel considers that DHA should be added to IF and FOF, even though there is currently no conclusive evidence for any effects beyond infancy of addition of DHA to IF or FOF on any of the health outcomes studied. The reasons for proposing this addition are that (1) DHA is an essential structural component of the nervous tissue and the retina, and is involved in normal brain and visual development (EFSA, 2009); (2) the developing brain has to accumulate large amounts of DHA in the first two years of life; (3) although DHA can be synthesised in the body from ALA, the intake of pre-formed DHA generally results in an erythrocyte DHA status more closely resembling that of a breast-fed infant than is achieved with ALA alone (Brenna et al., 2009); and (4) although, to date, there is no convincing evidence that the addition of DHA to IF and FOF has benefits beyond infancy on any functional outcomes, there is also a lack of long-term follow-up data on specific aspects of cognitive and behavioural function from adequately powered RCTs of DHA addition to IF and FOF to demonstrate any purported biologically plausible effect of DHA on these aspects. Considering all of
these factors, it seems prudent to provide pre-formed DHA to formula-fed infants in similar amounts as breast-fed infants, even though benefits beyond infancy of this practice cannot be established based on the currently available data.

The Panel notes that even though studies have shown that feeding an IF containing DHA alone, (without addition of ARA) leads to lower concentrations of ARA in erythrocytes compared with the consumption of control formula without DHA, no direct functional consequences have been observed in relation to growth and neurodevelopment and this lower concentration of ARA in erythrocytes seems not to be associated with a decrease in concentrations of ARA in the brain. The adverse effects on growth which had been reported in one RCT in pre-term infants have not been replicated in several more recent trials. Therefore, the Panel considers that there is no necessity to add ARA to IF even in the presence of DHA.

With respect to the EPA:DHA ratio, the SCF (2003b) recommended that the ratio should be kept below 1. However, there are no studies which investigated any potential health risk of high intakes of EPA in infants, but the content of EPA in breast milk is usually low, typically in the range 0.05-0.4 FA % (Lauritzen and Carlson, 2011).

5.3.6.3. Molecular speciation of fatty acids

In breast milk, PLs that constitute the fat globule membrane have a high content of LCPUFAs compared with the TAG molecules in the core of the milk globules (Abrahamse et al., 2012). The PLs supplied by breast milk are expected to play a role, together with bile PLs, in the emulsification of the fat in the infant gut and thus promote digestion, absorption and transport (Ramirez et al., 2001). It has been proposed that, specifically, LCPUFAs may be better utilised if supplied in PLs owing to increased absorption and tissue incorporation (Abrahamse et al., 2012). Furthermore, as constituents of the membranes of all cells in the infant, PLs are involved in a variety of physiological processes, but these are usually not expected to be influenced by dietary intake of PLs (German, 2011; Küllenberg et al., 2012; Oosting et al., 2012; Tanaka et al., 2013). Few studies have looked at functional consequences of inclusion of PLs in IF. A meta-analysis that specifically evaluated the effect of formula LCPUFAs on infant growth did not find any differences depending on whether these were added as PLs or TAG (Makrides et al., 2005). The Panel considers that there is no convincing evidence for a beneficial effect of LCPUFAs supplied as PLs instead of TAG in IF or FOF. There are no adverse effects reported of the use of PLs to supply LCPUFAs in IF and/or FOF instead of TAG. Lecithins are authorised by Regulation (EC) No 1333/200815 to be added to IF and FOF as emulsifier in an amount of 1 g/L.

5.3.6.4. TAG with palmitic acid predominantly in the sn-2 position

Structured triglycerides in which palmitic acid has been predominantly esterified in the sn-2 position in order to imitate breast milk have been studied for a number of health outcomes in healthy term infants, including mineral absorption and retention, bone mineral density (BMD), growth, stool consistency, blood lipid profiles and infant crying time.

In these studies, no effects on infant growth (Kennedy et al., 1999; Nelson and Innis, 1999; Litmanovitz et al., 2013) or on phosphorus and magnesium absorption (Carnielli et al., 1996) were observed. In addition, no cause and effect relationship could be established by the Panel previously between the feeding of formula high in sn-2 palmitate and stool consistency (EFSA NDA Panel, 2014d). The study by Yao et al. (2014), which was published after the opinion of the Panel, reported a significantly higher percentage of mushy soft stools and a significantly lower percentage of formed stools in the group consuming formula high in sn-2 palmitate than in controls. However, results from the pre-planned analyses on the average stool consistency scores between groups and on the percentage of stools in the other stool consistency categories (in total five) were not reported. The

studies investigating calcium absorption (EFSA NDA Panel, 2011) and infant crying time (Kennedy et al., 1999; Litmanovitz et al., unpublished; Zhong et al., unpublished) reported inconsistent results. The only study which used dual-energy X-ray absorptiometry (DXA) to measure BMD showed that infants fed a formula with high sn-2 palmitate had higher BMD than those fed a control formula. However, DXA measurements were available only for a sub-group of subjects, and bone mineral content of the radius obtained using single photon absorptiometry in all infants did not differ between groups (Kennedy et al., 1999). A small study (Yaron et al., 2013) evaluated the effect of formula with high sn-2 palmitate compared with a formula with low sn-2 palmitate on infant gut microbiota composition, reporting increases in *Clostridium*, *Escherichia coli*, *Pseudomonas* and *Staphylococcus* numbers, but only by plate counting and without providing further characterisation of the bacterial groups analysed to infer possible physiological/clinical consequences of the changes reported. One study which investigated the effect of sn-2 palmitate on blood lipids found lower high-density lipoprotein (HDL)-cholesterol and apolipoprotein A1 concentrations and higher apolipoprotein B concentrations in the group being fed high sn-2 palmitate formula (Nelson and Innis, 1999), but the relevance of this finding in infants is unknown. The Panel considers that there is no convincing evidence for a beneficial effect of the use of TAG with palmitic acid predominantly esterified in the sn-2 position in IF and/or FOF instead of other TAGs. There are no adverse effects reported of the use of TAG with palmitic acid predominantly esterified in the sn-2 position in IF and/or FOF instead of other TAGs.

5.3.7. Recommendations

5.3.7.1. Total fat

According to Directive 2006/141/EC and in line with the SCF (2003b), IF have to provide fat in the range of 40-55 E% and FOF in the range of 35-55 E%. The Panel had concluded in its previous opinion (EFSA NDA Panel, 2013a) that intakes of fat of 50-55 E% and 40 E% were adequate for the majority of infants for the first and second half year of life, respectively. The Panel considers that there is no scientific reason to differentiate the fat content of IF and FOF and that complementary foods that contribute to the dietary intake in the latter half of infancy have a low fat content.

Therefore, the Panel proposes a minimum fat content of IF and FOF of 40 E% (i.e. 4.4 g/100 kcal (1.1 g/100 kJ)) and a maximum fat content of 55 E% (i.e. 6.0 g/100 kcal (1.4 g/100 kJ)).

5.3.7.2. Linoleic acid (LA)

The range of LA concentrations in IF and FOF can be derived based on the level of LA intakes (4 E%) which the Panel had considered to be adequate for the majority of infants (EFSA NDA Panel, 2013a) and the highest concentrations of LA observed in human milk (24 FA%) (Sanders and Reddy, 1992). These derivations translate into a lower bound of the range of 500 mg/100 kcal (120 mg/100 kJ, equivalent to 4.5 E%) and an upper bound of the range of 1200 mg/100 kcal (300 mg/100 kJ, equivalent to 10.8 E%), in line with what has been recommended previously by the SCF (2003b).

5.3.7.3. Alpha-linolenic acid (ALA)

In line with the approach for LA, a lower bound for ALA in IF and FOF can be derived based on the level of ALA intakes (0.5 E%) which the Panel had considered to be adequate for the majority of infants (EFSA NDA Panel, 2013a) and an upper bound can be derived based on the highest ALA concentrations observed in human milk (2 FA%) (Mäkelä et al., 2013). These derivations translate into a lower bound of the range of 50 mg/100 kcal (12 mg/100 kJ, equivalent to 0.5 E%) and an upper bound of the range of 100 mg/100 kcal (24 mg/100 kJ, equivalent to 0.9 E%).

The Panel considers that there is no necessity to set a specific ratio for LA:ALA in the presence of LCPUFAs in IF and FOF.
5.3.7.4. Long-chain polyunsaturated fatty acid (LCPUFAs)

In line with the approach for LA and ALA, a lower bound for DHA in IF and FOF can be derived based on the level of DHA intakes (100 mg/day) which the Panel had considered to be adequate for the majority of infants (EFSA NDA Panel, 2013a) and an upper bound can be derived based on the highest observed DHA concentrations in human milk (around 1 FA %) (Brenna et al., 2009). These derivations translate into a lower bound of the range of 20 mg/100 kcal (4.8 mg/100 kJ, approx. 0.36-0.49 FA %) and an upper bound of the range of 50 mg/100 kcal (12 mg/100 kJ, approx. 0.90-1.23 FA %).

The Panel considers that there is no necessity to set a specific minimum content of ARA or EPA in IF or FOF or a specific ratio for DHA:ARA. Considering that the DHA content in breast milk always exceeds the content of EPA, the Panel proposes that, for IF and FOF also, the amount of EPA should not be higher than that of DHA.

The Panel notes that there is no convincing evidence that the addition of DHA to IF and FOF has benefits beyond infancy on any functional outcomes. However, the proposal of the Panel to add DHA to IF and FOF is based on its structural role in the nervous tissue and the retina and its involvement in normal brain and visual development, the need of the developing brain to accumulate large amounts of DHA in the first two years of life and the consideration that the intake of pre-formed DHA generally results in an erythrocyte DHA status more closely resembling that of a breast-fed infant than is achieved with ALA alone.

5.3.7.5. Saturated fatty acids (SFAs) and trans-fatty acids (TFAs)

The Panel considers that there is no evidence which allows for the proposal of lower or upper bounds of a range for specific types of SFA (MCFAs or lauric, myristic or palmitic acid) in IF or FOF. For TFAs, the Panel considers the current specifications for TFA content in IF and FOF (< 3 FA %) to be adequate. These specifications allow for the use of milk as a source of fat for formulae.

5.3.7.6. Vegetable oils

The Panel considers that the vegetable oils used in the production of IF and FOF should be safe from a toxicological point of view (regarding the content of erucic acid, cyclopentene fatty acids, etc.). The use of partially hydrogenated vegetable oils in IF and FOF should be avoided because of their TFA content.

5.3.7.7. Phospholipids (PLs)

Taking into account the lack of convincing evidence for a beneficial effect of LCPUFAs supplied as PLs instead of TAG in IF or FOF, the Panel considers that there is no necessity to use PLs as a source of LCPUFAs instead of TAG in IF and FOF. PLs are naturally present in milk and ISP, and may be added to IF and FOF for technological purposes, for example as an emulsifier or as a source of LCPUFAs.

5.3.7.8. TAG with palmitic acid predominantly in the sn-2 position

Taking into account the lack of convincing evidence for a benefit of using TAG with palmitic acid predominantly esterified in the sn-2 position in IF and/or FOF, the Panel considers that there is no necessity to use TAG with palmitic acid predominantly esterified in the sn-2 position in IF and FOF instead of TAG from other fat sources.

Table 9 provides an overview of the proposed minimum and maximum content of total fat and an adequate range of fatty acids in IF and FOF.
Table 9: Proposed minimum and maximum content of fat and adequate range of fatty acids in IF and FOF

<table>
<thead>
<tr>
<th></th>
<th>Minimum content</th>
<th>Maximum content</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mg/100 kcal</td>
<td>mg/100 kJ</td>
</tr>
<tr>
<td>Total fat</td>
<td>4 400</td>
<td>1 052</td>
</tr>
<tr>
<td>LA</td>
<td>500</td>
<td>120</td>
</tr>
<tr>
<td>ALA</td>
<td>50</td>
<td>12</td>
</tr>
<tr>
<td>DHA (a)</td>
<td>20</td>
<td>4.8</td>
</tr>
<tr>
<td>TFA</td>
<td>--</td>
<td>--</td>
</tr>
</tbody>
</table>

(a): The amount of EPA should not be higher than the amount of DHA.

5.4. Carbohydrates

Nutritionally, two broad categories of carbohydrates can be differentiated: “glycaemic carbohydrates”, i.e. carbohydrates digested and absorbed in the human small intestine with a substantial subsequent rise in blood glucose, and “dietary fibre”, i.e. non-glycaemic carbohydrates passing undigested to the large intestine and with no rise in blood glucose. The absolute dietary requirement for glycaemic carbohydrates is not known because there is no indispensable carbohydrate. For practical purposes, recommendations for glycaemic carbohydrates will depend on the amount of fat and protein ingested. The main glycaemic carbohydrates are monosaccharides, disaccharides, malto-oligosaccharides and starch. Dietary fibre is defined to include all non-digestible carbohydrates (plus lignin) (EFSA NDA Panel, 2010b), but for IF and FOF only resistant oligosaccharides (fructo-oligosaccharides (FOS), galacto-oligosaccharides (GOS), other resistant oligosaccharides) and resistant starch and chemically and/or physically modified starches are of relevance.

5.4.1. Current compositional requirements of IF and FOF

Permitted carbohydrates in IF are lactose, maltose, sucrose, glucose, maltodextrins, glucose syrup (or dried glucose syrup), pre-cooked starch and gelatinised starch free from gluten. These carbohydrates can be used under the conditions outlined in Table 10. For FOF, there are no restrictions with respect to the type of carbohydrates that can be used as long as they are free from gluten. If honey is used (for FOF only), it has to be treated in order to destroy spores of Clostridium botulinum.

Table 10: Current compositional requirements for IF and FOF with respect to glycaemic carbohydrates and FOS plus GOS according to Directive 2006/141/EC

<table>
<thead>
<tr>
<th>g/100 kcal</th>
<th>Milk protein</th>
<th>IF with ISP</th>
<th>Protein hydrolysates</th>
<th>Milk protein</th>
<th>FOF with ISP</th>
<th>Protein hydrolysates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbohydrates</td>
<td>9-14</td>
<td>9-14</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>of which</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lactose</td>
<td>≥ 4.5</td>
<td>NR (a)</td>
<td>≥ 20 % of total</td>
<td>≥ 4.5</td>
<td>NR (a)</td>
<td>≥ 20 % of total</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>carbohydrates (b) (c)</td>
<td></td>
<td></td>
<td>carbohydrates (b)</td>
</tr>
<tr>
<td>Sucrose</td>
<td>Not to be added</td>
<td>≤ 20 % of total carbohydrates (b) (c)</td>
<td>Sum of sucrose, fructose, sugar from honey</td>
<td>Not to be added</td>
<td>≤ 2 (b) (c)</td>
<td></td>
</tr>
<tr>
<td>Fructose</td>
<td>Not to be added</td>
<td>≤ 2 (b) (c)</td>
<td>Not to be added</td>
<td>Unrestricted within specifications for total carbohydrates</td>
<td>Unrestricted within specifications for total carbohydrates</td>
<td></td>
</tr>
<tr>
<td>Glucose</td>
<td>Not to be added</td>
<td>≤ 2 (b) (c)</td>
<td>Not to be added</td>
<td>≤ 2 (b) (c)</td>
<td>Not to be added</td>
<td></td>
</tr>
<tr>
<td>Maltose, maltodextrins (b)</td>
<td>Unrestricted within specifications for total carbohydrates</td>
<td>Unrestricted within specifications for total carbohydrates</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Starches (b)</td>
<td>≤ 2 g/100 mL and total carbohydrates (d)</td>
<td>Unrestricted within specifications for total carbohydrates as long as free of gluten</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FOS + GOS (b) (e)</td>
<td>≤ 0.8 g/100 mL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(a): Not required (NR) if more than 50 % of the protein content is from ISP.
(b): Voluntary addition.
(c): To mask the bitter taste.
(d): Pre-cooked or gelatinised starch only.
(e): A combination of 90 % oligagalactosyl-lactose and 10 % high-molecular-weight oligofructosyl-saccharose only.

5.4.2. Carbohydrate content of human milk

5.4.2.1. Digestible (glycaemic) carbohydrates

The Panel proposes to differentiate between glycaemic and non-glycaemic carbohydrates to underline the difference in their physiological function. The first source of glycaemic carbohydrates in infants is human milk, in which lactose, a disaccharide of glucose and galactose, is the primary sugar. Lactose occurs exclusively in milk and milk products. Human milk has the highest lactose content of all milks, about 55-70 g/L or 8.2-10.4 g/100 kcal (corresponding to 33-42 E %), whereas the content of monosaccharides is only about 1 % of total carbohydrates (Coppa et al., 1994). Human milk does not contain sucrose or fructose but does contain small amounts of sugar alcohols, including inositol (Cavalli et al., 2006).

5.4.2.2. Non-digestible (non-glycaemic) carbohydrates in human milk

The third main component in human milk after lactose and fat are neutral and acid oligosaccharides in concentrations between around 5-15 g/L (Aggett et al., 2003; Coppa et al., 2011). The structure of about 200 human milk oligosaccharides has been identified (Kunz et al., 2000). These oligosaccharides are typically composed of 3–23 monosaccharide units, including glucose, galactose, N-acetylglucosamine, fucose and siaic acid. Approximately 20 oligosaccharides make up more than 90 % of the total amount of oligosaccharides in human milk, with the principal oligosaccharides being fucosyllactoses, lacto-N-tetraose, lacto-N-neotetraose, sialyllactoses, lacto-N-fucopentaoses (I–V) and lacto-N-difucohexaoses (I–III). The neutral linear and branched-chain oligosaccharides are fucosylated to a varying degree and make up 80-85 % of the total amount of oligosaccharides in human milk, whereas the acidic oligosaccharides contain siaic acid and make up 15-20 % of the total amount. The production of oligosaccharides is genetically determined and the individual pattern of oligosaccharides differs between women (Ninonuevo et al., 2006).

The oligosaccharides of human milk are considered to be one of the principal growth factors, for example, for bifidobacteria in the infant gut and are responsible for the composition of the gut microbiota found in breast-fed infants. The fermentation of non-digestible oligosaccharides leads to the generation of organic acids (lactic acid) and SCFAs such as acetic, propionic and butyric acids. Butyrate is a main source of energy for the colonocytes and has effects on cell differentiation. Acetate and propionate are absorbed from the colon and thus provide energy to the host (Aggett et al., 2003). Fermentation products, i.e. SCFAs, contribute to the energy content of the diet, but to a lesser extent than glycaemic carbohydrates. Human milk oligosaccharides are not considered in the estimation of the energy content of the milk.

5.4.3. Carbohydrate requirements of infants

In the Panel’s previous Opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded on a Reference Intake range (RI) for total carbohydrates of 40-45 E % for infants below six months of age and of 45-55 E % for infants from 6 to < 12 months. Fibre intakes are usually not considered in recommendations up to one year of life.

5.4.4. Carbohydrate intake of infants

5.4.4.1. Digestible (glycaemic) carbohydrates

Assuming a human milk intake of 0.8 L/day and a lactose content of 70 g/L, a breast-fed infant would consume 56 g of lactose per day (around 50 E %) during the first six months of life. Mean total carbohydrate intakes in mostly formula-fed infants have been reported in the range of around 63-93 g/day or 46-50 E % (Hilbig, 2005; Noble and Emmett, 2006; Fantino and Gourmet, 2008;
Lennox et al., 2013). In infants older than six months, mean total carbohydrate intakes reportedly amount to around 80-140 g/day or 49-58 E% (Lagström et al., 1997; Noble and Emmett, 2001; Hilbig, 2005; de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008; Marriott et al., 2008; Thordsdottir et al., 2008; Lennox et al., 2013).

5.4.4.2. Non-digestible (non-glycaemic) carbohydrates

Assuming an intake of 0.8 L/day of human milk and an oligosaccharide content of 5-15 g/L, a breast-fed infant would consume between 4 and 12 g per day of non-digestible oligosaccharides during the first half of the first year of life. There are no data on the oligosaccharide intakes in infants. In some European countries (Germany, France, Finland and the Netherlands) the dietary fibre intake of infants older than six months has been reported to be around 4-10 g/day (Lagström et al., 1997; Noble and Emmett, 2001; Hilbig, 2005; de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008).

5.4.5. Health consequences

5.4.5.1. Type of carbohydrates

Currently, only carbohydrates which are free of gluten can be used in IF and FOF. The risk of developing coeliac disease (CD) and type 1 diabetes mellitus (T1DM) has been related to the timing of gluten introduction into the infant’s diet. In 2009, the Panel concluded, based on available data, that the early (less than four months of age) introduction of gluten might increase the risk of CD and T1DM, whilst the introduction of gluten between four and six months of age, preferably while the infant is still being breast fed, might decrease the risk of CD and T1DM (EFSA NDA Panel, 2009). CD is a multi-organ disease, triggered by gluten and related prolamins in genetically predisposed subjects. The prevalence in Europe is in the range of 0.5-1 % (Fasano, 2001; Virta et al., 2009; Catassi et al., 2012).

A current European intervention study on 1 000 infants positive for human leucocyte antigen (HLA) DQ2/DQ8 and randomised to receive about 100 mg of gluten per day or placebo is expected to provide further evidence regarding the role of gluten introduction into the infant’s diet. However, detailed results of this study have not yet been published.

The Panel considers that the available data suggest that gluten-containing complementary foods could be introduced between four and six months of age in small amounts, preferably while the infant is still being breast fed. However, in the case of FOF feeding together with complementary foods, the use of gluten-containing starches in such formulae could result in amounts of gluten that are too high to be tolerated in genetically predisposed infants. Therefore, gluten-containing starches should not be added to IF and FOF.

5.4.5.2. Glycaemic carbohydrates

Glycaemic carbohydrates provide carbohydrates to body cells, mainly in the form of glucose. Only cells in the central nervous system, red blood cells and some other cells dependent on anaerobic glycolysis have an absolute requirement for glucose. The body can in principle synthesise glucose from protein and glycerol, but this is not efficient and may lead to ketosis. Therefore, the DRV for carbohydrates is based on the energy gap between the energy provided by the sum of recommended protein and fat intakes and the total energy requirement.

**Lactose**

Lactose should be the preferred carbohydrate in IF and FOF although no absolute requirement for dietary galactose intake exists. This preference for lactose in formulæ is justified by the predominance of lactose in human milk, the newborn’s capacity to hydrolyse lactose from human milk and the absence of advantages that other glycaemic carbohydrates might have compared with lactose.
The capacity of the newborn to metabolise lactose was demonstrated in a study of 24 infants of 36 weeks’ gestation, post-natal age 2-16 days, and taking full enteral feeding (n = 6 breast milk, n = 5 formula, n = 11 mixed) and which showed that, although lactose from formula or human milk provides glucose and galactose in equimolar amounts to the portal vein, galactose is cleared almost completely by the liver within 60 minutes after a meal and reaches only 1-2% of the glucose concentration in plasma, whilst glucose increased in both the hepatic and systemic circulation without net hepatic uptake. There was a positive influence of post-natal age on hepatic galactose clearance that could be attributed to either maturation of enzymes or closure of a patent ductus venosus (shunting blood from the left portal vein to the vena cava) (Brown et al., 2008).

Evidence that lactose is not a requirement for healthy growth is provided by two RCTs, of 12 weeks’ duration, with lactose-free formulae with maltodextrin and sucrose (Heubi et al., 2000; Lasekan et al., 2011) performed on healthy term infants in comparison with a standard lactose-containing formula in which growth parameters did not differ. As soy does not contain digestible lactose or galactose naturally and formulae containing ISP may be used in infants with galactosaemia, these formulae should not contain any lactose.

**Sucrose, glucose and fructose**

The ingestion of sucrose and fructose by infants with fructose intolerance, a hereditary disease affecting approximately 1 in 26 000 infants in Central Europe (Santer et al., 2005), can lead to severe symptoms, including poor feeding, vomiting and overall failure to thrive (Coffee and Tolan, 2010). The consumption of sucrose and fructose by healthy infants does not have any advantages over the consumption of lactose and may, because of their greater sweetness, increase the preference for sweet tastes in infants. Sucrose may be added to IF containing hydrolysed protein to camouflage the taste of the hydrolysate. Because complementary food will provide other glycaemic carbohydrates than lactose, there is no reason to restrict their use in FOF as long as certain maximum levels are not exceeded.

Glucose is rapidly absorbed with a rapid rise in blood glucose and has, moreover, a higher osmotic activity than di-, oligo- and polysaccharides. Hyperosmolar feeds may lead to an increased incidence of diarrhoea. Small amounts of glucose may, however, help mitigate the disagreeable taste of IF and FOF containing protein hydrolysates.

**Maltodextrins and starches**

Maltodextrins and starches have the advantage of producing lower osmolality in products than mono- and disaccharides. The SCF (2003b) recommended that maltodextrins with 5-9 glucose units should be preferred because this corresponds to the chain-length specificity of the intestinal glucoamylase.

Pancreatic α-amylase concentrations in the infant’s duodenum are lower than in adults (Christian et al., 1999). Shulman et al. (1983) compared the effects of feeding glucose, glucose polymers and precooked corn starch, which were substituted for saccharose in the basal diet for one meal at a dose of 1 g/kg body weight in 16 healthy infants aged between three and four weeks, on breath 13CO2, breath hydrogen and stool 13C abundance taking into account the natural 13C abundance in the different formulae. The calculated oxidation rate was comparable for the different carbohydrates studied, but hydrogen production increased with carbohydrate complexity, indicating that more undigested carbohydrates reached the colon with increasing complexity of the carbohydrates. This finding is similar to the findings of another study (Shulman et al., 1986) in which it was found that long-chain glucose polymers are absorbed less, and with greater individual variation, than glucose or short-chain glucose polymers. Carbohydrates that are not digested and absorbed in the small intestine may be fermented by colonic bacteria. This fermentation increases the net utilisation of complex carbohydrates, but the capacity for bacterial fermentation can be exceeded by high intakes of complex carbohydrates (Shulman et al., 1983). Earlier studies reviewed by Fomon (1993) suggested that starch is tolerated up to daily intakes of 5.5-6 g/kg body weight per day and that most infants from one to five months of age are able to digest 10-25 g of starch per day.
5.4.5.3. Non-digestible (non-glycaemic) carbohydrates

Because of the variety, variability, complexity and polymorphism of human milk oligosaccharides, the addition to IF and FOF of a mixture of oligosaccharides mimicking those found in breast milk is not feasible and oligosaccharides which are currently added to IF and FOF are not comparable to human milk oligosaccharides. Instead, oligofructosyl-saccharose (oligofructose; FOS) and oligogalactosyl-lactose (oligogalactose; GOS) have been used in IF and FOF. FOS is not found in human milk and GOS is found only in trace amounts.

Cow’s milk contains only trace amounts of oligosaccharides (0.03-0.06 g/L), mostly sialylated derivatives, whilst the content of neutral and acidic oligosaccharides (AOS) in goat milk is four to five times higher than in cow’s milk (Martinez-Ferez et al., 2006).

The SCF (2001d) has previously assessed the safety of a formula with the addition of 0.8 g/100 mL of a mixture of 90 % GOS and 10 % high-molecular-weight FOS and found no reason for concern or conclusive proof of potential beneficial effects for infants in the second half of the first year of life. It found the evidence insufficient to establish the safety for infants below six months of age. It recommended that additional information on the suitability and safety of resistant short-chain oligosaccharides should be submitted, with particular attention to possible effects on water balance. When reviewing the available evidence in 2003, the SCF (2003b) concluded that the particular mixture of GOS and FOS which had been evaluated previously did not give rise to any safety concerns at concentrations used in both IF and FOF up to a maximum of 0.8 g/100 mL. The SCF also reaffirmed its conclusions that further information on the safety and benefits of this combination as well as of other forms of oligosaccharides in IF and FOF should be gathered.

Since the report by the SCF (2003b), other oligosaccharides or combinations of oligosaccharides (e.g. GOS, inulin-type fructans or their combination or with mixtures of polydextrose and AOS) have been studied for a number of health outcomes, such as bowel function, gastrointestinal and respiratory tract infections, atopic dermatitis, eczema, urticaria and asthma. They have also been studied in relation to any potential untoward effects, such as delayed growth, diarrhoea and an increased risk of inadequate water balance.

Two recent systematic reviews on the effects of the addition of oligosaccharides to IF and FOF comprised 12 RCTs (Mugambi et al., 2012) and 23 RCTs (Braegger et al., 2011).

The systematic review by the ESPGHAN Committee on Nutrition (Braegger et al., 2011) builds upon and updates two earlier systematic reviews on “prebiotic” supplementation of full-term infants (Rao et al., 2009) and on “prebiotics” in the prevention of allergic disease and food hypersensitivity (Osborn and Sinn, 2007) and included 23 publications of RCTs performed in healthy term infants with durations between two weeks and six months. The “prebiotics” were added to IF, and in two studies to FOF. In most studies, a 9:1 mixture of short-chain GOS and long-chain FOS was used (Moro et al., 2002; Moro et al., 2003; Bakker-Zierikzee et al., 2005; Decsi et al., 2005; Haarman and Knol, 2005; Knol et al., 2005; Bakker-Zierikzee et al., 2006; Moro et al., 2006; Alliet et al., 2007; Costalos et al., 2008; Magne et al., 2008; Scholtens et al., 2008), four studies used GOS alone (Ben et al., 2004b; Bakker-Zierikzee et al., 2005; Bettler and Euler, 2006; Ben et al., 2008), and one each AOS (Fanaro et al., 2005), GOS/FOS/AOS together (Fanaro et al., 2005), FOS plus inulin (Brunser et al., 2006) and polydextrose plus GOS (with or without lactulose) (Ziegler et al., 2007; Nakamura et al., 2009). The concentration in the formula ranged from 0.15 to 0.8 g/100 mL.

The review by Braegger et al. (2011) considered all studies included in the review by Mugambi et al. (2012) except for the studies by Bruzzese et al. (2009) and Moro et al. (2005). Therefore, the Panel has taken the review by Braegger et al. (2011) as a basis for the evaluation of data but has also considered the studies by Bruzzese et al. (2009) and Moro et al. (2005), both of which used GOS/FOS. The Panel is aware of a recent study which investigated the effect of the addition of a 50:50 mixture of FOS and long-chain inulin to an IF (Closa-Monasterolo et al., 2013). Three additional studies conducted in term
infants were identified during the public consultation of the draft opinion. In the studies by Ashley et al. (2012) and Scalabrin et al. (2012), the addition of a 50:50 mixture of polydextrose and GOS to IF was investigated, and in the study by Veereman-Wauters et al. (2011) a GOS/FOS mixture was evaluated. The studies by Ashley et al. (2012) and by Veereman-Wauters et al. (2011) also assessed the addition of GOS alone to IF.

Some of the studies reviewed assessed the effect of different oligosaccharides on the reduction of stool pH, SCFA production or the number of bifidobacteria or lactobacilli in stools. Although some of the studies reported significant effects on these outcomes for some of the oligosaccharides used, the relevance of these effects for infant health is unclear. None of the studies which investigated the effects on numbers of potentially pathogenic microorganisms in stools reported significant effects on this outcome (GOS/FOS: five studies (Moro et al., 2002; Moro et al., 2003; Ben et al., 2004b; Decsi et al., 2005; Alliet et al., 2007; Costalos et al., 2008); GOS/FOS/AOS: one study (Fanaro et al., 2005)).

The studies which examined the impact of supplementing formula with GOS/FOS (three studies) (Moro et al., 2002; Moro et al., 2003; Moro et al., 2006; Costalos et al., 2008) or with a mixture of FOS and long-chain inulin (Closa-Monasterolo et al., 2013) on stool frequency reported statistically significant effects on stool frequency in infants, whereas the study by Veereman-Wauters et al. (2011), which used GOS/FOS and GOS alone, the study by Brunser et al. (2006), which used a combination of FOS and inulin, and the studies by Ashley et al. (2012) and Scalabrin et al. (2012), which used a polydextrose-GOS mixture and GOS alone, did not. The Panel notes that all these studies had considerable methodological limitations which severely hamper the conclusions which can be drawn from them.

The effect of GOS/FOS on stool consistency was examined in five studies. Four of these studies reported statistically significant effects on this outcome (Moro et al., 2002; Moro et al., 2003; Moro et al., 2006; Costalos et al., 2008; Veereman-Wauters et al., 2011), while one did not (Knol et al., 2005). The studies which used a combination of GOS/FOS/AOS (Fanaro et al., 2005), polydextrose plus GOS (Ziegler et al., 2007; Ashley et al., 2012; Scalabrin et al., 2012) or a mixture of FOS and long-chain inulin (Closa-Monasterolo et al., 2013) and a study in which GOS alone was used (Veereman-Wauters et al., 2011) reported effects on stool consistency, but not the study by Brunser et al. (2006), which also used a combination of FOS and inulin, and also not a study which used GOS alone (Ashley et al., 2012). The Panel notes that all these studies had considerable methodological limitations which severely hamper the conclusions which can be drawn from them.

The effect of oligosaccharides on the incidence of infections has been studied for GOS/FOS in two studies (one reported in three publications) (Moro et al., 2006; Arslanoglu et al., 2007; Arslanoglu et al., 2008; Bruzzese et al., 2009) and for a combination of FOS and inulin in one study (Brunser et al., 2006). For the administration of GOS/FOS, a statistically significantly reduced cumulative incidence of fever and of infectious episodes of the upper respiratory tract requiring antibiotic treatment was reported in one study (Arslanoglu et al., 2007; Arslanoglu et al., 2008), whilst there was no difference in the incidence of lower respiratory tract, gastrointestinal and urinary tract infections. In contrast, Bruzzese et al. (2009) did not report any effect of GOS/FOS on upper respiratory tract infections, but on gastrointestinal infections. For the administration of a combination of FOS and inulin (Brunser et al., 2006) there was no effect reported on the incidence of gastrointestinal infections. The Panel notes that the findings of these studies are inconsistent and that they had considerable methodological limitations which severely hamper the conclusions which can be drawn from them.

GOS/FOS have also been studied with respect to the occurrence of allergic manifestations. A reduced cumulative incidence of atopic dermatitis, of recurrent wheezing and of allergic urticaria was reported in one study (Arslanoglu et al., 2007; Arslanoglu et al., 2008). The Panel notes that this study had considerable methodological limitations which severely hamper the conclusions which can be drawn from it.
The Panel notes that most of the studies which investigated the effect of non-digestible oligosaccharide addition to formula had considerable limitations, including a high drop-out rate, lack of consideration of missing values, unclear sequence generation and unclear achievement of allocation concealment and/or blinding. All these limitations and the resulting uncertainties greatly limit the conclusions which can be drawn from these studies. None of the studies gave rise to concerns on any of the studied non-digestible oligosaccharides with respect to growth and adverse effects.

On the basis of the data available and in consideration of the modest quality of the available studies, the Panel considers that there is insufficient evidence for beneficial effects on infant health of the non-digestible oligosaccharides that have been tested to date in RCTs when added to IF or FOF.

5.4.6. Recommendations

5.4.6.1. Total carbohydrates

The minimum and maximum content of carbohydrates in IF and FOF can be calculated based on the residual energy in formulae that contain the permitted minimum and maximum amounts of protein and fat, and converting this energy into grams of carbohydrates (4 kcal/g). The corresponding calculations are given in Table 11.

Table 11: Calculation of total minimum and maximum carbohydrate content in IF and FOF

<table>
<thead>
<tr>
<th>Proposed amounts</th>
<th>IF and FOF with Milk protein</th>
<th>IF and FOF with ISP and hydrolysed protein</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Min</td>
<td>Max</td>
</tr>
<tr>
<td>Protein (g/100 kcal)</td>
<td>1.8</td>
<td>2.5</td>
</tr>
<tr>
<td>Protein (E %)</td>
<td>7.2</td>
<td>10</td>
</tr>
<tr>
<td>Fat (g/100 kcal)</td>
<td>4.4</td>
<td>6.0</td>
</tr>
<tr>
<td>Fat (E %)</td>
<td>39.6</td>
<td>54</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Corresponding calculated amounts</th>
<th>Max</th>
<th>Min</th>
<th>Max</th>
<th>Min</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbohydrates (E %) (a)</td>
<td>53.2</td>
<td>36</td>
<td>51.4</td>
<td>34.8</td>
</tr>
<tr>
<td>Carbohydrates (g/100 kcal)</td>
<td>13.3</td>
<td>9</td>
<td>12.85</td>
<td>8.7</td>
</tr>
</tbody>
</table>

(a): Calculated as: 100 – E % protein – E % fat.

Rounding up, the Panel proposes a minimum carbohydrate content in IF and FOF of 9 g/100 kcal (2.2 g/100 kJ) and a maximum content of 14 g/100 kcal (3.3 g/100 kJ) for all types of formulae.

The Panel considers that only carbohydrates free of gluten should be used in IF and FOF.

5.4.6.2. Glycaemic carbohydrates

Lactose

The Panel considers that lactose should be the preferred carbohydrate in IF and FOF. In line with the opinion of the SCF (2003b), the Panel proposes a minimum content of lactose in IF and FOF based on milk protein and in IF and FOF containing hydrolysed protein of 4.5 g/100 kcal (1.1 g/100 kJ), unless the formulae are intended to be labelled as “lactose free”. In this case, IF and FOF should comply with the existing criterion of a “lactose-free” formula and provide at most 0.01 g/100 kcal (0.0024 g/100 kJ) lactose.

The Panel notes that the minimum lactose content has its origin in the traditional practice of diluting cow’s milk to make it more suitable for infant feeding with respect to protein. IF and FOF containing ISP were traditionally manufactured without lactose, which made such formulae suitable for feeding infants who could not metabolise lactose.
Sucrose, glucose and fructose

The Panel considers that sucrose, glucose and fructose, irrespective of their sources, should not be added to IF, as sucrose and fructose do not have any advantage over lactose for healthy infants, but may pose a risk to infants with fructose intolerance and saccharase deficiency and as the addition of glucose may increase the osmolality of the formula. For FOF, the use of sucrose and fructose can be tolerated since an infant will receive both from complementary foods. The sum of sucrose, fructose and sugars from honey in FOF should not constitute more than 20 % of total carbohydrates. Honey should be treated in order to destroy spores of \textit{C. botulinum}.

However, for gustatory reasons, sucrose and glucose are currently permitted to be added to IF containing protein hydrolysates and glucose is currently permitted to be added to FOF containing protein hydrolysates in order to mask the bitter taste of these formulae. The maximum concentrations which may currently be added are \( \leq 20 \% \) of total carbohydrates for sucrose and \( \leq 2 \text{ g/100 kcal} \) (\( \leq 0.5 \text{ g/100 kJ} \)) for glucose. The Panel proposes to retain these values.

Maltose and maltodextrins

In line with the opinion of the SCF (2003b), the Panel does not consider it necessary to propose any minimum and maximum amounts for maltose and maltodextrins in IF and FOF, as long as the maximum content of carbohydrates in IF and FOF is not exceeded.

Starches

Based on the evidence described in section 5.4.5.2.3 and assuming that infants can tolerate starch in amounts of around 5.5 g/kg body weight per day and that average body weight at birth is 3.25 kg (WHO Multicentre Growth Reference Study Group, 2006), this would translate into a daily starch intake of 18 g/day which could theoretically be tolerated by newborns. However, lower tolerances have also been reported. Assuming an average formula consumption of 500 kcal/day, a daily starch intake of 18 g/day would be equivalent to a starch content in formula of 2.2-2.5 g/100 mL. The Panel notes that this calculated theoretical value is not much higher than the maximum content of starch which was proposed by the SCF (2003b) (i.e. 2 g/100 mL). The Panel also notes that there are considerable uncertainties about the amount of starch which can be tolerated by newborns and that no adverse effects from current amounts of starch in IF have been reported.

Therefore, the Panel proposes, in line with the SCF (2003b), that starches should not be added in concentrations higher than 2 g/100 mL (2.9-3.3 g/100 kcal (0.7-0.8 g/100 kJ)) and that they should not constitute more than 30 % of total carbohydrates. For FOF, no restrictions need to apply. The Panel agrees with the SCF (2003b) that only pre-cooked and gelatinised starches free of gluten are suitable for use in IF and FOF.

5.4.6.3. Non-digestible (non-glycaemic) carbohydrates

In the absence of convincing evidence of any beneficial effects of non-digestible oligosaccharides on infant health, the Panel considers that there is no necessity to add non-digestible oligosaccharides to IF or FOF. The Panel considers that there is no evidence to change the previous conclusions of the SCF (2001d) that a mixture of 90 % GOS and 10 % of high-molecular-weight FOS is safe under the current conditions of use (i.e. \( \leq 0.8 \text{ g/100 mL} \)) in IF and FOF. The safety of any other non-digestible oligosaccharides or any new mixture of non-digestible oligosaccharides in IF and FOF should be established by clinical evaluation.

Table 12 summarises the conclusions of the Panel regarding the composition of IF and FOF with respect to glycaemic carbohydrates.
### Table 12: Proposed composition of IF and FOF with respect to glycaemic carbohydrates

<table>
<thead>
<tr>
<th>g/100 kcal</th>
<th>Milk protein</th>
<th>IF with ISP</th>
<th>Protein hydrolysates</th>
<th>Milk protein</th>
<th>FOF with ISP</th>
<th>Protein hydrolysates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbohydrates</td>
<td>9-14 (a)</td>
<td>≥ 4.5 (b,c)</td>
<td>≥ 4.5 (b,c)</td>
<td>9-14 (a)</td>
<td>≥ 4.5 (b,c)</td>
<td>≥ 4.5 (b,c)</td>
</tr>
<tr>
<td>of which</td>
<td></td>
<td>NR (d)</td>
<td></td>
<td></td>
<td>NR (d)</td>
<td></td>
</tr>
<tr>
<td>Lactose</td>
<td>≥ 4.5 (b,c)</td>
<td>NR (d)</td>
<td>≥ 4.5 (b,c)</td>
<td></td>
<td>NR (d)</td>
<td>≥ 4.5 (b,c)</td>
</tr>
<tr>
<td>Sucrose</td>
<td>Not to be added</td>
<td>≤ 20 % of total carbohydrates (e,f)</td>
<td></td>
<td></td>
<td>Sum of sucrose, fructose, sugar from honey ≤ 20 % of total carbohydrates (e)</td>
<td></td>
</tr>
<tr>
<td>Fructose</td>
<td>Not to be added</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose</td>
<td>Not to be added</td>
<td>≤ 2 (e,g)</td>
<td></td>
<td></td>
<td>≤ 2 (e,g)</td>
<td></td>
</tr>
<tr>
<td>Maltose, maltodextrins (e)</td>
<td>Unrestricted within specifications for total carbohydrates</td>
<td></td>
<td></td>
<td></td>
<td>Unrestricted within specifications for total carbohydrates</td>
<td></td>
</tr>
<tr>
<td>Starches (e)</td>
<td>≤ 2 g/100 mL carbohydrates (b)</td>
<td>≤ 30 % of total carbohydrates</td>
<td></td>
<td></td>
<td>Unrestricted within specifications for total carbohydrates as long as free of gluten</td>
<td></td>
</tr>
</tbody>
</table>

(a): 2.2-3.3 g/100 kcal.  
(b): Not applicable to formulae declared as “lactose-free”; in such case the lactose content should not exceed 0.01 g/100 kcal (0.0024 g/100 kJ).  
(c): 1.1 g/100 kcal.  
(d): Not required (NR) if more than 50 % of the protein content is from ISP.  
(e): Voluntary addition.  
(f): To mask the bitter taste.  
(g): 0.5 g/100 kJ.  
(h): Pre-cooked or gelatinised starch only, free of gluten.

## 6. Minimum content of micronutrients in IF and FOF

From a nutritional point of view, the minimum contents proposed by the Panel cover the nutritional needs of virtually all healthy infants born at term and there is no need to exceed these amounts in formulae, as nutrients which are not used or stored have to be excreted and this may put a burden on the infant’s metabolism and/or other physiological functions. Therefore, the Panel emphasises that the proposed minimum contents should be understood as target values for micronutrient contents of IF and FOF.

### 6.1. Calcium

#### 6.1.1. Current compositional requirements of IF and FOF

Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and maximum calcium contents in IF and FOF of 50 mg/100 kcal and 140 mg/100 kcal, respectively, with a calcium-to-available phosphorus ratio of between 1 and 2.

#### 6.1.2. Calcium content of human milk

Calcium in breast milk was found to be in the range of 200-300 mg/L (31-46/100 kcal) (Rodriguez Rodriguez et al., 2002; Hicks et al., 2012; Olausson et al., 2012). The ratio of calcium to phosphorus in human milk is about 2:1 on a weight basis or about 1.6:1 on a molar basis (Specker et al., 1991; Steichen and Koo, 1992).

#### 6.1.3. Calcium requirements of infants

In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a calcium intake of 200 mg/day and 400 mg/day was adequate for the majority of infants in the first half and in the second half of the first year of life, respectively.
6.1.4. Calcium intakes of infants

Assuming a human milk intake of 0.8 L/day and a calcium content of 250 mg/L, an exclusively breast-fed infant would consume 200 mg calcium per day during the first six months of life. Mean/median calcium intakes of mostly formula-fed infants below six months of age are reported to be around 370-560 mg/day (Hilbig, 2005; Noble and Emmett, 2006; Fantino and Gourmet, 2008; Lennox et al., 2013). Mean/median calcium intakes in infants aged 6 to < 12 months are in the range of 450-730 mg/day (Noble and Emmett, 2001; Hilbig, 2005; de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008; Marriott et al., 2008; Thorsdottir et al., 2008; Lennox et al., 2013).

6.1.5. Health consequences

Calcium is an integral component of the skeleton, in which it has a structural role, and is needed for bone rigidity, strength and elasticity. Calcium deficiency in children leads to inadequate growth and bone deformity. No UL for calcium was set for infants owing to insufficient data. The UL for adults of 2 500 mg per day is based on the absence of adverse effects in long-term human intervention studies in which 2 500 mg calcium per day was administered (EFSA NDA Panel, 2012b).

The concept of maintaining a certain calcium-to-phosphorus ratio in the diet has little relevance in adults but may have some utility under conditions of rapid growth. An absorbed calcium-to-phosphorus molar ratio of around 1.3:1 is assumed to be sufficient to support the sum of bony and soft tissue growth in infants (IoM, 1997). In order to derive an intake ratio, this value has to be corrected for the fractional absorption of calcium and phosphorus. Assuming an absorption efficiency of 60 % for calcium and of 80 % for phosphorus, the US Institute of Medicine has suggested a calcium-to-phosphorus molar intake ratio of 2:1 for infants. However, fractional absorption may vary with age and type of formula consumed and the ratio by itself is of limited value if the consumption of absolute quantities of both nutrients is insufficient to support adequate growth (IoM, 1997). The currently permitted lower calcium-to-phosphorus ratio of 1:1 reflects the calcium-to-phosphorus molar ratio of cow’s milk, which does not change if cow’s milk is diluted for the manufacturing of formula. There are no reports which indicate that the currently permitted calcium-to-phosphorus ratio together with the current minimum content of calcium and phosphorus in IF and FOF is insufficient to ensure adequate growth of infants.

6.1.6. Recommendations

Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as a basis the intake levels of calcium considered adequate by the Panel for this age group of 200 mg/day based on calcium intakes from breast milk, this would convert into a required minimum calcium intake of 40 mg/100 kcal.

The SCF (2003b) considered mean calcium absorption from cow’s milk to be around 20 percentage points lower than from human milk and therefore corrected the theoretical minimum level derived based on breast milk content by this factor, yielding a minimum calcium content of 50 mg/100 kcal. Calcium absorption efficiency was assumed to be about 58 % from human milk and about 38 % from milk-based IF during the first four months of life. More recent studies have reported calcium absorption efficiencies from IF based on milk protein and IF containing hydrolysed protein of around 60 % (Abrams, 2010; Hicks et al., 2012; Leite et al., 2013). One of these studies (Hicks et al., 2012) also assessed fractional calcium absorption from human milk and reported an absorption efficiency from breast milk of 76 %. No information on calcium absorption from formula containing ISP is available. However, there is no evidence that current amounts of calcium in formulae containing ISP would be insufficient for infants.

Considering the potential difference in absorption efficiency of calcium between human milk and formula, the Panel considers it prudent to maintain the recommendations of the SCF (2003b) with respect to the minimum calcium content in IF and FOF of 50 mg/100 kcal.
Therefore, the Panel proposes a minimum calcium content in IF and FOF of 50 mg/100 kcal (12 mg/100 kJ).

With respect to the molar ratio of calcium-to-available phosphorus (based on measured bioavailability, or calculated as 80% of total phosphorus in milk protein-based formulae or formulae containing protein hydrolysates and as 70% of total phosphorus in formulae containing ISP), the Panel proposes a calcium-to-available phosphorus molar ratio of not less than 1.0 and not greater than 2.0.

6.2. Phosphorus

6.2.1. Current compositional requirements of IF and FOF

Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and maximum phosphorus contents in IF and FOF based on milk protein and IF and FOF containing hydrolysed protein of 25 mg/100 kcal and 90 mg/100 kcal, respectively. For IF and FOF containing ISP, the minimum content should be 30 mg/100 kcal and the maximum 100 mg/100 kcal. The calcium-to-available phosphorus ratio should be between 1 and 2.

With respect to the determination of the amount of available phosphorus, the SCF (2003b) concluded that the amount of available phosphorus should be either measured or calculated as 80% of total phosphorus for milk protein or as 70% for ISP and that at least 20 mg/100 kcal and at most 70 mg/100 kcal of available phosphorus should be contained in the formula.

6.2.2. Phosphorus content of human milk

The reported phosphorus content of human milk has been reported to be in the range 107-164 mg/L (17-25 mg/100 kcal) (Fomon, 1993), peaking in early lactation and decreasing as lactation progresses (Fomon, 1993; Atkinson et al., 1995) with an average concentration of around 120 mg/L (19 mg/100 kcal) (Atkinson et al., 1995). Motil et al. (1997) reported average ± SD concentrations falling from 184 ± 16 mg/L (28 ± 2.4 mg/100 kcal) at six weeks of lactation to 155 ± 17 mg/L (24 ± 2.6 mg/100 kcal) at 24 weeks.

6.2.3. Phosphorus requirements of infants

In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a phosphorus intake of 100 mg/day and 300 mg/day was adequate for the majority of infants in the first half and in the second half of the first year of life, respectively.

6.2.4. Phosphorus intakes of infants

Assuming a human milk intake of 0.8 L/day and a phosphorus content of 120 mg/L, an exclusively breast-fed infant would consume around 100 mg phosphorus per day during the first six months of life. Mean/median phosphorus intakes of mostly formula-fed infants below six months of age are reported to be between around 210 mg/day and 330 mg/day (Hilbig, 2005; Fantino and Gourmet, 2008). Mean/median phosphorus intakes in infants aged 6 to < 12 months are in the range of around 360-700 mg/day (Hilbig, 2005; de Boer et al., 2006; Fantino and Gourmet, 2008; Thorsdottir et al., 2008).

6.2.5. Health consequences

Although phosphorus in the form of phosphate ions is essential for numerous body functions, its metabolism is intricately linked to that of calcium because of the actions of calcium-regulating hormones. Adequate phosphorus and calcium intakes are needed not only for skeletal growth and maintenance, but also for many cellular roles, such as energy production (i.e. adenosine triphosphate (ATP)). Too much phosphorus, in relation to too little dietary calcium, may contribute to bone loss, and too little phosphorus along with too little dietary calcium may not adequately maintain bone mass (Anderson, 2005). Data were insufficient to establish a UL for phosphorus (EFSA, 2005d).
6.2.6. Recommendations

Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as a basis the intake levels of phosphorus considered adequate by the Panel for this age group of 100 mg/day based on phosphorus intakes from breast milk, this converts into a required minimum intake of available phosphorus of 20 mg/100 kcal. Assuming that 80 % of total phosphorus from milk protein and 70 % from ISP is available, this translates into a minimum phosphorus content in IF and FOF based on milk protein of 25 mg/100 kcal and for IF and FOF containing ISP of 28.6 mg/100 kcal (rounded up to 30 mg/100 kcal).

Therefore, the Panel proposes a minimum phosphorus content in IF and FOF based on milk protein and IF and FOF containing protein hydrolysates of 25 mg/100 kcal (6.0 mg/100 kJ) and in IF and FOF containing ISP of 30 mg/100 kcal (7.2 mg/100 kJ).

The molar ratio of calcium-to-available phosphorus (based on measured bioavailability, or calculated as 80 % of total phosphorus in milk protein-based formulae or formulae containing protein hydrolysates and as 70 % of total phosphorus in formulae containing ISP) should be not less than 1.0 and not greater than 2.0.

6.3. Magnesium

6.3.1. Current compositional requirements of IF and FOF

Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and maximum magnesium contents in IF and FOF of 5 mg/100 kcal and 15 mg/100 kcal, respectively.

6.3.2. Magnesium content of human milk

Reported concentrations of magnesium in breast milk vary over a wide range (15-64 mg/L (2.3-9.8 mg/100 kcal)), with a median value of 31 mg/L (4.8 mg/100 kcal) and 75 % of reported mean concentrations below 35 mg/L (5.4 mg/100 kcal) (Dorea, 2000).

6.3.3. Magnesium requirements of infants

In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a magnesium intake of 25 mg/day and 80 mg/day was adequate for the majority of infants in the first half and in the second half of the first year of life, respectively.

6.3.4. Magnesium intakes of infants

Assuming a human milk intake of 0.8 L/day and a magnesium content of 31 mg/L, an exclusively breast-fed infant would consume 25 mg magnesium per day during the first six months of life. Mean/median magnesium intakes of mostly formula-fed infants below six months of age are reported to be between 43 and 70 mg/day (Hilbig, 2005; Fantino and Gourmet, 2008; Lennox et al., 2013). Mean/median magnesium intakes in infants aged 6 to < 12 months are in the range of around 75-140 mg/day (Hilbig, 2005; de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008; Marriott et al., 2008; Lennox et al., 2013).

6.3.5. Health consequences

Magnesium is the second most abundant intracellular cation after sodium and is a critical cofactor in several enzymatic reactions. Severe magnesium deficiency is rare and causes neuromuscular manifestations (Feillet-Coudray and Rayssiguier, 2005). No UL for magnesium normally present in foods could be established by the SCF. A UL related to readily dissociable forms of magnesium was set at 250 mg/day for children aged from four years upwards and adults (SCF, 2001a).
6.3.6. Recommendations

Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as a basis the intake levels of magnesium considered adequate by the Panel for this age group of 25 mg/day based on magnesium intakes from breast milk, this converts into a required minimum magnesium content in formula of 5 mg/100 kcal.

Therefore, the Panel proposes a minimum magnesium content in IF and FOF of 5 mg/100 kcal (1.2 mg/100 kJ).

6.4. Sodium

6.4.1. Current compositional requirements of IF and FOF

Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and maximum sodium contents in IF and FOF of 20 mg/100 kcal and 60 mg/100 kcal, respectively.

6.4.2. Sodium content of human milk

The average sodium concentration in human milk has been reported to be in the range of 140-160 mg/L (22-25 mg/100 kcal) (IoM, 2005b).

6.4.3. Sodium requirements of infants

In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a sodium intake of 120 mg/day was adequate for the majority of infants in the first half-year of life. The Panel also concluded that a sodium intake of 170-370 mg/day was adequate for the majority of infants from 6 to < 12 months of age.

6.4.4. Sodium intakes of infants

Assuming a human milk intake of 0.8 L/day and a sodium content of 150 mg/L, an exclusively breast-fed infant would consume 120 mg sodium per day during the first six months of life. Mean/median sodium intakes in mostly formula-fed infants from 0 to < 6 months of age have been reported to be in the range of around 180-240 mg/day (Fantino and Gourmet, 2008; Lennox et al., 2013) and in the second half of the first year of life are in the range 270-730 mg/day (DGE, 2008; Fantino and Gourmet, 2008; Marriott et al., 2008; Lennox et al., 2013).

6.4.5. Health consequences

Cell membrane potentials in cells throughout the body are controlled by the concentrations of sodium and potassium. The concentration gradients of sodium and potassium are tightly regulated as they provide the potential for neural transmission, muscle contraction and vascular tone as well as the drive for active transport of nutrients (e.g. glucose). Sodium deficiency arising from inadequate dietary intakes is unlikely because of the ubiquity of this element (SCF, 1993b). The major adverse effect of increased sodium chloride intake is elevated blood pressure. It has also been suggested that taste preferences later in life are influenced by salt intakes in early life (Stein et al., 2012). No UL for sodium could derived by the Panel owing to insufficient data (EFSA, 2005b).

6.4.6. Recommendations

Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as a basis the intake level of sodium considered adequate by the Panel for this age group of 120 mg/day based on sodium intakes from breast milk, this converts into a required minimum sodium content of formula of 24 mg/100 kcal (after rounding 25 mg/100 kcal).

Therefore, the Panel proposes a minimum sodium content in IF and FOF of 25 mg/100 kcal (6.0 mg/100 kJ).
6.5. Chloride

6.5.1. Current compositional requirements of IF and FOF

Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and maximum chloride contents in IF and FOF of 50 mg/100 kcal and 160 mg/100 kcal, respectively.

6.5.2. Chloride content of human milk

The average chloride content in human milk has been reported to be around 400 mg/L (IoM, 2005b).

6.5.3. Chloride requirements of infants

In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a chloride intake of 300 mg/day was adequate for the majority of infants in the first half-year of life. The Panel also concluded that a chloride intake of 270-570 mg/day was adequate for the majority of infants from 6 to < 12 months of age.

6.5.4. Chloride intakes of infants

Assuming a human milk intake of 0.8 L/day and a chloride content of 400 mg/L, an exclusively breast-fed infant would consume 320 mg chloride per day during the first six months of life. No information on chloride intakes in infants living in Europe is available.

6.5.5. Health consequences

Chloride is the most abundant anion in the extracellular fluid and counterbalances the intracellular negative charges provided by proteins. Chloride also plays a major role as a constituent of hydrochloric acid excreted in the gastric juice. Chloride deficiency arising from inadequate dietary intakes is unlikely because of the ubiquity of this element (SCF, 1993b). The major adverse effect of increased intake of chloride, as sodium chloride, is elevated blood pressure. No UL for chloride was derived by the Panel owing to insufficient data (EFSA, 2005a).

6.5.6. Recommendations

Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as a basis the intake level of chloride considered adequate by the Panel for this age group of 300 mg/day based on chloride intakes from breast milk, this converts into a minimum chloride content of formula of 60 mg/100 kcal.

Therefore, the Panel proposes a minimum chloride content in IF and FOF of 60 mg/100 kcal (14.3 mg/100 kJ).

6.6. Potassium

6.6.1. Current compositional requirements of IF and FOF

Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and maximum potassium contents in IF and FOF of 60 mg/100 kcal and 160 mg/100 kcal, respectively.

6.6.2. Potassium content of human milk

The average content of potassium in human milk has been reported to be around 500 mg/L (80 mg/100 kcal) (IoM, 2005b).

6.6.3. Potassium requirements of infants

In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a potassium
intake of 400 mg/day was adequate for the majority of infants in the first half-year of life. The Panel also concluded that a potassium intake of 800 mg/day was adequate for the majority of infants from 6 to < 12 months of age.

6.6.4. Potassium intakes of infants

Assuming a human milk intake of 0.8 L/day and a potassium content of 500 mg/L, an exclusively breast-fed infant would consume 400 mg potassium per day during the first six months of life. Mean/median potassium intakes of mostly formula-fed infants in the first half-year of life ranged from around 490 to 900 mg/day (Hilbig, 2005; Noble and Emmett, 2006; Lennox et al., 2013) and in the second half-year of life they ranged from around 1 000 to 1 400 mg/day (Noble and Emmett, 2001; Hilbig, 2005; DGE, 2008; Marriott et al., 2008; Lennox et al., 2013).

6.6.5. Health consequences

Cell membrane potentials in cells throughout the body are controlled by the concentrations of sodium and potassium. The concentration gradients of sodium and potassium are tightly regulated as they provide the potential for neural transmission, muscle contraction and vascular tone as well as the drive for active transport of nutrients (e.g. glucose). Potassium deficiency arising from inadequate dietary intakes is unlikely because of the ubiquity of the element (SCF, 1993b). No UL for potassium was derived by the Panel owing to insufficient data (EFSA, 2005e). Prolonged high potassium intake can lead to high concentrations of blood potassium that may affect cardiac function, especially in infants with impaired kidney function.

6.6.6. Recommendations

Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as a basis the intake level of potassium considered adequate by the Panel for this age group of 400 mg/day, based on potassium intakes from breast milk, this converts into a required minimum potassium content in formula of 80 mg/100 kcal.

Therefore, the Panel proposes a minimum potassium content in IF and FOF of 80 mg/100 kcal (19.1 mg/100 kJ).

6.7. Iron

6.7.1. Current compositional requirements of IF and FOF

Currently permitted minimum and maximum content of iron in IF and FOF compared with the recommendations by the SCF (2003b) are shown in Table 13.

Table 13: Currently permitted minimum and maximum content of iron in IF and FOF as laid down in Directive 2006/141/EC in comparison with the recommendations by the SCF (2003b)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>min</td>
<td>max</td>
<td>min</td>
<td>max</td>
</tr>
<tr>
<td>Cow’s milk</td>
<td>0.30</td>
<td>1.30</td>
<td>0.30</td>
<td>1.30</td>
</tr>
<tr>
<td>Goat’s milk</td>
<td>0.30</td>
<td>1.30</td>
<td>0.30</td>
<td>1.30</td>
</tr>
<tr>
<td>Protein hydrolysates</td>
<td>0.30</td>
<td>1.30</td>
<td>0.30</td>
<td>1.30</td>
</tr>
<tr>
<td>ISP</td>
<td>0.45</td>
<td>2.00</td>
<td>0.45</td>
<td>1.90</td>
</tr>
</tbody>
</table>

6.7.2. Iron content of human milk

The iron concentration in human milk is around 0.2-0.4 mg/L (0.03-0.06 mg/100 kcal). The average concentration given by the US Institute of Medicine is 0.35 mg/L (0.05 mg/100 kcal) (IoM, 2001). In
line with previous published values is a new analysis showing concentrations of iron in breast milk to be 0.28 mg/L (0.054 mg/100 kcal) (Concha et al., 2013). The absorption of iron from human milk is high. Absorption efficiencies up to 50% have been reported but have been observed to vary down to 25% with infant age and total dietary iron intake (Domellöf et al., 2002; Domellöf, 2007; Quinn, 2014).

6.7.3. Iron requirements of infants

Full-term infants have iron stores sufficient to cover their needs for a couple of months and, when exclusively breast fed, most healthy term infants need no extra iron up to six months of age (Domellöf et al., 2002; Domellöf, 2007, 2011; Jonsdottir et al., 2012).

Most of the body iron in healthy, term newborns is in haemoglobin and about one-quarter is in iron stores. Haemoglobin falls from an average of 170 g/L to about 120 g/L during the first six weeks of life and, as iron from erythrocytes is recycled, the size of the body’s iron stores grows. In the coming months iron is moved back from stores to red blood cells (Domellöf, 2007). Together with the intake of iron from breast milk or other foods, these iron stores serve as back-up for the growing infant for increasing blood volume and for meeting other needs. Exclusive breast-feeding during this period can meet the infant’s additional iron requirements despite the low concentration of iron in breast milk as iron absorption from breast milk is high, and the newborn’s iron needs are also supported through the iron stores at birth and the recycling.

The Panel considered in its opinion on nutrient requirements and dietary intakes of infants and young children in the European Union that observed mean iron intakes from breast milk of 0.3 mg/day are generally sufficient to ensure that iron status in the first half-year of life remains within the normal range for most healthy term infants in industrialised countries (Jonsdottir et al., 2012; EFSA NDA Panel, 2013a). This advice was based on an assumed iron content in breast milk of 0.35 mg/L assuming an average consumption of breast milk of 8.0 L/day, equal to around 500 kcal/day, leading to iron intakes of 0.28 mg/day (rounded up to 0.3 mg/day). With the absorption efficiency of iron in human milk taken as 50%, around 0.15 mg of iron per day is thus supplied to the body. This value would be lower if a lower absorption efficiency and a lower iron content of breast milk is assumed. Therefore, the estimate of 0.15 mg/day of absorbed iron could be considered a high estimate.

When iron is provided through formula, in which it is assumed to be less available than in breast milk, a daily iron intake of 0.3 mg can no longer be considered to be adequate for the majority of infants, and additional dietary iron needs to be provided in these formulae in order to ensure a sufficient iron supply to formula-fed infants. Assuming that, on average, 0.15 mg/day of iron has to be absorbed from formula in the first four to six months of life and that under a conservative assumption the absorption efficiency is around 10% (range 7-14%) (Quinn, 2014), an iron intake from formula of 1.5 mg/day in the first four to six months of life would ensure a sufficient iron supply to the infant.

For the second half-year of life, the Panel considered an iron intake of 8 mg/day adequate for the majority of infants (EFSA NDA Panel, 2013a).

6.7.4. Iron intakes of infants

Mean/median iron intakes of infants below six months of age are reported to be between 0.3 and 8 mg/day in mostly formula-fed infants (Hilbig, 2005; Noble and Emmett, 2006; Fantino and Gourmet, 2008; Lennox et al., 2013). Mean/median iron intakes in infants aged 6 to <12 months are in the range of around 4-10 mg/day (Noble and Emmett, 2001; Hilbig, 2005; de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008; Marriott et al., 2008; Thorsdottir et al., 2008; Lennox et al., 2013).

6.7.5. Health consequences

Iron has the biological ability to donate and accept an electron and change between two oxidation states, ferrous (Fe²⁺) and ferric (Fe³⁺) iron. Iron has many functions in the body, such as in the oxygen-
transporting haemoglobin and myoglobin and in the enzymes of many metabolic pathways in the liver, brain and endocrine organs. The growth and development of the central nervous system is rapid during early childhood, and iron is critical for this process. Iron deficiency and iron deficiency anaemia can have a serious impact on the health and later development of infants and children, i.e. alteration of the immune status, adverse effects on morbidity, delayed behavioural and mental development, below average school achievements and growth retardation, as well as adverse effects on cognition that may or may not be reversible with iron supplementation (Moffatt et al., 1994; Iannotti et al., 2006; Hermos et al., 2011). Even severe iron deficiency anaemia in infancy may pass unnoticed, as symptoms such as pallor, fatigue and developmental or behavioural disturbances are quite subtle.

Active excretion of iron in humans is minimal. An overload of iron in the body is a risk for those with hereditary haemochromatosis, a relatively common disorder, especially in Northern Europe, with a reported frequency of homozygosity for the C282Y mutation of around 0.7 % (Thorstensen et al., 2010), but overload may also occur in infants without this hereditary disease. Studies suggest that the absorption of iron cannot be down-regulated before the age of nine months (Domellöf and Hernell, 2002), with a risk of overload in those infants with sufficient iron stores but high iron intakes. Iron-replete infants might therefore be at risk of negative health consequences if given extra iron.

The evidence for risk and benefit of iron supplementation in infancy and young childhood in developing countries was reviewed by Iannotti et al. (2006). Iron doses were 10-50 mg/day. It was reported that 3 out of 10 studies showed a lower weight gain in the iron-fortified groups, and 4 out of 16 studies showed an increased incidence of infections. The authors concluded that supplementation may need to be targeted to iron-deficient children. A study on infants in Sweden and Honduras observed negative growth consequences associated with higher iron intakes (supplementation at 1 mg/kg body weight per day vs. no supplementation), although the effects were small, i.e. 0.2-0.6 cm difference in length gain in both Honduras and Sweden between the ages of four and nine months and, in Swedish infants, there was a difference in weight gain of 100-200 g and in head circumference of 0.2-0.3 cm over the five-month period (Dewey et al., 2002). In this study, there was an increased likelihood of diarrhoea in a sub-group of infants with adequate iron status. In a follow-up of the study by Walter et al. (1998) at 10 years of age (Lozoff et al., 2012), scores on tests for spatial memory and visual motor integration, but not on tests for IQ, visual perception, motor coordination and arithmetic achievement, were statistically significantly lower in the group who had received high-iron formula (1.95 mg/100 kcal). Effects were generally small. Among a sub-group of children with the highest haemoglobin concentrations at six months of age, scores on all tests (i.e. IQ, spatial memory, visual motor integration, visual perception, motor coordination and arithmetic achievement) were statistically significantly lower in the children who had been fed the high-iron formula. The drop-out rate between infancy and the age of 10 years was over 40 %. Other studies which investigated FOF with the currently permitted maximum concentrations of iron (i.e. 2 mg/100 kcal (12-14 mg/L)) (Fuchs et al., 1993; Stevens and Nelson, 1995; Daly et al., 1996; Gill et al., 1997; Morley et al., 1999; Williams et al., 1999) did not find any adverse effects at the levels of iron intake provided by these formulae.

The Panel notes that even though some data suggest that iron supplementation in iron-replete infants may lead to impaired growth and development and an increased risk of infections, the evidence is limited and does not allow conclusions to be drawn for the establishment of maximum iron content in IF and FOF.

In a recent review of the evidence, the ESPGHAN Committee on Nutrition (Domellöf et al., 2014) considered that formula-fed infants should receive a formula with a minimum iron content of 4 mg/L (around 0.6 mg/100 kcal) based on current fortification practices, but acknowledged that based on theoretical considerations a minimum level of iron of 2 mg/L (around 0.3 mg/100 kcal) would be sufficient. Some RCTs have investigated the impact of feeding formulae of varying iron concentrations to infants before the age of six months. Three trials performed in the United Kingdom, Sweden and Canada (Moffatt et al., 1994; Hernell and Lönnberd, 2002; Tuthill et al., 2002) investigated the impact of feeding IF with iron concentrations at or below currently required minimum iron concentrations in IF (i.e. 1.8-2.1 mg/L (around 0.3 mg/100 kcal)) on iron status in infants below
six months of age. The studies by Tuthill et al. (2002) and by Hernell and Lönnerdal (2002), which investigated the effect on iron status of IF with iron concentrations of < 1 vs. 5 mg/L (around < 0.2 vs. 0.8 mg/100 kcal) (Tuthill et al. 2002) and 2 vs. 4 mg/L (around 0.3 vs. 0.6 mg/100 kcal) (Hernell and Lönnerdal, 2002) did not find any differences in iron status at either three and six months of age. However, study formulae in the study by Tuthill et al. (2002) were consumed only in the first three months of life, which does not allow any conclusions to be drawn with respect to the effect of a formula with a similar iron content consumed for the entire period of six months. The study by Moffatt et al. (1994), which investigated the impact of a formula with an iron concentration of 1.1 vs. 12.8 mg/L (around 0.2 vs. 2 mg/100 kcal), found a statistically significant difference in iron status between the two formula groups. However, this study was conducted in a poor population with a high prevalence of anaemia which could not necessarily be considered representative of the current European infant population.

These data show that an IF providing iron at an amount of 0.3 mg/100 kcal (2 mg/L) is adequate to maintain iron status within the normal range within the first six months of life, and this conclusion is also supported by the theoretically calculated value of 1.5 mg/day based on iron concentrations in breast milk and differences in absorption efficiency.

One RCT (Walter et al., 1998) investigated the effect on iron status of FOF containing 2.3 mg/L (0.35 mg/100 kcal) iron (n = 405) compared with a formula providing 12.7 mg/L (1.95 mg/100 kcal) iron (n = 430), which were fed for six months to six-month-old infants who had been partially or exclusively breast fed. Iron status was assessed in infants at 12 months, and at 18 months of age in those infants who were not classified as anaemic at the 12-months’ follow-up. Iron deficiency was defined as two out of three measures of iron status in the abnormal range (serum ferritin < 12 µg/L, erythrocyte protoporphyrin > 100 µg/L red blood cells, or mean cell volume < 70 fl). At 12 months of age, 39% of infants were classified as iron deficient in the low-iron formula group, compared with 20% in the high-iron formula group (p < 0.001). At 18 months of age, this was 35% vs. 17% (p < 0.01). There was no significant difference in the prevalence of iron deficiency anaemia between groups at either time point.

The Panel notes that consumption of FOF containing 0.35 mg/100 kcal iron led to a significantly lower iron status in infants older than six months of age than formula with higher iron content. However, the prevalence of iron deficiency was also high in the group consuming high-iron formula and there were no indications of long-term adverse effects on cognitive outcomes of consumption of a formula containing 0.35 mg/100 kcal iron during the second half of infancy. The Panel considers that in the absence of data investigating the impact of varying concentrations of iron, especially in the lower range of iron concentrations in FOF, no conclusions can be drawn from this study with respect to the nutritional adequacy of a FOF containing 0.35 mg/100 kcal iron and consumed throughout the second half of the first year of life.

FOF containing the lowest currently permitted concentrations of iron (0.6 mg/100 kcal) would provide around 2.3 mg iron per day, if an average formula consumption of 600 mL/day is assumed at this age (Fantino and Gourmet, 2008). Such concentrations require that complementary foods provide around 70% of the daily iron intake. In the survey by Lennox et al. (2013), conducted in the framework of the UK Rolling Programme, complementary foods contributed around 52% of the total daily iron intakes of infants between seven and nine months of age and 58% at 10-11 months of age, with median total iron intakes of 7.4 mg/day and 7.6 mg/day, respectively. In a study in US breast-fed infants, iron intakes from complementary foods at seven and nine months were reported to be 1.5 mg/day and 7.2 mg/day, respectively, in the group consuming meat and 7.2 mg/day and 8.5 mg/day, respectively, in the group consuming iron fortified cereal (Krebs et al., 2006). Therefore, the Panel considers that, if a FOF with a minimum content of iron of 0.6 mg/100 kcal is consumed, it is reasonable to assume that complementary foods could provide the remaining iron, around 5.7 mg per day, necessary to reach daily iron intakes of 8 mg/day.
6.7.6. Recommendations

The physiological changes in iron metabolism during the first year of life are considerable. Until the age of six months, most infants need little dietary iron and endogenous iron compensates for low intakes.

Based on clinical data indicating that an IF providing iron at a level of 0.3 mg/100 kcal is adequate to maintain iron status within the normal range within the first four to six months of life, the Panel proposes a minimum iron content in IF of 0.3 mg/100 kcal (0.07 mg/100 kJ). This is supported by the theoretically calculated value based on iron concentrations in breast milk and assumed differences in absorption efficiency.

Based on the consideration that around 70% of daily iron (equivalent to 5.7 mg iron per day) could be supplied by complementary foods, a minimum content of iron in FOF of 0.6 mg/100 kcal is proposed, in line with the SCF (2003b).

There is no new evidence regarding the impact of different iron contents in IF and FOF containing ISP. Therefore, the Panel proposes to maintain the recommendations of the SCF (2003b) with respect to the minimum iron content in such formulae (i.e. 0.45 mg/100 kcal), taking into account a potentially lower absorption efficiency of iron from formulae containing ISP.

Therefore, the Panel proposes the minimum iron contents in IF and FOF given in Table 14.

Table 14: Proposed minimum content of iron in IF and FOF

<table>
<thead>
<tr>
<th></th>
<th>Minimum IF mg/100 kcal</th>
<th>Minimum IF mg/100 kJ</th>
<th>Minimum FOF mg/100 kcal</th>
<th>Minimum FOF mg/100 kJ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cow’s milk</td>
<td>0.30</td>
<td>0.07</td>
<td>0.60</td>
<td>0.14</td>
</tr>
<tr>
<td>Goat’s milk</td>
<td>0.30</td>
<td>0.07</td>
<td>0.60</td>
<td>0.14</td>
</tr>
<tr>
<td>Protein hydrolysates</td>
<td>0.30</td>
<td>0.07</td>
<td>0.60</td>
<td>0.14</td>
</tr>
<tr>
<td>ISP</td>
<td>0.45</td>
<td>0.11</td>
<td>0.90</td>
<td>0.22</td>
</tr>
</tbody>
</table>

If the same formula is to be used from the first months of infancy and be suitable for the whole first year of life, the minimum iron content should be 0.6 mg/100 kcal (0.14 mg/100 kJ) for milk-based formulae and formulae containing protein hydrolysates and 0.9 mg/100 kcal (0.22 mg/100 kJ) for formulae containing ISP.

6.8. Zinc

6.8.1. Current compositional requirements of IF and FOF

Directive 2006/141/EC provides for minimum and maximum zinc contents in IF and FOF, irrespective of the protein source, of 0.5 mg/100 kcal and 1.5 mg/100 kcal, respectively. Contrary to the Directive, the SCF (2003b) recommended a higher zinc content in IF and FOF containing ISP, namely 0.75 mg/100 kcal and 2.4 mg/100 kcal for the minimum and maximum content, respectively.

6.8.2. Zinc content of human milk

A comprehensive review of breast milk zinc concentrations which covered 63 studies globally, including 12 from European countries (Brown KH et al., 2009), reported zinc concentrations (mean ± SD) of 4.11 ± 1.50 mg/L below 1 month (n = 74), 1.91 ± 0.53 mg/L at 1-2 months (n = 42), 0.98 ± 0.35 mg/L at 3-5 months (n = 24) and 0.77 ± 0.22 mg/L at 6–11 months (n = 24) post partum.

For the first four to six months of life, breast milk provides sufficient zinc for infants (Prasad, 2003).
6.8.3. Zinc requirements of infants

In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded on levels of zinc intakes which can be considered adequate. For the majority of breast-fed infants in the first half-year of life, an adequate zinc intake would be 2 mg/day, and for the majority of infants in the second half of the first year of life a zinc intake of 4 mg/day is considered adequate. In a more recent draft opinion on DRVs for zinc (EFSA NDA Panel, 2014a) released for public consultation, the Panel proposes a PRI for infants in the second half of the first year of life of 2.9 mg/day.

6.8.4. Zinc intakes of infants

Assuming a human milk intake of 0.8 L/day, with a zinc content of 4 mg/L at two weeks of life and of 1.5 mg/L at three months of life, an exclusively breast-fed infant would consume 3.2 mg zinc per day during the first month of life and 1.2 mg/day at around three months of life. Mean/median zinc intakes of mostly formula-fed infants below six months of age are reported to range from 2.1 to 4.7 mg/day (Hilbig, 2005; Noble and Emmett, 2006; Fantino and Gourmet, 2008; Lennox et al., 2013), with the two studies which investigated zinc intakes from only formula-fed infants reporting intakes of around 4 mg/day. For infants aged 6 to < 12 months, zinc intakes were observed to be in the range 3.1-6.7 mg/day (Noble and Emmett, 2001; Hilbig, 2005; de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008; Marriott et al., 2008; Thorsdottir et al., 2008; Lennox et al., 2013).

6.8.5. Health consequences

Zinc is involved in many aspects of cell metabolism, with several enzymes depending on zinc for catalytic activity. It plays a role in immune function, protein synthesis, wound healing, deoxyribonucleic acid (DNA) synthesis and cell division. The current understanding of zinc deficiency in humans, much of which is marginal zinc deficiency, is based on responses to zinc supplementation. Studies have shown that physical growth and cognitive performance improved following zinc supplementation in zinc-deficient children (Fischer Walker and Black, 2004). While signs of acute zinc intoxication are gastrointestinal disturbances, chronic zinc toxicity is associated with symptoms of copper deficiency. A UL for zinc of 7 mg/day for one- to three-year-old children was derived by the SCF (2002a).

6.8.6. Recommendations

The Panel’s previous opinion (EFSA NDA Panel, 2013a) provided advice only on the levels of zinc intake considered adequate for the majority of breast-fed infants (approx. 0.4 mg/100 kcal) but did not include formula-fed infants. Therefore, the conclusions on the minimum amount of zinc in IF cannot be based on the Panel’s previous considerations. Evidence supports the concept that zinc in formula can be less available than from human milk, which needs to be considered in the establishment of the minimum content of zinc in IF and FOF.

As there are no reports that zinc deficiency occurs in formula-fed infants at current levels of zinc intakes from formulae, the Panel proposes to maintain the minimum content of zinc in IF and FOF based on milk protein or IF and FOF containing protein hydrolysates proposed by the SCF (2003b).

As phytic acid has been shown to reduce zinc absorption efficiency (Lönnerdal et al., 1984; Davidsson et al., 1994; Davidsson et al., 2004), the Panel proposes to also retain the minimum content of zinc in IF and FOF containing ISP established by the SCF (2003b).

Therefore, the Panel proposes a minimum zinc content in IF and FOF based on milk protein or IF and FOF containing protein hydrolysates of 0.5 mg/100 kcal (0.12 mg/100 kJ). For IF and FOF containing ISP a minimum content of 0.75 mg/100 kcal (0.18 mg/100 kJ) is proposed.
6.9. **Copper**

6.9.1. **Current compositional requirements of IF and FOF**

Based on the opinion of SCF (2003b), Directive 2006/141/EC lays down a minimum content of copper in IF and FOF of 35 μg/100 kcal and maximum content of 100 μg/100 kcal.

6.9.2. **Copper in human milk**

Mean concentrations of copper in breast milk observed in Europe range from 329 to 390 μg/L (51-60 μg/100 kcal), with medians between 368 and 400 μg/L (57-62 μg/100 kcal) (Krachler et al., 1998; Rodriguez Rodriguez et al., 2002; Leotsinidis et al., 2005).

6.9.3. **Copper requirements of infants**

In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded on levels of copper intakes which were considered adequate for the majority of infants of 300 μg/day.

6.9.4. **Copper intakes of infants**

Assuming a human milk intake of 0.8 L/day and a copper content of 350 μg/L, an exclusively breast-fed infant would consume 280 μg copper per day during the first six months of life. Mean/median copper intakes of breast-fed and formula-fed infants below six months of age are 200-400 μg/day (Hilbig, 2005; Lennox et al., 2013). Median copper intakes of infants from 6 to < 12 months are 400-900 μg/day (Hilbig, 2005; Marriott et al., 2008; Lennox et al., 2013).

6.9.5. **Health consequences**

Copper is an essential nutrient and an indispensable cofactor of many proteins including enzymes involved in oxidative reactions, in the production of collagen and of pigment, in iron metabolism and in the function of the heart, brain and the immune system. Copper deficiency is rare in humans and occurs predominantly in premature and small-for-gestational-age infants fed cow’s milk formulae, patients with malnutrition and patients receiving total parenteral nutrition (TPN) devoid of copper or subjects consuming high-dose zinc supplements. Signs of severe copper deficiency include anaemia, leucopenia and neutropenia. Osteoporosis has also been observed (Turnlund, 2006). Copper excess is rare and results acutely in gastrointestinal symptoms and chronically in liver and kidney dysfunction. A UL for copper of 1 000 μg/day was derived by the SCF (2003a) for children aged one to three years.

6.9.6. **Recommendations**

Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as a basis the intake levels of copper considered adequate by the Panel for this age group of 300 μg/day based on copper intakes from breast milk, this converts into a required minimum copper content of formulae of 60 μg/100 kcal.

Therefore, the Panel proposes a minimum copper content in IF and FOF of 60 μg/100 kcal (14.3 μg/100 kJ).

6.10. **Selenium**

6.10.1. **Current compositional requirements of IF and FOF**

Directive 2006/141/EC provides for minimum and maximum selenium contents in IF and FOF of 1 μg/100 kcal and 9 μg/100 kcal, respectively, while the SCF (2003b) had recommended minimum and maximum contents of 3 μg/100 kcal and 9 μg/100 kcal, respectively.
6.10.2. Selenium content of human milk

A wide range of selenium concentrations in human milk have been observed, depending on the amount of selenium consumed by the mother from natural foods. Breast milk concentrations of selenium in Europe range from 3 to 84 µg/L (0.46-12.9 µg/100 kcal), with a mean (SD) value of 16.3 ± 4.7 µg/L (2.51 ± 0.72 µg/100 kcal) (Krachler et al., 1998; Zachara and Pilecki, 2000; Navarro-Blasco and Alvarez-Galindo, 2003; Özdemir et al., 2008).

6.10.3. Selenium requirements of infants

In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a selenium intake of 12.5 µg/day and 15 µg/day is adequate for the majority of infants in the first half and in the second half of the first year of life, respectively. This is in line with a more recent draft opinion of the Panel on DRVs for selenium (EFSA NDA Panel, 2014g) released for public consultation.

6.10.4. Selenium intakes of infants

Assuming a human milk intake of 0.8 L/day and a selenium content of 16 µg/L, an exclusively breast-fed infant would consume 12.8 µg selenium per day during the first six months of life. Mean selenium intakes in breast-fed and formula-fed infants in the first half-year of life were reported to be 15 µg/day in one study in the United Kingdom (Lennox et al., 2013). For infants in the second half-year of the first year of life, selenium intakes in the range 18-22 µg/day were reported in the Netherlands and the United Kingdom (de Boer et al., 2006; Lennox et al., 2013).

6.10.5. Health consequences

Selenocysteine is an indispensable constituent of 25 different selenoproteins. Most selenoproteins are involved in redox reactions, and three deiodinases convert thyroxine to triiodothyronine. Selenium deficiency, for example following long-term TPN, malabsorption syndromes or use of special diets containing insufficient selenium, leads to impaired muscle function and loss of pigment in hair and skin. Chronic selenium excess is characterised by hair loss and nail dystrophy, breath smelling of garlic, dermatitis and neurological and endocrinological symptoms (selenosis). The SCF (2000b) has set a UL for selenium of 60 µg per day for children aged one to three years.

6.10.6. Recommendations

Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as a basis the intake levels of selenium considered adequate by the Panel for this age group of 12.5 µg/day based on selenium intakes from breast milk, this converts into a required minimum selenium content in formula of 2.5 µg/100 kcal (rounding up to 3 µg/100 kcal)

Therefore, the Panel proposes a minimum selenium content in IF and FOF of 3 µg/100 kcal (0.72 µg/100 kcal).

6.11. Iodine

6.11.1. Current compositional requirements of IF and FOF

Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and maximum iodine contents in IF and FOF of 10 µg/100 kcal and 50 µg/100 kcal, respectively.

6.11.2. Iodine content of human milk

Average iodine concentrations of breast milk in Europe have been observed to be around 50-100 µg/L (8-15 µg/100 kcal) (Costeira et al., 2009; EFSA NDA Panel, 2014e).
6.11.3. Iodine requirements of infants

In its scientific opinion on the DRVs for iodine (EFSA NDA Panel, 2014e), the Panel proposed an AI of iodine of 70 µg/day for infants from 7-11 months of age. No AI was set for infants from birth to six months of age, during which period exclusive breast-feeding is assumed to provide an adequate iodine supply. In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that an iodine intake of 90 µg/day is adequate for the majority of infants. Since there is no reason to assume that infants from birth to six months of age need more iodine than infants in the second half of the first year of life, the Panel considers, in line with its most recent evaluation (EFSA NDA Panel, 2014e), that an intake of iodine of 70 µg/day is adequate for the majority of infants from birth to 12 months of age.

6.11.4. Iodine intakes of infants

Assuming a human milk intake of 0.8 L/day and an iodine content of 50-100 µg/L, an exclusively breast-fed infant would consume 40-80 µg iodine per day during the first six months of life. Mean/median iodine intakes in breast-fed and formula-fed infants below six months of age were reported to range from around 35 to 94 µg/day in Germany and the United Kingdom (Hilbig, 2005; Noble and Emmett, 2006; Lennox et al., 2013). In infants from 6 to < 12 months, mean/median iodine intakes were between 42 and 118 µg/day in Germany and the UK (Noble and Emmett, 2001; Hilbig, 2005; DGE, 2008; Lennox et al., 2013).

6.11.5. Health consequences

The most critical physiological role for iodine is the normal functioning of the thyroid gland. Iodine deficiency disorders (IDDs) are caused by insufficient iodine intake leading to hypothyroidism. IDDs are particularly of concern in pregnancy and infancy because of the risk of developmental brain damage. Chronic iodine deficiency may also lead to compensatory thyroid hyperplasia with goitre. Chronic excessive iodine intake can also lead to goitre. A UL for iodine was set at 200 µg/day for children aged one to three years based on biochemical changes in thyroid-stimulating hormone levels (SCF, 2002d).

6.11.6. Recommendations

Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as the basis the intake levels of iodine considered adequate by the Panel for this age group of 70 µg/day based on iodine intakes from breast milk, this converts into a required minimum iodine content of formula of 14 µg/100 kcal (rounded up to 15 µg/100 kcal).

Therefore, the Panel proposes a minimum iodine content in IF and FOF of 15 µg/100 kcal (3.6 µg/100 kJ).

6.12. Chromium

6.12.1. Current compositional requirement of IF and FOF

The SCF (2003b) concluded that there were no biological or nutritional data to use to define minimum and maximum contents of chromium in IF and FOF. No minimum and maximum chromium contents in IF and FOF are specified by Directive 2006/141/EC.

6.12.2. Chromium content of human milk

In Europe, mean concentrations of chromium in mature breast milk are highly variable, ranging from 0.19 to 10.8 µg/L (0.03-1.7 µg/100 kcal) (Kumpulainen and Vuori, 1980; Kumpulainen et al., 1980; Clemente et al., 1982; Deelstra et al., 1988; Bougle et al., 1992; Cocho et al., 1992; Aquilio et al., 1996; Wappelhorst et al., 2002).
6.12.3. Chromium requirements of infants
No AR and no PRI for chromium for the performance of physiological functions can be defined.

6.12.4. Health consequences
The case for the essentiality of dietary Cr³⁺ for humans was uncertain when the SCF considered the element 20 years ago (SCF, 1993b); then, as now, the postulation of its essentiality was almost entirely based on case reports of patients on long-term TPN who developed metabolic and neurological defects which responded to Cr³⁺. The Panel considers that there is as yet no convincing evidence that chromium is an essential nutrient, because no specific physiological changes due to experimental chromium deficiency have been identified. No AR for the performance of essential physiological functions can be defined. Owing to limited data, the SCF (2003d) was unable to set a UL. It was stated that in a number of limited studies there was no evidence of adverse effects in adults associated with supplementary intake of chromium up to a dose of 1 mg/day. A Tolerable Daily Intake (TDI) for Cr³⁺ of 0.3 mg/kg body weight per day was derived by the EFSA CONTAM Panel (2014).

6.12.5. Recommendations
Because of the unproven essentiality of chromium together with the fact that no specific physiological function can be ascribed to chromium, the Panel considers that there is no necessity to add chromium to IF and FOF.

6.13. Molybdenum

6.13.1. Current compositional requirements of IF and FOF
The SCF (2003b) concluded that there were no biological or nutritional data to use to define minimum and maximum contents of molybdenum in IF and FOF. No minimum and maximum molybdenum contents in IF and FOF are specified by Directive 2006/141/EC.

6.13.2. Molybdenum content of human milk
Mean molybdenum concentrations in human milk were reported to range between 0.72 µg/L and 4 µg/L (0.11-0.62 µg/100 kcal), with a mean of around 2.5 µg/L (0.38 µg/100 kcal) (EFSA NDA Panel, 2013c).

6.13.3. Molybdenum requirements of infants
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a molybdenum intake of 2 µg/day and 10 µg/day was adequate for the majority of infants in the first half and in the second half of the first year of life, respectively.

6.13.4. Molybdenum intakes of infants
Assuming a human milk intake of 0.8 L/day and a molybdenum content of 2.5 µg/L, an exclusively breast-fed infant would consume 2 µg molybdenum per day during the first six months of life. No data on molybdenum intakes in infants in the first year of life living in Europe are available.

6.13.5. Health consequences
In humans, sulphite oxidase, xanthine oxidoreductase, aldehyde oxidase and mitochondrial amidoxime reducing component require molybdenum linked with a pterin (molybdopterin) as cofactor. Only one human case of likely dietary molybdenum deficiency has been reported in an adult patient on TPN because of short-bowel syndrome (Abumrad et al., 1981). A UL for molybdenum for children one to three years old was set at 100 µg/day (SCF, 2000c). This UL was extrapolated from the UL for adults (600 µg/day), which was based on reproductive toxicity and adverse effects on growth in rats.
6.13.6. Recommendations
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as the basis the intake levels of molybdenum considered adequate by the Panel for this age group of 2 µg/day based on molybdenum intakes from breast milk, this converts into a required minimum molybdenum content of formulae of 0.4 µg/100 kcal.

Therefore, the Panel proposes a minimum molybdenum content in IF and FOF of 0.4 µg/100 kcal (0.1 µg/100 kJ).

6.14. Manganese

Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and maximum manganese contents of 1 µg/100 kcal and 100 µg/100 kcal, respectively, in IF and FOF.

The mean manganese concentrations of human milk of European mothers vary from 3 to 30 µg/L (0.46-4.6 µg/100 kcal), but most values are around 4 µg/L (0.62 µg/100 kcal) (Mullee et al., 2012).

6.14.3. Manganese requirements of infants
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a manganese intake of 3 µg/day and 20-500 µg/day was adequate for the majority of infants in the first half and in the second half of the first year of life, respectively.

6.14.4. Manganese intakes of infants
Assuming an average milk intake of 0.8 L/day and a manganese content of 3-30 µg/L, an exclusively breast-fed infant would consume 2.4-24 µg manganese per day in the first six months of life. Median manganese intakes of infants have been reported only for German infants (Hilbig, 2005) and were 30 µg/day for breast-fed and formula-fed infants between birth and six months of age and 500 µg/day for infants from 6 to < 12 months of age.

6.14.5. Health consequences
Manganese is an essential dietary mineral for mammals; it is a component of metalloenzymes such as superoxide dismutase, arginase and pyruvate carboxylase, and is involved in amino acid, lipid and carbohydrate metabolism. In animals, glycosyltransferases and xylosyltransferases, which are involved in proteoglycan synthesis (e.g. for bone formation), are sensitive to manganese status (Nielsen, 1999). No specific manganese deficiency syndrome has been described in humans. The symptoms of manganese toxicity can result in a permanent neurological disorder known as manganism (ATSDR, 2012). Professional exposure by inhalation is the main cause of manganism but oral exposure to manganese, especially from contaminated water sources, can also cause adverse health effects, which are similar to those observed from inhalation exposure. No UL for manganese has been set (SCF, 2000a).

6.14.6. Recommendations
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as the basis the intake levels of manganese considered adequate by the Panel for this age group of 3 µg/day based on manganese intakes from breast milk, this would convert into a required minimum manganese content in IF and FOF of 0.6 µg/day. Taking into account that manganese from formula may be absorbed less than manganese from human milk, the Panel proposes to retain the minimum manganese content in IF and FOF of 1 µg/100 kcal as proposed by the SCF (2003b).
Therefore, the Panel proposes a minimum manganese content in IF and FOF of 1 µg/100 kcal (0.24 µg/100 kJ).

6.15. **Fluoride**

6.15.1. **Current compositional requirements of IF and FOF**

Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for a maximum fluoride content in IF and FOF of 100 µg/100 kcal.

6.15.2. **Fluoride content of human milk**

Fluoride concentrations in human milk vary from non-detectable to 100 µg/L (15.4 µg/100 kcal), with a trend for lower concentrations in regions with low fluoride concentrations in drinking water (≤ 0.3 mg/L) (EFSA NDA Panel, 2013b).

6.15.3. **AI of fluoride in infants**

Fluoride is not an essential nutrient. Nevertheless, the Panel considered in its opinion on DRVs for fluoride (EFSA NDA Panel, 2013b) that the setting of an AI was appropriate because of the beneficial effects of dietary fluoride on prevention of dental caries. For infants below six months of age, the Panel concluded in its previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a) that a fluoride intake of 0.08 mg/day is adequate for the majority of infants below six months of age. For infants between 6 and < 12 months, this AI was set at 0.4 mg/day (0.05 mg/kg body weight per day). The AI covers fluoride intake from all sources, including non-dietary sources.

6.15.4. **Fluoride intakes of infants**

Major fluoride food sources are water and water-based beverages or foods reconstituted with water, for example IF. The fluoride content of food is generally low. Breast-fed infants have a low fluoride intake. An intake of 0.8 L of human milk by an infant corresponds to a fluoride intake of 1.6-8 µg/day. No data on fluoride intakes in infants living in Europe are available.

6.15.5. **Health consequences**

Fluoride has a beneficial effect on tooth health by decreasing the risk of caries development. Dental fluorosis is an undesirable side-effect of excessive fluoride intake during critical periods of amelogenesis of both primary and secondary teeth. Chronic high intake of fluoride increases the risk of bone fractures and of the development of skeletal fluorosis in adults. Based on its effects on dental fluorosis, the UL for fluoride for children up to the age of eight years was set by the Panel (EFSA, 2005c) at 100 µg/kg body weight per day or at 1.5 mg/day for children aged one to three years.

6.15.6. **Recommendations**

Taking into account that fluoride is not an essential nutrient, the Panel considers that there is no necessity to add fluoride to IF and FOF. The fluoride content of ready-to-feed formulae will depend on the fluoride content of the water used for preparation. In this context, the Panel notes the importance of the quality of water, in relation to its fluoride content, used to reconstitute powdered formulae.

6.16. **Vitamin A**

6.16.1. **Current compositional requirements of IF and FOF**

Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and maximum vitamin A contents in IF and FOF of 60 µg retinol equivalents (RE)/100 kcal and 180 µg RE/100 kcal, respectively. Retinol sources authorised for use in IF and FOF are retinol and two forms of retinyl esters, i.e. retinyl palmitate and retinyl acetate. Carotenoids are not considered as a source of vitamin A in infants owing to a lack of knowledge on the bioconversion of carotenoids in infants.
6.16.2. Vitamin A content of human milk

Pre-formed vitamin A concentrations in human milk in Western countries were traditionally considered to be between 450 and 600 µg RE/L (69-92 µg RE/100 kcal), whereas considerably lower values were reported in two recent studies in Europe: 80 µg RE/L (12 µg RE/100 kcal) (Tijerina-Saenz et al., 2009) and 85 µg RE/L (13 µg RE/100 kcal) (Szlagatys-Sidorkiewicz et al., 2012).

6.16.3. Vitamin A requirements of infants

In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a vitamin A intake of 350 µg RE/day is adequate for the majority of infants. This was based on an assumed mean vitamin A content in breast milk of 450 µg/L and a daily intake of 0.8 L and rounding down.

6.16.4. Vitamin A intakes of infants

Assuming a human milk intake of 0.8 L/day and a pre-formed vitamin A content of 450 µg/L, an exclusively breast-fed infant would consume 360 µg of pre-formed vitamin A per day during the first six months of life. Mean/median vitamin A intakes of mostly formula-fed infants below six months of age are reported to range from around 510 to 980 µg RE/day (Hilbig, 2005; Noble and Emmett, 2006; Fantino and Gourmet, 2008; Lennox et al., 2013). For infants aged 6 to <12 months, mean/median total vitamin A intakes were observed to be in the range 530-1 090 µg RE/day (Noble and Emmett, 2001; Hilbig, 2005; de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008; Marriott et al., 2008; Thorsdottir et al., 2008; Lennox et al., 2013).

6.16.5. Health consequences

Vitamin A has several important functions, including a role in vision, maintenance of epithelial surfaces, immune competence, growth, development and reproduction (Nordic Council of Ministers, 2014). Deficiency of vitamin A leads to neonatal growth retardation and affects several functions such as vision, immunity and reproduction. The most specific clinical consequence of severe vitamin A deficiency is xerophthalmia and deficient dark adaptation (night blindness). The deficient dark adaptation due to inadequate vitamin A intake disappears after retinol or β-carotene supplementation (Chase et al., 1971; Sauberlich et al., 1974). In a systematic review and meta-analysis of studies on children living in Asia, Africa and Latin America aged six months to five years, vitamin A supplementation was associated with reductions in mortality, morbidity and vision problems (Mayo-Wilson et al., 2011). Vitamin A deficiency in healthy, exclusively breast-fed and formula-fed infants has not been observed in Europe. Children are particularly sensitive to vitamin A, with daily intakes of about 450 µg RE/kg body weight per day leading to toxicity (Bendich and Langseth, 1989; Hathcock et al., 1990; Coghlan and Cranswick, 2001; Allen and Haskell, 2002). Signs of chronic hypervitaminosis A in infants are reported as loss of appetite, dermal dryness, loss of hair, fissuring of the corners of the mouth, bone pain, hepatomegaly, increased intracranial pressure and failure to thrive (Fomon, 1993). A UL for pre-formed vitamin A (retinol and retinyl esters) for children one to three years of age of 800 µg RE/day has been set based on the risk of hepatotoxicity and teratogenicity and subsequent extrapolation to children (SCF, 2002b).

There is an interaction between iron and vitamin A. Vitamin A deficiency impairs iron mobilisation and vitamin A supplementation improves haemoglobin concentrations. Iron supplementation combined with vitamin A seems to be more effective than iron alone in increasing haemoglobin concentrations (Michelazzo et al., 2013). No consistent relationship between zinc and vitamin A status has been established in humans (Christian and West, 1998), although zinc supplementation improves dark adaptation in zinc-deficient patients (Morrison et al., 1978).

6.16.6. Recommendations

Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as a basis the intake levels of vitamin A considered adequate by the Panel for this age group of 350 µg...
RE/day based on pre-formed vitamin A intakes from breast milk, this converts into a required minimum vitamin A content of formula of 70 µg RE/100 kcal.

Therefore, the Panel proposes a minimum vitamin A content in IF and FOF of 70 µg RE/100 kcal (16.7 µg RE/100 kJ).

The vitamin A activity in IF and FOF should be provided by retinol or retinyl esters. In view of the existing uncertainties as to the relative equivalence of β-carotene and retinol in infants, any content of carotenes should not be included in the calculation and declaration of vitamin A activity.

6.17. Vitamin D

6.17.1. Current compositional requirements of IF and FOF

Based on the opinion of the SCF (2003b), Directive 2006/141/EC lays down 1 µg/100 kcal as the minimum and 2.5 µg/100 kcal as the maximum vitamin D content in IF and 1 µg/100 kcal as the minimum and 3 µg/100 kcal as the maximum vitamin D content in FOF.

6.17.2. Vitamin D content of human milk

The mean vitamin D content of breast milk in healthy women has been reported to be in the range 0.25-2.0 µg/L (0.04-0.31 µg/100 kcal) (Dawodu and Tsang, 2012). There is general agreement that human milk does not contain sufficient vitamin D to prevent rickets (Olafsdottir et al., 2001).

6.17.3. Vitamin D requirements of infants

In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a vitamin D intake of 10 µg/day is adequate for the majority of infants having minimal sun exposure. Vitamin D can also be synthesised in the skin under the influence of ultraviolet B light. Consequently, requirements of dietary vitamin D depend also on geographical area and lifestyle factors determining the exposure of skin to sunlight.

6.17.4. Vitamin D intakes of infants

Mean/median vitamin D intakes of formula-fed infants below six months of age are reported to be around 9-10 µg/day in formula-fed infants (Noble and Emmett, 2006; Fantino and Gourmet, 2008; Lennox et al., 2013) and 3.5 µg/day in breast-fed infants (Lennox et al., 2013). For infants aged 6 to < 12 months, mean/median vitamin D intakes were observed to be in the range 3.6-10.4 µg/day (Noble and Emmett, 2001; de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008; Marriott et al., 2008; Thorsdottir et al., 2008; Lennox et al., 2013). The Panel notes that, given that vitamin D can be synthesised endogenously, low vitamin D intakes do not necessarily lead to an inadequate vitamin D status.

6.17.5. Health consequences

Vitamin D plays a key role in calcium and phosphate metabolism and is essential for bone health. There is no evidence from interventional studies to support vitamin D supplementation for other health benefits (muscle strength, prevention of infectious or allergic diseases or T1DM) in infants and young children (Braegger et al., 2013). Early signs of vitamin D deficiency are subclinical and include decreased serum concentrations of calcium and phosphorus, while later signs comprise inadequate skeletal mineralisation (rickets and osteomalacia), bone deformities, bone pain, and alterations in muscle metabolism and respiratory function (SCF, 1993b). Reports of clinical manifestations of rickets in healthy infants have become few in Europe. In its recent consensus statement, the ESPGHAN Committee on Nutrition noted that reports on vitamin D intoxication are scarce and that there is no agreement on a vitamin D toxicity threshold (Braegger et al., 2013). However, a UL might be defined despite the lack of toxicity threshold data. Recent intervention studies using doses up to 25 µg vitamin D per day (plus the amount ingested via fortified IF) for up to five months after birth
did not indicate that these intakes were associated with hypercalcaemia in infants and a UL of 25 µg vitamin D per day has been established by the Panel (EFSA NDA Panel, 2012d).

6.17.6. Recommendations

Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as a basis the intake levels of vitamin D considered adequate by the Panel for this age group of 10 µg/day based on 25(OH)D vitamin serum concentrations, this converts into a minimum vitamin D content in formulae of 2 µg/100 kcal.

Therefore, the Panel proposes a minimum vitamin D content in IF and FOF of 2 µg/100 kcal (0.48 µg/100 kJ).

6.18. Vitamin E

6.18.1. Current compositional requirements of IF and FOF

Based on the opinion of the SCF (2003b), Directive 2006/141/EC lays down 0.5 mg α-tocopherol equivalents (TE)/g PUFA but not less than 0.5 mg TE/100 kcal as the minimum and 5 mg α-TE/100 kcal as the maximum vitamin E concentration in IF and FOF.

6.18.2. Vitamin E content of human milk

The α-tocopherol content in mature human milk has traditionally been taken as 3.5 mg α-tocopherol per litre (0.54 mg/100 kcal) (e.g. Jansson et al., 1981). A very similar value in three-month-old infants was reported in one recent study (3.5 mg α-tocopherol per litre (0.54 mg/100 kcal) (Antonakou et al., 2011), whereas different values have been reported in other studies, e.g. 2.3 mg α-tocopherol per litre (0.36 mg/100 kcal) (Tijerina-Saenz et al., 2009).

6.18.3. Vitamin E requirements of infants

In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a vitamin E intake of 3 mg α-tocopherol per day and 5 mg α-tocopherol per day was adequate for the majority of infants in the first and second half-year of life, respectively.

6.18.4. Vitamin E intakes of infants

Assuming a human milk intake of 0.8 L/day and a vitamin E content of 3.5 mg α-tocopherol/L, an exclusively breast-fed infant would consume 2.8 mg vitamin E per day during the first six months of life. Studies which have assessed nutrient intakes in infants have reported vitamin E intakes as TE only (including also tocopherols other than α-tocopherol as well as tocotrienols) and no information is available on intakes of α-tocopherol as such in this population group.

6.18.5. Health consequences

The major biological role of α-tocopherol is its antioxidant activity, contributing to the prevention of propagation of free radicals in various lipid structures within the organism. RRR-α-tocopherol is the principal isomer in animal tissues and, as this form is relatively unstable, more stable tocopherol esters are commonly used in the production of IF and FOF. These forms have a biological activity lower than that of RRR-α-tocopherol. Muscle and neurological problems can be a direct consequence of human vitamin E deficiency; however, they usually develop only in sick infants and young children (e.g. in those with fat malabsorption). Vitamin E appears to have very low toxicity, and amounts of 100-200 mg/day of synthetic α-tocopherols are consumed widely as supplements in adults without reported untoward effects. No adverse effects have been described from intakes provided by food sources (Nordic Council of Ministers, 2014). The SCF (2003c) did not set a UL for infants and children. For adults, a UL of 300 mg/day was derived.
6.18.6. Recommendations

Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as a basis the intake levels of vitamin E considered adequate by the Panel for this age group of 3 mg α-tocopherol per day based on vitamin E intakes from breast milk, this converts into a required minimum vitamin E content of formulae of 0.6 mg α-tocopherol/100 kcal as RRR-α-tocopherol.

Therefore, the Panel proposes a minimum vitamin E content in IF and FOF of 0.6 mg α-tocopherol/100 kcal (0.14 mg/100 kJ). This figure is based on vitamin E activity of RRR-α-tocopherol.

6.19. Vitamin K

6.19.1. Current compositional requirements of IF and FOF

Directive 2006/141/EC lays down 4 μg/100 kcal as the minimum and 25 μg/100 kcal as the maximum vitamin K content in IF and FOF, while the SCF (2003b) had proposed 4 μg/100 kcal as the minimum and 20 μg/100 kcal as the maximum content.

6.19.2. Vitamin K content of human milk

Mean vitamin K concentrations in human milk are around 2.5 μg/L (0.38 μg/100 kcal), but they vary considerably, from 0.85 to 9.2 μg/L (0.13-1.4 μg/100 kcal) (IoM, 2001).

6.19.3. Vitamin K requirements of infants

In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a vitamin K intake of 5 μg/day and 8.5 μg/day was adequate for the majority of infants in the first and second half-year of life respectively. These values were based on the guidance value proposed by the SCF (1993b) of 1 μg/kg body weight per day.

6.19.4. Vitamin K intakes of infants

Assuming a human milk intake of 0.8 L/day and a vitamin K content of 2.5 μg/L, an exclusively breast-fed infant would consume 2 μg vitamin K per day during the first six months of life. No information on vitamin K intakes in infants living in Europe is available.

6.19.5. Health consequences

Vitamin K is needed primarily for the synthesis of various factors and proteins involved in blood coagulation. No studies have been conducted following the post-natal period to assess any functional marker of vitamin K sufficiency or deficiency in infants and young children. The suggested associations between phylloquinone intakes and bone health or prevention of atherosclerosis are inconsistent (Nordic Council of Ministers, 2014). While low vitamin K stores at birth may predispose to haemorrhages in healthy neonates and young infants, later in life clinical consequences of vitamin K deficiency are seen almost exclusively in sick children. Natural vitamin K seems to be free of toxic side-effects. The SCF concluded in its opinion that there was no evidence of adverse effects associated with supplementary intakes of vitamin K in the form of phylloquinone of up to 10 mg/day for limited periods of time (SCF, 2003b).

6.19.6. Recommendations

Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as a basis the intake levels of vitamin K considered adequate by the Panel for this age group of 5 μg/day, this converts into a required minimum vitamin K content of formulae of 1 μg/100 kcal.

Therefore, the Panel proposes a minimum vitamin K content in IF and FOF of 1 μg/100 kcal (0.24 μg/100 kJ).
6.20. **Thiamin (vitamin B1)**

6.20.1. **Current compositional requirements of IF and FOF**

Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and maximum thiamin contents in IF and FOF of 60 µg/100 kcal and 300 µg/100 kcal, respectively.

6.20.2. **Thiamin content of human milk**

The average content of thiamin in human milk is 200 µg/L (31 µg/100 kcal) (IoM, 1998) with a range of 150-330 µg/L (23-51 µg/100 kcal) (SCF, 2003b).

6.20.3. **Thiamin requirements of infants**

The SCF (1993b) defined the AR and PRI for thiamin for all age groups to be 72 µg/MJ (30 µg/100 kcal) and 100 µg/MJ (42 µg/100 kcal), respectively. In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a thiamin intake of 200 µg/day and 300 µg/day was adequate for the majority of infants in the first half and in the second half of the first year of life, respectively.

6.20.4. **Thiamin intakes of infants**

Assuming a human milk intake of 0.8 L/day and a thiamin content of 200 µg/L, an exclusively breast-fed infant would consume 160 µg thiamin per day during the first six months of life. Mean/median thiamin intakes in mostly formula-fed infants from birth to six months are reported to range from around 150 to 700 µg/day (Hilbig, 2005; Noble and Emmett, 2006; Fantino and Gourmet, 2008; Lennox et al., 2013) and in infants from 6 to < 12 months from around 300 to 1000 µg/day (Noble and Emmett, 2001; Hilbig, 2005; de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008; Marriott et al., 2008; Thorsdottir et al., 2008; Lennox et al., 2013).

6.20.5. **Health consequences**

Thiamin in its phosphorylated forms is a coenzyme in the oxidative decarboxylation of 2-oxoacids, for example pyruvate, 2-oxoglutarate and branched-chain 2-oxoacids, and in the transketolase reaction among hexose and pentose phosphates. The rate of thiamin utilisation depends on carbohydrate intake and is related to energy intake. Thiamin deficiency as a consequence of dietary insufficiency has been shown to lead to growth restriction, recurrent infections and sudden infant death. Thiamin deficiency is rare in higher income countries but an outbreak of lactic acidosis and encephalopathy was reported in young infants who had received a formula unintentionally devoid of thiamin as the sole source of nutrition (Fattal-Valevski et al., 2005). There are no adverse effects known to be associated with excessive thiamin consumption. No UL for thiamin was set by the SCF (2001c).

6.20.6. **Recommendations**

Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as a basis the intake levels of thiamin considered adequate by the Panel for this age group of 200 µg/day based on thiamin intakes from breast milk, this converts into a required minimum thiamin content in formula of 40 µg/100 kcal.

Therefore, the Panel proposes a minimum thiamin content in IF and FOF of 40 µg/100 kcal (9.6 µg/100 KJ).


6.21.1. **Current compositional requirements of IF and FOF**

Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and maximum riboflavin contents in IF and FOF of 80 µg/100 kcal and 400 µg/100 kcal, respectively.
6.21.2. Riboflavin content of human milk

The average content of riboflavin in human milk is around 350-600 μg/L (54-92 μg/100 kcal) (Picciano, 1995; IoM, 1998).

6.21.3. Riboflavin requirements of infants

In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a riboflavin intake of 300 μg/day and 400 μg/day was adequate for the majority of infants in the first half and in the second half of the first year of life, respectively.

6.21.4. Riboflavin intakes of infants

Assuming a human milk intake of 0.8 L/day and a riboflavin content of 450 μg/L, an exclusively breast-fed infant would consume 360 μg riboflavin per day during the first six months of life. Mean/median riboflavin intakes in mostly formula-fed infants from birth to six months are reported to range from around 300 to 700 μg/day (Hilbig, 2005; Noble and Emmett, 2006; Fantino and Gourmet, 2008; Lennox et al., 2013) and in infants aged 6 to < 12 months from around 500 to 1 400 μg/day (Noble and Emmett, 2001; Hilbig, 2005; de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008; Marriott et al., 2008; Thorsdottir et al., 2008; Lennox et al., 2013).

6.21.5. Health consequences

Riboflavin is a precursor of two flavin coenzymes, flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). FMN and FAD have a role in many biochemical reactions, as components of enzymes that catalyse oxidation/reduction reactions in numerous metabolic pathways. They are required for lipid degradation, synthesis of steroids and glycogen and amino acid metabolism. Flavoenzymes are also involved in niacin synthesis from tryptophan, in the conversion of vitamin B6 into pyridoxal phosphate and in the production of methyl-tetrahydrofolate. There is an interaction with iron metabolism. Dietary riboflavin deficiency is rare. It leads to non-specific symptoms, particularly of mucosal tissues (cheilosis, glossitis, keratitis, gastrointestinal disturbances), and in a late stage to hypochromic anaemia. Excess riboflavin consumption has not been associated with adverse effects in humans. Therefore, no UL could be established by the SCF (2000e).

6.21.6. Recommendations

Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as a basis the intake levels of riboflavin considered adequate by the Panel for this age group of 300 μg/day based on riboflavin intakes from breast milk, this converts into a required minimum riboflavin content in formulae of 60 μg/100 kcal.

Therefore, the Panel proposes a minimum riboflavin content in IF and FOF of 60 μg/100 kcal (14.3 μg/100 kJ).

6.22. Niacin

6.22.1. Current compositional requirements of IF and FOF

Directive 2006/141/EC provides for minimum and maximum niacin contents in IF and FOF of 0.3 mg/100 kcal and 1.5 mg/100 kcal, respectively. The SCF (2003b) concluded in its opinion on minimum and maximum contents in IF and FOF of 0.3 mg/100 kcal and 1.2 mg/100 kcal, respectively.

6.22.2. Niacin content of human milk

The average content of niacin in mature human milk from European mothers has been reported to be in the range 1.8-2.2 mg/L (0.28-0.34 mg/100 kcal) (DHSS, 1977; Ford et al., 1983).
6.22.3. Niacin requirements of infants

Niacin requirements are given as niacin equivalents (NE), the sum of pre-formed niacin plus niacin produced from tryptophan (assuming that 60 mg tryptophan is equivalent to 1 mg NE); this definition is valid only when the diet contains both niacin and sufficient tryptophan. The niacin requirement is, moreover, dependent on the energy intake, with an AR and PRI for all age groups of 1.3 mg NE/MJ (0.55 mg NE/100 kcal) and 1.6 mg NE/MJ (0.67 mg NE/100 kcal), respectively.

In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a niacin intake of 2 mg NE/day and 5 mg NE/day was adequate for the majority of infants in the first half and in the second half of the first year of life, respectively. These values are in line with a more recent opinion on DRVs for niacin (EFSA NDA Panel, 2014f).

6.22.4. Niacin intakes of infants

Assuming a human milk intake of 0.8 L/day and a niacin content of 2 mg/L, an exclusively breast-fed infant would consume 1.6 mg niacin per day during the first six months of life. Mean/median niacin intakes in mostly formula-fed infants from birth to six months are reported to range from 4 to 10 mg NE/day (Hilbig, 2005; Noble and Emmett, 2006; Fantino and Gourmet, 2008; Lennox et al., 2013) and in infants aged 6 to < 12 months from 4.5 to 14 mg NE/day (Noble and Emmett, 2001; Hilbig, 2005; DGE, 2008; Fantino and Gourmet, 2008; Marriott et al., 2008; Thorsdottir et al., 2008; Lennox et al., 2013).

6.22.5. Health consequences

Niacin, that is both nicotinic acid and nicotinamide, is the precursor of the nicotinamide nucleotide coenzymes nicotine adenine dinucleotide (NAD) and nicotine adenine dinucleotide phosphate (NADP), which are crucial for many oxidation/reduction reactions and are associated with both catabolic and anabolic processes. Niacin can be provided in the diet and can be formed in the human body from its precursor amino acid, tryptophan. Long-term inadequate intake of niacin and tryptophan can lead to the development of pellagra. The profile of adverse effects after excessive intake of nicotinic acid and nicotinamide is different. For nicotinic acid, the main adverse effects are flushing and hepatotoxicity. For nicotinamide, no such adverse effects have been reported at intakes of several grams per day, except for hepatotoxicity in rare cases following consumption of slow-release preparations of nicotinamide. The ULs for children aged one to three years of nicotinic acid (2 mg/day) and nicotinamide (150 mg/day) have been derived from adult values on the basis of reference body weights (SCF, 2002c).

6.22.6. Recommendations

Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as a basis the intake levels of niacin considered adequate by the Panel for this age group of 2 mg/day based on niacin intakes from breast milk, this converts into a required minimum niacin content in formula of 0.4 mg/100 kcal.

Therefore, the Panel proposes a minimum niacin content in IF and FOF of 0.4 mg/100 kcal (0.10 mg/100 kJ). This is pre-formed niacin.

6.23. Pantothenic acid

6.23.1. Current compositional requirements of IF and FOF

Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and maximum pantothenic acid contents in IF and FOF of 0.4 mg/100 kcal and 2 mg/100 kcal, respectively.
6.23.2. Pantothenic acid content of human milk
The average content of pantothenic acid in human milk is reported to be around 2.5 mg/L (0.38 mg/100 kcal) (EFSA NDA Panel, 2014h).

6.23.3. Pantothenic acid requirements of infants
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a pantothenic acid intake of 2 mg/day and 3 mg/day was adequate for the majority of infants in the first half and in the second half of the first year of life, respectively. These values are in line with the more recent opinion of the Panel on DRVs for pantothenic acid (EFSA NDA Panel, 2014h).

6.23.4. Pantothenic acid intakes of infants
Assuming a human milk intake of 0.8 L/day and a pantothenic acid content of 2.5 mg/L, an exclusively breast-fed infant would consume 2 mg pantothenic acid per day during the first six months of life. No information on pantothenic acid intakes in infants living in Europe is available.

6.23.5. Health consequences
Pantothenic acid is required in the synthesis of coenzyme A (CoA) and acyl carrier proteins and thus has a central role in a wide variety of metabolic pathways. Pantothenic acid deficiency is rare because of the widespread nature of this nutrient. Deficiency occurs only in individuals on a diet free of pantothenic acid or given pantothenic acid antagonists (EFSA NDA Panel, 2013a). Pantothenic acid has a very low toxicity, and minor adverse gastrointestinal effects occur only at very high intake levels (10-20 g/day). The SCF estimated that no UL could be established for pantothenic acid (SCF, 2002e).

6.23.6. Recommendations
Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as the basis the intake levels of pantothenic acid considered adequate by the Panel for this age group of 2 mg/day based on pantothenic acid intakes from breast milk, this converts into a required minimum pantothenic acid content in formulae of 0.4 mg/100 kcal.

Therefore, the Panel proposes a minimum pantothenic acid content in IF and FOF of 0.4 mg/100 kcal (0.10 mg/100 kJ).

6.24. Vitamin B6

6.24.1. Current compositional requirements of IF and FOF
Directive 2006/141/EC provides for minimum and maximum vitamin B6 contents in IF and FOF of 35 µg/100 kcal and 175 µg/100 kcal. The SCF (2003b) concluded in its opinion on minimum and maximum contents in IF and FOF of 35 µg/100 kcal and 165 µg/100 kcal.

6.24.2. Vitamin B6 content of human milk
The content of vitamin B6 in breast milk varies greatly and is dependent on maternal intakes. The average concentration of vitamin B6 in milk of unsupplemented well-nourished mothers is 130 µg/L (20 µg/100 kcal), reflecting a maternal vitamin B6 intake of less than 2.5 mg/day (IoM, 1998). The pyridoxine content of human milk may be marginal for infants whose mothers’ vitamin B6 intake is low.

6.24.3. Vitamin B6 requirements of infants
In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a vitamin B6 intake of 100 µg/day and 400 µg/day was adequate for the majority of infants in the first half and in...
the second half of the first year of life, respectively. The dietary requirement for vitamin B6 varies in relation to the dietary consumption of protein (Hansen et al., 1996).

### 6.24.4. Vitamin B6 intakes of infants

Assuming a human milk intake of 0.8 L/day and a vitamin B6 content of 130 μg/L, an exclusively breast-fed infant would consume 104 μg vitamin B6 per day during the first six months of life. Mean/median vitamin B6 intakes in mostly formula-fed infants from birth to six months were reported to range from around 200-500 μg/day (Hilbig, 2005; Noble and Emmett, 2006; Fantino and Gourmet, 2008; Lennox et al., 2013) and in infants from 6 to < 12 months from around 400-1 150 μg/day (Noble and Emmett, 2001; Hilbig, 2005; de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008; Marriott et al., 2008; Thorsdottir et al., 2008; Lennox et al., 2013).

### 6.24.5. Health consequences

Pyridoxine and pyridoxal, found in plants and animal products, respectively, are converted to pyridoxal phosphate in tissues. Pyridoxal phosphate acts as a coenzyme in the metabolic transformation of amino acids, decarboxylation, transamination and racemisation, the metabolism of lipids and nucleic acids and in glycogen metabolism. Symptomatic dietary vitamin B6 deficiency was described in infants with pyridoxine-responsive convulsive seizures in the early 1950s, and was associated with hypochromic microcytic anaemia, vomiting, diarrhoea, failure to thrive, lethargy or hyper-irritability (Borschel, 1995). It was concluded that an intake below 50 μg/day can cause vitamin B6 deficiency whilst an intake of about 70 μg/day does not. Reversible acute neuropathy and encephalopathy were observed in an infant with infantile type I hyperoxaluria at age 10 weeks under treatment with megadoses of pyridoxine (1 000 mg/day); symptoms disappeared when the dose was reduced to 400 mg/day (de Zegher et al., 1985). The UL for vitamin B6 is based on neurotoxicity, which may occur in a mild form at doses of 100 mg/day in adults. By applying an uncertainty factor of 4, the UL of 25 mg for adults was derived. A UL for children aged one to three years of 5 mg/day has been set by extrapolation from adults (SCF, 2000g).

### 6.24.6. Recommendations

Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as a basis the intake levels of vitamin B6 considered adequate by the Panel for this age group of 100 μg/day based on vitamin B6 intakes from breast milk, this converts into a required minimum vitamin B6 content in formulae of 20 μg/100 kcal.

Therefore, the Panel proposes a minimum vitamin B6 content in IF and FOF of 20 μg/100 kcal (4.8 μg/100 kJ).

### 6.25. Biotin

#### 6.25.1. Current compositional requirements of IF and FOF

Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and maximum biotin contents in IF and FOF of 1.5 μg/100 kcal and 7.5 μg/100 kcal, respectively.

#### 6.25.2. Biotin content of human milk

The average content of biotin in human milk is around 5 μg/L (0.8 μg/100 kcal) (EFSA NDA Panel, 2014c).

#### 6.25.3. Biotin requirements of infants

In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a biotin intake of 4 μg/day and 6 μg/day was adequate for the majority of infants in the first half and in the second half.
of the first year of life, respectively. These values are in line with the more recent opinion of the Panel on DRVs for biotin (EFSA NDA Panel, 2014c).

6.25.4. Biotin intakes of infants

Assuming a human milk intake of 0.8 L/day and a biotin content of 5 µg/L, an exclusively breast-fed infant would consume 4 µg biotin per day during the first six months of life. No information on biotin intakes in infants from birth to six months living in Europe is available. For infants from 6 to < 12 months of age, data are available from one study only (DGE, 2008), which reported median biotin intakes of around 20-23 µg/day.

6.25.5. Health consequences

Biotin is a cofactor for the enzymes acetyl-CoA carboxylase, propionyl-CoA carboxylase, β-methylcrotonyl-CoA carboxylase and pyruvate carboxylase, which play critical roles in the synthesis of fatty acids, the catabolism of branched-chain amino acids and gluconeogenesis. Dietary biotin deficiency is rare and does not occur in breast-fed infants. It is characterised by fine, scaly dermatitis, hair loss, conjunctivitis, ataxia and delayed child development. Biotin deficiency has been observed in patients receiving long-term TPN without biotin supplementation and in patients with biotinidase deficiency, as well as in people who had consumed large amounts of raw eggs. The SCF estimated that no UL could be established for biotin (SCF, 2001b).

6.25.6. Recommendations

Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as a basis the intake levels of biotin considered adequate by the Panel for this age group of 4 µg/day based on biotin intakes from breast milk, this converts into a minimum biotin content in formulae of 0.8 µg/100 kcal (rounding up to 1 µg/100 kcal).

Therefore, the Panel proposes a minimum biotin content in IF and FOF of 1 µg/100 kcal (0.24 µg/100 kJ).

6.26. Folate

6.26.1. Current compositional requirements of IF and FOF

Directive 2006/141/EC provides for minimum and maximum folate contents in IF and FOF of 10 µg/100 kcal and 50 µg/100 kcal, respectively. In its opinion, the SCF (2003b) recommended minimum and maximum contents of folate in IF and FOF of 10 µg/100 kcal and 30 µg/100 kcal, respectively.

6.26.2. Folate content of human milk

The average content of folate in human milk was found to be around 80 µg/L (12.3 µg/100 kcal) (Lim et al., 1998; Mackey and Picciano, 1999; Kim et al., 2004; Khambalia et al., 2006; Houghton et al., 2009; West et al., 2012).

6.26.3. Folate requirements of infants

Because the absorption efficiency of folates varies depending on their chemical form, dietary folate equivalents (DFE) have been defined by IoM (1998) as 1 DFE = 1 µg food folate = 0.6 µg folic acid from fortified food or as a supplement consumed with food = 0.5 µg of a folic acid supplement taken on an empty stomach. In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a folate intake of 65 µg DFE/day and 80 µg DFE/day was adequate for the majority of infants in the first half and in the second half of the first year of life, respectively. This is in line with a more recent draft opinion of the Panel on DRVs for folate (EFSA NDA Panel, 2014b) released for public consultation.
6.26.4. Folate intakes of infants

Assuming a human milk intake of 0.8 L/day and a folate content of 80 µg/L, an exclusively breast-fed infant would consume 64 µg folate per day during the first six months of life. None of the surveys conducted in infants below six months of life reported folate intakes as DFE. For infants from 6 to < 12 months only, the German VELS study (Verzehrsstudie zur Ermittlung der Lebensmittelaufnahme von Säuglingen und Kleinkindern) (DGE, 2008) reported folate intakes as DFE. Median folate intakes in this study were 62 µg and 78 µg DFE per day in girls and boys, respectively.

6.26.5. Health consequences

Folate is essential for one-carbon transfer reactions, including those involved in glycine/serine and homocysteine/methionine interconversion, and in purine and pyrimidine synthesis. Folate deficiency impairs de novo DNA synthesis and consequently cellular replication. Folate deficiency has also been associated with irritability, forgetfulness, neuropathy and depression. Poor folate status in the periconceptual period increases the risk of neural tube defects. Folate deficiency has not been reported in breast-fed infants, even in the infants of mothers with low folate status. Excess dietary folate is mainly excreted in the urine. Consumption of high amounts of folic acid by subjects deficient in cobalamin increases the risk of neurological damage by masking the haematological manifestations of cobalamin deficiency. The SCF noted that, in nearly all studies showing neurological damage, the folic acid dose was ≥ 5 mg folic acid/day, which was taken to represent the Lowest Observed Adverse Effect Level (LOAEL). Using an uncertainty factor of 5, the UL for adults was set at 1 mg/day. The UL for folic acid for children aged one to three years of 200 µg/day was derived by extrapolation based on body weight (SCF, 2000d). A UL for food folate was not set.

6.26.6. Recommendations

Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as a basis the intake levels of folate considered adequate by the Panel for this age group of 65 µg DFE/day based on folate intakes from breast milk, this converts into a minimum folate content in formulae of 13 µg/100 kcal (rounded up to 15 µg/100 kcal).

The Panel proposes a minimum folate content in IF and FOF of 15 µg DFE/100 kcal (3.6 µg DFE/100 kJ).

6.27. Cobalamin (vitamin B12)

6.27.1. Current compositional requirements of IF and FOF

Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and maximum cobalamin contents in IF and FOF of 0.1 µg/100 kcal and 0.5 µg/100 kcal, respectively.

6.27.2. Cobalamin content of human milk

The mean value in breast milk of a group of 24 healthy Californian women, most of whom had consumed supplements containing 6 µg cobalamin/day during pregnancy, was 1.2 µg/L (0.18 µg/100 kcal) (range 0.2–5.0 µg/L (0.03-0.77 µg/100 kcal)) (Lildballe et al., 2009). In a recent longitudinal study, the cobalamin concentration of breast milk from 25 Danish mothers was measured at two weeks, four months and nine months of lactation (Greibe et al., 2013). Most women were taking daily multivitamin supplements providing 1.0–4.5 µg cobalamin. Median (range) concentrations of cobalamin in hindmilk were 1.03 (0.28–2.55), 0.39 (0.19–0.94) and 0.60 (0.22–2.63) µg/L at two weeks, four months and nine months, respectively. The corresponding concentrations per 100 kcal were 0.16 (0.04-0.39), 0.06 (0.03-0.14) and 0.09 (0.03-0.40) µg/100 kcal.

6.27.3. Cobalamin requirements of infants

In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a cobalamin
intake of 0.4 µg/day and 0.5 µg/day was adequate for the majority of infants in the first half and in the second half of the first year of life, respectively.

6.27.4. Cobalamin intakes of infants

Assuming a human milk intake of 0.8 L/day and a cobalamin content of 0.5 µg/L, an exclusively breast-fed infant would consume 0.4 µg cobalamin per day during the first six months of life. Mean/median cobalamin intakes in mostly formula-fed infants from birth to six months were reported to range from around 1.3 to 1.8 µg/day (Noble and Emmett, 2006; Fantino and Gourmet, 2008; Lennox et al., 2013) and in infants aged 6 to < 12 months from around 1.2 to 3.6 µg/day (Noble and Emmett, 2001; de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008; Marriott et al., 2008; Thorsdottir et al., 2008; Lennox et al., 2013).

6.27.5. Health consequences

In humans, cobalamin is required as a coenzyme for two reactions: the isomerisation of methylmalonyl-CoA to succinyl-CoA by mitochondrial methylmalonyl-CoA mutase and the methylation of homocysteine to methionine by methionine synthase. Cobalamin deficiency is rare in infants but can occur in infants breast fed by vegan mothers with (subclinical) cobalamin deficiency. In infants, cobalamin deficiency results in cerebral atrophy and symptoms of encephalopathy with developmental retardation. No adverse effects have been associated with excess cobalamin intake from food or supplements in healthy individuals. No UL could be established by the SCF for cobalamin (SCF, 2000f).

6.27.6. Recommendations

Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as a basis the intake levels of cobalamin considered adequate by the Panel for this age group of 0.4 µg/day based on cobalamin intakes from breast milk, this converts into a minimum cobalamin content in formulae of 0.08 µg/100 kcal (rounded up to 0.1 µg/100 kcal).

Therefore, the Panel proposes a minimum cobalamin content in IF and FOF of 0.1 µg/100 kcal (0.02 µg/100 kJ).

6.28. Vitamin C

6.28.1. Current compositional requirements of IF and FOF

Based on the opinion of the SCF (2003b), Directive 2006/141/EC provides for minimum and maximum vitamin C contents in IF and FOF of 10 mg/100 kcal and 30 mg/100 kcal, respectively.

6.28.2. Vitamin C content of human milk

Mean vitamin C concentrations in human milk are reported to range from 35 to 90 mg/L (5.4-13.8 mg/100 kcal) (EFSA NDA Panel, 2013e). The amount of vitamin C excreted via breast milk depends on the vitamin C status of the mother, and the vitamin C content in human milk reflects maternal vitamin C intake more than the infant’s requirement (WHO/FAO, 2004).

6.28.3. Vitamin C requirements of infants

In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a vitamin C intake of 20 mg/day is adequate for the majority of infants.

6.28.4. Vitamin C intakes of infants

Assuming a human milk intake of 0.8 L/day and a vitamin C content of 60 mg/L, an exclusively breast-fed infant would consume 48 mg vitamin C per day during the first six months of life. Mean/median vitamin C intakes in mostly formula-fed infants from birth to six months are reported to
range from around 40 to 90 mg/day (Hilbig, 2005; Noble and Emmett, 2006; Fantino and Gourmet, 2008; Lennox et al., 2013) and in infants aged 6 to < 12 months from around 33 to 94 mg/day (Noble and Emmett, 2001; Hilbig, 2005; de Boer et al., 2006; DGE, 2008; Fantino and Gourmet, 2008; Marriott et al., 2008; Thorsdottir et al., 2008; Lennox et al., 2013).

6.28.5. Health consequences

Vitamin C (L-ascorbic acid and dehydroascorbic acid) is an enzyme cofactor for biochemical reactions catalysed by mono-oxygenases, dioxygenases and mixed function oxygenases. Vitamin C plays an important role in the biosynthesis of collagen, is essential for the synthesis of carnitine and catecholamines and is also involved in the metabolism of cholesterol to bile acids. Vitamin C in aqueous solution readily scavenges reactive oxygen and nitrogen species, as well as singlet oxygen and hypochlorite, and is part of the antioxidant network of the body (EFSA NDA Panel, 2013e). Frank vitamin C deficiency leads to scurvy but has been observed only after the sixth month of life in infants fed a diet consisting of cow’s milk with no fruits and vegetables. Vitamin C is of low acute toxicity and available data on adverse effects are limited. No UL has been set by the Panel, but available human data suggest that supplemental daily doses of vitamin C up to about 1 g in addition to normal dietary intakes in adults are not associated with adverse effects (EFSA, 2004).

6.28.6. Recommendations

Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as the basis the intake levels of vitamin C considered adequate by the Panel for this age group of 20 mg/day, based on three times the amount known to prevent scurvy, this converts into a minimum vitamin C content in formulae of 4 mg/100 kcal.

Therefore, the Panel proposes a minimum vitamin C content in IF and FOF of 4 mg/100 kcal (0.96 mg/100 kJ).

7. Maximum content of micronutrients in IF and FOF

As the different protein and fat sources used in the manufacture of formulae and the water used to reconstitute powdered formulae contribute to the total nutrient content of a formula in varying amounts, maximum contents of nutrients have been established in order to ensure the safe use of formulae while limiting technological manipulations of the natural nutrient content of food constituents used in the production of formulae.

From a nutritional point of view, the minimum contents proposed by the Panel cover the nutritional needs of virtually all healthy infants born at term and there is no need to exceed these amounts in formulae, as nutrients which are not used or stored have to be excreted, and this may put a burden on the infant’s metabolism. Therefore, the Panel emphasises that maximum amounts should be interpreted not as target values but rather as upper limits of a range which should not be exceeded.

Specifications for the currently permitted maximum amounts of micronutrients in formulae were mostly calculated as three to five times the minimum amounts established at the time, took into account established history of apparent safe use (Codex Stan 72-1981, Codex Stan 156-1987, Directive 2006/141/EC and the SCF (2003b)), and were not based on scientific evidence for adverse effects owing to the lack of such evidence for most nutrients.

The Panel notes that there are no reports of any adverse effects associated with the use of formulae complying with the current specifications as laid down in Directive 2006/141/EC, although there are no studies available which were designed to investigate the short- or long-term health consequences of consumption of formulae containing the currently permitted maximum amounts of micronutrients in IF or FOF.

The Panel acknowledges that the scientific data available to derive ULs for infants remain scarce for most micronutrients and a UL for infants could be set only for vitamin D (EFSA NDA Panel, 2012d).
For magnesium, zinc, selenium, iodine, molybdenum, vitamin A, niacin, vitamin B6 and folic acid, ULs for children aged one to three years have been established (SCF, 2000g, 2000d, 2000e, 2000b, 2001a, 2002b, 2002c, 2002d, 2002a). Assuming an energy intake from formula of 500 kcal/day (average of the AR for energy of boys and girls aged three to four months), regular consumption of a formula by an infant containing the currently permitted maximum amounts of zinc, iodine, vitamin A and folate (if the whole amount is provided in the form of folic acid) would imply that the ULs would be exceeded for these nutrients. Assuming an energy intake from formula of 700 kcal/day (highest observed mean energy intakes in infants below six months of age), intakes of selenium would also exceed the UL. The Panel acknowledges that the ULs used in this estimation were those derived for young children and there is considerable uncertainty with respect to the extrapolation to infants.

8. Specifications for other ingredients in IF and FOF

8.1. Choline

Choline is currently mandatory in IF, and Directive 2006/141/EC provides for minimum and maximum choline contents of 7 mg/100 kcal and 50 mg/100 kcal, respectively. In its opinion, the SCF (2003b) concluded on minimum and maximum contents of choline in IF of 7 mg/100 kcal and 30 mg/100 kcal, respectively.

In human milk, choline is found as free choline, phosphocholine, glycerophosphocholine, sphingomyelin and phosphatidylcholine, all of which are available to the nursing infant. Total choline concentrations in human milk are influenced by maternal choline intake, length of lactation and genetic polymorphisms. The concentration of total choline in mature milk is 160-210 mg/L (25-32 g/100 kcal) (Holmes-McNary et al., 1996; Holmes et al., 1996). In one study (reported in two publications), mean choline levels were found to range between 144 and 170 mg/L (22-26 mg/100 kcal) and to increase from 70 mg/L (11 mg/100 kcal) in colostrum to 151 mg/L (23 mg/100 kcal) (range 57-318 mg/L (9-49 mg/100 kcal)) in mature milk (Ilcol et al., 2005; Allen, 2012). In a second study (Fischer et al., 2010) comparing breast milk concentrations in unsupplemented and supplemented mothers, the average choline content in breast milk amounted to 125 and 149 mg/L (19 and 23 mg/100 kcal), respectively. The average total choline concentration in mature human milk can be taken to be around 160 mg/L (20 mg/100 kcal).

Choline is predominantly provided via the diet, but the human body can also form choline de novo via two pathways that both lead to phosphatidylcholine. The extent to which choline is a required dietary constituent under normal circumstances is not clear. However, in conditions of increased need or of impaired synthesis, choline is considered to be conditionally indispensable. Choline has a number of important functions: it is a precursor of phospholipids, platelet-activating factor, betaine and the neurotransmitter acetylcholine and it is involved in the metabolism and transport of lipids. Dietary deficiency of choline in adults has been reported to cause liver steatosis (Buchman et al., 1995) and liver (Zeisel et al., 1991) and muscle damage (Fischer et al., 2007). Choline was not considered in the derivation of ULs in the EU. A UL for choline of 1 g/day for children aged one to three years has been set by IoM (1998). The UL was extrapolated from the UL of adults based on relative body weights. The UL for adults was based on a case report of hypotension and several studies involving cholinergic effects and fishy body odour after oral administration of large doses of choline. No UL for infants was derived owing to the lack of data and concerns about the infant’s ability to handle excess amounts.

In the Panel’s previous opinion on nutrient requirements and dietary intakes of infants and young children in the European Union (EFSA NDA Panel, 2013a), the Panel concluded that a choline intake of 130 mg/day was adequate for the majority of infants below six months of age and of 150 mg/day for infants aged 6 to < 12 months.

Assuming an average energy intake of an infant below six months of age of 500 kcal/day and taking as a basis the intake level of choline considered adequate by the Panel for this age group of 130 mg/day based on choline intakes from breast milk, this converts into a minimum choline content in formulae
of 26 mg/100 kcal (rounded down to 25 mg/100 kcal). Therefore, the Panel proposes a minimum choline content in IF of 25 mg/100 kcal (6.0 mg/100 kJ). There is no necessity to add choline to FOF.

There are no reports of adverse effects occurring with the current specifications of choline in IF.

8.2. Inositol

Inositol is currently mandatory in IF, and Directive 2006/141/EC provides for minimum and maximum inositol contents of 4 mg/100 kcal and 40 mg/100 kcal, respectively, in line with the SCF (2003b).

In addition to sugars such as lactose, glucose, galactose and mannose, human milk also contains sugar alcohols/polyols, in particular inositol, mostly as myo-inositol, either free or in phosphorylated forms. The myo-inositol concentration has been found to be higher in colostrum and reaches a relatively stable concentration of around 130-325 mg/L (20-50 mg/100 kcal) in mature human milk (Cavalli et al., 2006; Jóźwik et al., 2013). Inositol plays a role in many important biological functions including the regulation of cell osmolality, processes of cell signalling, as structural components of the developing neural system and in the production of the phospholipids for pulmonary surfactant. Endogenous de novo synthesis of inositol appears to be efficient in newborn infants. Together with inositol provided by human milk, this makes it unlikely that healthy, term, breast-fed infants could become depleted of inositol (Brown LD et al., 2009). However, it is not known if endogenous inositol synthesis is sufficient in the absence of dietary inositol.

Considering that it is unknown if endogenous synthesis of inositol in newborns is sufficient in the absence of dietary inositol, the Panel proposes to maintain the minimum inositol content in IF of 4 mg/100 kcal (0.96 mg/100 kJ) proposed in 2003 by the SCF. The Panel considers that there is no necessity to add inositol to FOF, as the supply from complementary food is sufficient in older infants.

There are no reports of adverse effects occurring with the current specifications of inositol in IF.

8.3. Taurine

The addition of taurine to IF and FOF is currently permitted by Directive 2006/141/EC on a voluntary basis up to a maximum of 12 mg/100 kcal. Taurine concentrations in milk from mothers of term infants have been found to be around 4.7 mg/100 kcal (Zhang et al., 2013), with highest observed taurine concentrations of around 12 mg/100 kcal (Rassin et al., 1978).

It has been suggested that taurine plays a role in intestinal fat absorption, hepatic function and auditory and visual development in pre-term or low-birth weight infants. However, clinical data on long-term effects on neurological development in these infants are lacking (Verner et al., 2007), as is evidence that the addition of taurine to IF has any clinical benefits for term infants.

Taking into account the lack of convincing evidence for a benefit of the addition of taurine to IF and/or FOF, the Panel considers that there is no necessity to add taurine to IF or FOF.

There are no reports of adverse effects occurring with the current specifications of taurine in formulae.

8.4. L-Carnitine

The addition of L-carnitine at an amount of at least 1.2 mg/100 kcal is currently mandatory for IF containing ISP or protein hydrolysates but not for IF based on cow’s or goat’s milk protein, as the latter are considered to provide L-carnitine naturally from the milk source.

L-Carnitine is considered an indispensable nutrient for newborn infants because of a temporarily insufficient synthesising capacity. In studies investigating L-carnitine concentrations in milk from different species, mean total carnitine concentrations have been reported to be in the range 0.9-1.6 mg/100 kcal in human milk (Sandor et al., 1982; Penn et al., 1987; Ferreira, 2003),
4.1-6.7 mg/100 kcal in cow’s milk (Sandor et al., 1982; Penn et al., 1987; Ferreira, 2003) and 3.2-4.4 mg/100 kcal in goat’s milk (Sandor et al., 1982; Penn et al., 1987). The natural carnitine content of animal milks may be decreased by dilution or fractionation of the milk source when cow’s and goat’s milk proteins are used in the manufacture of IF. Therefore, a minimum L-carnitine content should be also set for IF based on milk protein.

The Panel notes that no new data have become available since the opinion of the SCF (2003b) which would indicate that a minimum content of L-carnitine of 1.2 mg/100 kcal in IF is insufficient to ensure adequate growth and development of infants. The Panel proposes a minimum L-carnitine content in IF of 1.2 mg/100 kcal (0.3 mg/100 kJ), irrespective of the protein source used, which is an amount similar to the content of L-carnitine in human milk. The Panel considers that there is no necessity to add L-carnitine to FOF, as the supply from complementary food and from endogenous synthesis is sufficient in older infants.

8.5. Nucleotides and nucleosides

The addition of nucleotides to IF and FOF is currently permitted by Directive 2006/141/EC on a voluntary basis up to a maximum of 5 mg/100 kcal. If added, the maximum nucleotide content is regulated to be cytidine 5′-monophosphate (CMP) 2.5 mg/100 kcal, uridine 5′-monophosphate (UMP) 1.75 mg/100 kcal, adenosine 5′-monophosphate (AMP) 1.50 mg/100 kcal, guanosine 5′-monophosphate (GMP) 0.50 mg/100 kcal and inosine 5′-monophosphate (IMP) 1.00 mg/100 kcal.

Nucleotides and nucleosides are dispensable nutrients synthesised de novo in human metabolism. Nucleotides are structural components of ribonucleic acid (RNA) and DNA. Nucleotides, such as ATP, transfer chemical energy. Other nucleotides are involved in the synthesis of proteins, lipids and carbohydrates (e.g. NAD, FAD) (SCF, 2003b).

Human milk contains free nucleosides, free nucleotides, RNA and DNA. The concentrations of “total potentially available nucleotides”, defined by some authors as the sum of free nucleosides, free nucleotides, nucleotide-containing adducts (such as NAD and uridine diphosphate (UDP) glucose) and nucleotide polymers, were reported to be around 10.5-11.0 mg/100 kcal in milk from Asian, American and European mothers. The major sources were nucleotide polymers, primarily RNA (around 43-48 %), free nucleotides (around 36-40 %) and free nucleosides (around 6.5-8 %) (Leach et al., 1995; Tressler et al., 2003). Average concentrations of nucleotides in human milk were observed to be in the range 0.7-4.5 mg/100 kcal for CMP, 0.3-2.3 mg/100 kcal for UMP, 0.05-1.9 mg/100 kcal for GMP, 0.2-1.7 mg/100 kcal for AMP and 0-1.4 mg/100 kcal for IMP (Gil and Sanchez-Medina, 1982; Janas and Picciano, 1982; Leach et al., 1995; Thorell et al., 1996; Tressler et al., 2003; Liao et al., 2011), with four studies out of six reporting IMP concentrations below the limit of detection.

It should be noted that the presence of nucleotides and nucleosides in human milk does not necessarily indicate a specific benefit for the infants as they may also be by-products of milk formation that reflect metabolic activity of the mammary gland tissue, shedding of somatic cells and occurrence of microorganisms, without having a specific function for the infant (SCF, 2003b).

Nucleotides have been studied in healthy, term infants with respect to their effect on clinically relevant outcomes such as antibody titres after vaccination (Pickering et al., 1998; Yau et al., 2003; Schaller et al., 2004; Hawkes et al., 2006), the incidence or severity of infections (Carver et al., 1991; Brunser et al., 1994; Yau et al., 2003), the incidence of diarrhoea (Brunser et al., 1994; Yau et al., 2003; Singhal et al., 2008) and growth (Carver et al., 1991; Pickering et al., 1998; Lasekan et al., 1999; Yau et al., 2003; Schaller et al., 2004; Singhal et al., 2010). The Panel notes that, although effects on some of the antibody titres measured in the studies were observed, these effects were not consistent and that no effects of nucleotides on the incidence or severity of infections, on the incidence of diarrhoea or on growth were observed.

Taking into account the lack of convincing evidence for a benefit of the addition of nucleotides to IF and/or FOF, the Panel considers that there is no necessity to add nucleotides to IF or FOF.
There are no reports of adverse effects occurring with the current specifications of nucleotides in formula.

8.6. “Probiotics” and “synbiotics”

The addition of live microorganisms to IF and FOF is not mentioned in the relevant Directives, except for production of acidified IF and FOF, for which the use of non-pathogenic L-(+)-lactic acid-producing bacterial cultures is permitted (Regulation (EC) No 1333/2008). However, according to Directive 2006/141/EC, IF and FOF may contain food ingredients other than those listed in Annexes I and II, provided those ingredients have been shown to be suitable for infants through a systematic review of the available data or, when necessary, by appropriate studies (Articles 5 and 6).

IF and FOF with added live bacteria and claiming to confer health benefits (generally referred to as “probiotics”) have been introduced into the EU market. Several bacterial strains included in IF and FOF have been evaluated with regard to safety and potential beneficial health effects to date. These include *Bifidobacterium animalis* subsp. *lactis* CNCMI-3446 (also named *B. bifidum* and *B. lactis* Bb12), alone or in combination with either *Streptococcus thermophilus* or with both *S. thermophilus* and *Lactobacillus helveticus*, *L. johnsonii* La1, *B. longum* BL999 plus *L. rhamnosus* LPR, *L. rhamnosus* GG, *L. reuteri* ATCC 55730, *L. salivarius* CECT5713 and *L. fermentum* CECT5716 (Braegger et al., 2011; Gil-Campos et al., 2012; Maldonado et al., 2012; Mugambi et al., 2012).

The health outcomes evaluated in RCTs include growth, gastrointestinal infections/diarrhoea, respiratory tract infections/symptoms, colic/irritability, allergic manifestations, stool frequency and consistency and antibody production (Braegger et al., 2011; Gil-Campos et al., 2012; Holscher et al., 2012; Mugambi et al., 2012; Szajewska and Chmielewska, 2013).

The most recent systematic reviews (Mugambi et al., 2012; Szajewska and Chmielewska, 2013) concluded that many of the studies conducted with IF and FOF supplemented with “probiotic” bacteria did not find significant physiological or health effects compared with non-supplemented formulae. These reviews also revealed uncertainty regarding the beneficial effects reported for formulae supplemented with some of the strains through lack of consistency across studies, to methodological limitations and to the existence of data from single studies only (Braegger et al., 2011; Szajewska and Chmielewska, 2013). Such uncertainty applies to the effects of IF supplemented with *B. animalis* subsp. *lactis* CNCMI-3446 (alone or in combination) on diarrhoea, which were not consistent across studies with substantial methodological limitations and also applies to the effects of other strains evaluated only in single studies such as *L. johnsonii* La1 and *L. salivarius* CECT5713 on diarrhoea, *L. salivarius* CECT 5713 on respiratory tract infections, and *L. rhamnosus* LGG on defecation frequency and stool consistency (Braegger et al., 2011).

A couple of recent studies have evaluated the effects of the strain *L. fermentum* CECT 5716, isolated from human milk, added to GOS containing IF compared with the same IF without the bacterium. The first study was designed to evaluate the safety and tolerance of the IF supplemented with *L. fermentum* CECT 5716 in infants of one to six months of age and, as secondary outcomes, also evaluated infections, reporting reductions in the incidence of gastrointestinal infections, but not of respiratory or total infections (Gil-Campos et al., 2012). The second study was conducted on healthy six-month-old infants and reported a reduced incidence rate of gastrointestinal and upper respiratory tract infections, but not of lower respiratory tract infections, otitis, urinary tract infections or febrile episodes, between the ages of 6 and 12 months in the *L. fermentum* CECT 5716 group compared with the control group (Maldonado et al., 2012). The Panel notes that the two studies were not consistent regarding the effects on respiratory tract infections and that one of the studies on gastrointestinal infections was designed not for this purpose, but for evaluating safety. Another recent single study reported that *B. animalis* subsp. *lactis* CNCMI-3446 added to formula containing partially hydrolysed whey protein increased anti-poliovirus-specific immunoglobulin A (IgA) concentration (p < 0.05) but not anti-rotavirus-specific IgA, following immunisation, and only in a sub-group of infants delivered by caesarean section (Holscher et al., 2012).
IF and FOF containing “probiotics” have also been studied in relation to any potential untoward effects, such as delayed growth, diarrhoea and allergic reactions (Braegger et al., 2011; Gil-Campos et al., 2012; Maldonado et al., 2012; Azad et al., 2013). It has been generally concluded that currently evaluated “probiotic”-supplemented IF do not raise safety concerns with regard to growth or other adverse effects, although in many studies adverse events were inconsistently reported (Azad et al., 2013) and further evaluations of safety in long-term studies are needed (Braegger et al., 2011).

A few studies have been conducted with IF or FOF supplemented with combinations of “probiotics” and “prebiotics” (named “synbiotics”) on growth, infections, asthma/wheezing, crying and stool frequency/constipation (reviewed by Braegger et al., 2011; and Azad et al., 2013). The synbiotics evaluated in RCTs in infants include B. longum BL999 plus GOS/FOS, B. longum BL999 plus L. rhamnosus LPR plus GOS/FOS, B. longum BL999 plus L. paracasei ST11 plus GOS/FOS, L. paracasei subsp. paracasei plus B. animalis subsp. lactis plus GOS and B. breve M-16V plus GOS/FOS. The evidence on the effectiveness is very limited and only data from single studies are available. These have reported effects on increased stool frequency for three of the synbiotics tested (B. longum BL999 plus GOS/FOS, B. longum BL999 plus L. rhamnosus LPR plus GOS/FOS and L. paracasei subsp. paracasei plus B. animalis subsp. lactis plus GOS) (reviewed by Braegger et al., 2011) and on parent-reported asthma-like symptoms, but not on total serum IgE and specific IgE against aeroallergens (van der Aa et al., 2011 reviewed by Azad et al., 2013).

Safety of “synbiotics” added to IF and FOF has also been evaluated and it was concluded that they do not give rise to concerns with regard to growth or other adverse effects, although the evidence is limited (Braegger et al., 2011).

The Panel notes that the evidence available so far on beneficial effects of IF or FOF supplemented with “probiotics” and “synbiotics” on infant health mainly comes from single studies and studies with methodological limitations, or it is inconsistent across the few studies that are comparable. Therefore, the Panel considers that there is insufficient information to draw conclusions on beneficial effects on infant health of “the probiotics strains” added to IF and FOF under the conditions of use investigated so far in humans and even less in the case of the “synbiotics” tested (detailed above). There is no evidence that gives rise to concerns about the safety of the tested “probiotics” or “synbiotics”.

Taking into account the lack of convincing evidence for a benefit of the addition of the “probiotics” or the “synbiotics” evaluated in humans so far added to IF and/or FOF, the Panel considers that there is no necessity to add those “probiotics” and/or “synbiotics” to IF or FOF.

9. Use of formulae by young children

The Panel was also asked to advise the Commission with respect to the appropriate age range of use and the essential composition of so-called “growing-up milks” or young-child formulae.

In its previous opinion (EFSA NDA Panel, 2013a), the Panel considered that, despite the fact that an adequate amount of energy and nutrients can be supplied by a balanced and varied diet, intakes of ALA, DHA, iron, vitamin D and iodine in some infants and young children living in Europe are low and some sub-groups in this population may be at risk of inadequacy. This consideration was based on assessment of nutrient intake data and on studies investigating the nutrient status of infants and young children living in Europe.

In the same opinion, the Panel noted that formulae, including young-child formulae, are one of several means to increase intakes of these critical nutrients in infants and young children living in Europe with inadequate or at risk of inadequate status of these nutrients. However, other means, such as fortified cow’s milk, fortified cereals and cereal-based foods, supplements or the early introduction of meat and fish into complementary feeding and their continued regular consumption, are efficient alternatives to increase intakes of these nutrients. The selection of the appropriate form and vehicle through which these nutrients are provided in the diet will depend on national dietary habits, health authorities, the regulatory context and caregivers’ preference.
The Panel concluded that no unique role of young-child formulae with respect to the provision of critical nutrients in the diet of infants and young children living in Europe can be identified, so that they cannot be considered as a necessity to satisfy the nutritional requirements of young children when compared with other foods that may be included in the normal diet of young children. The median content of ALA, DHA (if added), iron, vitamin D and iodine in currently marketed young-child formulae is within the range of permitted concentrations in FOF and, except for iron, also in IF. The Panel notes that formulae consumed during the first year of life can continue to be used by young children. Therefore, the Panel does not consider it necessary to propose specific compositional criteria for formulae consumed after one year of age.

10. **Recommendations for further research**

The Panel emphasises:

- the necessity to generate reliable analytical data on the amino acid pattern of human milk protein at different stages of lactation;
- the necessity for appropriate studies to fill the gaps in the knowledge of protein requirements of infants in the second half of the first year of life;
- the lack of human studies evaluating the safety and adequacy of most IF and FOF presently on the market containing protein hydrolysates;
- the necessity to generate data on the decrease of bioavailability of certain amino acids through different methods of processing;
- the lack of non-digestible oligosaccharides that mimic those present in human milk and the lack of appropriate human studies evaluating the safety and potential health benefits of non-digestible oligosaccharides and bacteria whose growth in the infant’s gut is promoted by breast milk.

**CONCLUSIONS**

The Panel concludes that:

- There is consensus that breast milk is the preferred food for all healthy infants and provides an adequate supply of all nutrients to support growth and development (with the exception of vitamin K during the first weeks of life and of vitamin D).

- All formulae intended for infants must be safe and suitable to meet the nutritional requirements and to promote growth and development of infants born at term when used as a sole source of nutrition during the first months of life and when used as the principal liquid element in a progressively diversified diet after the introduction of appropriate complementary feeding. Nutrients and substances should be added to formulae for infants only in amounts that serve a nutritional or other benefit.

- The minimum content of a nutrient in formulae proposed in this opinion is derived from the intake levels the Panel had considered adequate for the majority of infants in the first half of the first year of life in its previous opinion and an average amount of formulae consumed during this period (500 kcal/day). From a nutritional point of view, the minimum contents proposed by the Panel cover the nutritional needs of virtually all healthy infants born at term and there is no need to exceed these amounts in formulae, as nutrients which are not used or stored have to be excreted, and this may put a burden on the infant’s metabolism and/or physiological functions.

- Specifications for the currently permitted maximum amounts of micronutrients in formulae were mostly calculated as three to five times the minimum amounts established at the time and took into account an established history of apparent safe use (Codex Stan 72-1981, Codex...
Stan 156-1987, the Directive 2006/141/EC, and SCF (2003b)) and were not based on scientific evidence of adverse effects owing to the lack of such evidence for most nutrients. It is emphasised that maximum amounts should be interpreted not as target values but rather as upper limits of a range which should not be exceeded.

- There are no reports on any adverse effects associated with the use of formulae complying with the current specifications for micronutrients as laid down in Directive 2006/141/EC, although there are no studies available which were designed to investigate the short- or long-term health consequences of consumption of IF or FOF containing the currently permitted maximum amounts of micronutrients. Assuming an energy intake from formula of 500 kcal/day (average of the AR for energy of boys and girls aged three to four months), regular consumption of a formula by an infant containing the currently permitted maximum amounts of zinc, iodine, vitamin A and folate (if the whole amount is provided in the form of folic acid) would imply that the ULs would be exceeded for these nutrients. Assuming an energy intake from formula of 700 kcal/day (highest observed mean energy intakes in infants below six months of age), intakes of selenium would also exceed the UL. The Panel acknowledges that the ULs used in this estimation were those derived for young children and there is uncertainty with respect to the extrapolation to infants.

- Cow’s milk, goat’s milk and ISP are safe and suitable protein sources for use in IF and FOF based on intact protein. The use of other protein sources in IF and FOF and/or the introduction of new technologies need clinical evaluation and their safety and suitability should be established in the target population prior to their general use in IF and FOF.

- Formulae containing protein hydrolysates are insufficiently characterised by the declared protein content even if they fulfil regulatory criteria concerning amino acid patterns and contents; therefore, the safety and suitability of each specific IF or FOF containing protein hydrolysates has to be established by clinical evaluation.

- The use of a default conversion factor of 6.25 to calculate the protein content from the total nitrogen content is proposed, irrespective of the protein source.

- IF and FOF should provide on an energy basis indispensable and conditionally indispensable amino acids in amounts at least equal to the reference protein (i.e. breast milk), irrespective of the protein source and the following reference pattern is proposed:

<table>
<thead>
<tr>
<th>Amino acid</th>
<th>g/100 g protein</th>
<th>mg/100 kcal</th>
<th>mg/100 kJ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cysteine</td>
<td>2.1</td>
<td>38</td>
<td>9</td>
</tr>
<tr>
<td>Histidine</td>
<td>2.2</td>
<td>40</td>
<td>10</td>
</tr>
<tr>
<td>Isoleucine</td>
<td>5.0</td>
<td>90</td>
<td>22</td>
</tr>
<tr>
<td>Leucine</td>
<td>9.2</td>
<td>166</td>
<td>40</td>
</tr>
<tr>
<td>Lysine</td>
<td>6.3</td>
<td>113</td>
<td>27</td>
</tr>
<tr>
<td>Methionine</td>
<td>1.3</td>
<td>23</td>
<td>5</td>
</tr>
<tr>
<td>Phenylalanine</td>
<td>4.6</td>
<td>83</td>
<td>20</td>
</tr>
<tr>
<td>Threonine</td>
<td>4.3</td>
<td>77</td>
<td>18</td>
</tr>
<tr>
<td>Tryptophan</td>
<td>1.8</td>
<td>32</td>
<td>8</td>
</tr>
<tr>
<td>Tyrosine</td>
<td>4.2</td>
<td>76</td>
<td>18</td>
</tr>
<tr>
<td>Valine</td>
<td>4.9</td>
<td>88</td>
<td>21</td>
</tr>
</tbody>
</table>

- The sum of methionine and cysteine and the sum of tyrosine and phenylalanine in IF may be used for calculation purposes. If the ratio of methionine to cysteine or the ratio of tyrosine to phenylalanine exceeds 2, this must be justified by clinical evaluation. For FOF, no restrictions with respect amino acid ratios need to apply, because complementary foods will contribute to amino acid intakes and the metabolism of older infants is more mature with respect to the capacity to convert methionine to cysteine and phenylalanine to tyrosine.
The following composition of IF and FOF based on intact cow’s and goat’s milk protein is proposed:

<table>
<thead>
<tr>
<th></th>
<th>Range IF</th>
<th>Range FOF</th>
<th>Unit</th>
<th>Range IF</th>
<th>Range FOF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Energy kcal/100 mL</td>
<td>60-70</td>
<td></td>
<td>kcal/100 mL</td>
<td>250-293</td>
<td></td>
</tr>
<tr>
<td>Protein g/100 kcal</td>
<td>1.8-2.5</td>
<td></td>
<td>g/100 kcal</td>
<td>0.43-0.60</td>
<td></td>
</tr>
<tr>
<td>Total fat g/100 kcal</td>
<td>4.4-6.0</td>
<td></td>
<td>g/100 kcal</td>
<td>1.1-1.4</td>
<td></td>
</tr>
<tr>
<td>LA mg/100 kcal</td>
<td>50-1200</td>
<td>mg/100 kcal</td>
<td>120-300</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALA mg/100 kcal</td>
<td>50-100</td>
<td>mg/100 kcal</td>
<td>12-24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DHA(ω3) mg/100 kcal</td>
<td>20-50</td>
<td>mg/100 kcal</td>
<td>4.8-12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TFA FA%</td>
<td>≤ 3</td>
<td></td>
<td>FA%</td>
<td>≤ 3</td>
<td></td>
</tr>
<tr>
<td>Carbohydrates g/100 kcal</td>
<td>9-14</td>
<td></td>
<td>g/100 kcal</td>
<td>2.2-3.3</td>
<td></td>
</tr>
<tr>
<td>Lactose, unless “lactose-free” g/100 kcal</td>
<td>4.5</td>
<td></td>
<td>g/100 kcal</td>
<td>1.1-1.4</td>
<td></td>
</tr>
<tr>
<td>Sucrose, fructose and sugars from honey % of total CHO</td>
<td>0</td>
<td>≤ 20</td>
<td>% of total CHO</td>
<td>0</td>
<td>≤ 20</td>
</tr>
<tr>
<td>Glucose g/100 kcal</td>
<td>0</td>
<td>0</td>
<td>g/100 kcal</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Starches ≤ 2 g/100 mL, not more than 30 % of total CHO for IF, unrestricted within maximum amounts as long as free of gluten</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcium mg/100 kcal</td>
<td>50</td>
<td>mg/100 kcal</td>
<td>12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phosphorus mg/100 kcal</td>
<td>25</td>
<td>mg/100 kcal</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Magnesium mg/100 kcal</td>
<td>5</td>
<td>mg/100 kcal</td>
<td>1.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium mg/100 kcal</td>
<td>25</td>
<td>mg/100 kcal</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chloride mg/100 kcal</td>
<td>60</td>
<td>mg/100 kcal</td>
<td>14.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Potassium mg/100 kcal</td>
<td>80</td>
<td>mg/100 kcal</td>
<td>19.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iron mg/100 kcal</td>
<td>0.3-0.6</td>
<td>mg/100 kcal</td>
<td>0.07-0.14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zinc mg/100 kcal</td>
<td>0.5</td>
<td>mg/100 kcal</td>
<td>0.12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Copper μg/100 kcal</td>
<td>60</td>
<td>μg/100 kcal</td>
<td>14.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selenium μg/100 kcal</td>
<td>3</td>
<td>μg/100 kcal</td>
<td>0.72</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iodine μg/100 kcal</td>
<td>15</td>
<td>μg/100 kcal</td>
<td>3.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Molybdenum μg/100 kcal</td>
<td>0.4</td>
<td>μg/100 kcal</td>
<td>0.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Manganese μg/100 kcal</td>
<td>1</td>
<td>μg/100 kcal</td>
<td>0.24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin A(α) μg/100 kcal</td>
<td>70</td>
<td>μg/100 kcal</td>
<td>16.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin D μg/100 kcal</td>
<td>2</td>
<td>μg/100 kcal</td>
<td>0.48</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin E(β) mg α-TE/100 kcal</td>
<td>0.6</td>
<td>mg α-TE/100 kcal</td>
<td>0.14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin K μg/100 kcal</td>
<td>1</td>
<td>μg/100 kcal</td>
<td>0.24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thiamin μg/100 kcal</td>
<td>40</td>
<td>μg/100 kcal</td>
<td>9.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Riboflavin μg/100 kcal</td>
<td>60</td>
<td>μg/100 kcal</td>
<td>14.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Niacin(γ) mg/100 kcal</td>
<td>0.4</td>
<td>mg/100 kcal</td>
<td>0.10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pantothenic acid mg/100 kcal</td>
<td>0.4</td>
<td>mg/100 kcal</td>
<td>0.10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin B6 μg/100 kcal</td>
<td>20</td>
<td>μg/100 kcal</td>
<td>4.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biotin μg/100 kcal</td>
<td>1</td>
<td>μg/100 kcal</td>
<td>0.24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Folate μg DFE/100 kcal</td>
<td>15</td>
<td>μg DFE/100 kcal</td>
<td>3.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cobalamin μg/100 kcal</td>
<td>0.1</td>
<td>μg/100 kcal</td>
<td>0.02</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin C mg/100 kcal</td>
<td>4</td>
<td>mg/100 kcal</td>
<td>0.96</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choline mg/100 kcal</td>
<td>25</td>
<td>mg/100 kcal</td>
<td>6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>L-Carnitine mg/100 kcal</td>
<td>1.2</td>
<td>mg/100 kcal</td>
<td>0.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inositol mg/100 kcal</td>
<td>4</td>
<td>mg/100 kcal</td>
<td>0.96</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The amount of EPA should not be higher than the amount of DHA.

Pre-formed vitamin A.

Vitamin E activity of RRR-α-tocopherol.

Pre-formed niacin.

For IF and FOF containing hydrolysed protein, the same requirements as for formulae based on intact cow’s and goat’s milk protein should apply, except for the minimum protein content, which cannot be proposed, and the adequacy of the protein content of a specific IF or FOF containing hydrolysed proteins needs to be established based on clinical evaluation. The maximum protein content should, however, not exceed 2.8 g/100 kcal (0.67 g/100 kJ).

Furthermore, for IF and FOF containing ISP, the same requirements as for formulae based on intact cow’s and goat’s milk protein should apply, except for a minimum and maximum protein content of 2.25-2.8 g/100 kcal (0.54-0.67 g/100 kJ), a minimum phosphorus content of 30 mg/100 kcal (7.2 mg/100 kJ), a minimum iron content of 0.45 mg/100 kcal (0.11 mg/100 kJ) for IF and of 0.90 mg/100 kcal (0.22 mg/100 kJ) for FOF and a minimum zinc content of 0.75 mg/100 kcal (0.18 mg/100 kJ). There should be no requirement for a minimum lactose content in IF and FOF containing ISP.

The minimum content of nutrients in IF and FOF proposed by the Panel is identical with the exception of iron. If the same formula is to be used from the first months of infancy, and is to be suitable for the whole first year of life, the minimum iron content should be 0.6 mg/100 kcal (0.14 mg/100 kJ) for formulae based on intact cow’s and goat’s milk protein and formulae containing protein hydrolysates, and 0.9 mg/100 kcal (0.22 mg/100 kJ) for formulae containing ISP.

There is no necessity to add ARA, EPA, chromium, fluoride, taurine, nucleotides, non-digestible oligosaccharides, “probiotics” or “synbiotics” to IF and FOF. There is also no necessity to use PL as a source of LCPUFAs instead of TAG in IF and FOF or to use TAG with palmitic acid predominantly esterified in the sn-2 position in IF and FOF instead of TAG from other fat sources. For FOF, in contrast to IF, the addition of L-carnitine, inositol and choline is not necessary.

As formulae consumed during the first year of life can continue to be used by young children, the Panel did not consider it necessary to propose specific compositional criteria for formula consumed after one year of age.

**DOCUMENTATION PROVIDED TO EFSA**

Evidence report related to an extensive literature search and review as preparatory work for the evaluation of the essential composition of infant and follow-on formulae and growing-up milks provided by Pallas Health Research and Consultancy following a procurement procedure.

**REFERENCES**


Agostoni C and Caroli M, 2012. Role of fats in the first two years of life as related to later development of NCDs. Nutrition Metabolism and Cardiovascular Diseases, 22, 775-780.


Bakker-Zierikzee AM, van Tol EAF, Kroes H, Alles MS, Kok FJ and Bindels JG, 2006. Faecal SIgA secretion in infants fed on pre- or probiotic infant formula. Pediatric Allergy and Immunology, 17, 134-140.


Essential composition of infant and follow-on formulae


Courtney-Martin G, Moore AM, Ball RO and Pencharz PB, 2010. The addition of cysteine to the total sulphur amino acid requirement as methionine does not increase erythrocytes glutathione synthesis in the parenterally fed human neonate. Pediatric Research, 67, 320-324.


clinical trial with multiple dietary levels of docosahexaenoic acid. Early Human Development, 87, 223-230.


EFSA (European Food Safety Authority), 2005f. Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies (NDA Panel) on a request from the Commission related to the safety and suitability for particular nutritional use by infants of formula based on whey protein partial hydrolysates with a protein content of at least 1.9 g protein/100 kcal. The EFSA Journal 2005, 280, 1-16. doi:10.2903/j.efsa.2005.280


EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition, and Allergies), 2010c. Scientific Opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty
Essential composition of infant and follow-on formulae


Essential composition of infant and follow-on formulae


Hicks PD, Hawthorne KM, Berseth CL, Marunycz JD, Heubi JE and Abrams SA, 2012. Total calcium absorption is similar from infant formulas with and without prebiotics and exceeds that in human milk-fed infants. BMC Pediatrics, 12, 118.


Holmes HC, Snodgrass GJ and Iles RA, 1996. The choline content of human breast milk expressed during the first few weeks of lactation. Biochemical Society Transactions, 24, 350S.


House JD, Thorpe JM, Wykes LJ, Pencharz PB and Ball RO, 1998. Evidence that phenylalanine hydroxylation rates are overestimated in neonatal subjects receiving total parenteral nutrition with a high phenylalanine content. Pediatric Research, 43, 461-466.

Hsieh AT and Brenna JT, 2009. Dietary docosahexaenoic acid but not arachidonic acid influences central nervous system fatty acid status in baboon neonates. Prostaglandins Leukotrienes and Essential Fatty Acids, 81, 105-110.


SCF (Scientific Committee on Food), 2000a. Opinion on the Tolerable Upper Intake Level of manganese.

SCF (Scientific Committee on Food), 2000b. Opinion on the Tolerable Upper Intake Level of selenium.

SCF (Scientific Committee on Food), 2000c. Opinion on the Tolerable Upper Intake Level of molybdenum.

SCF (Scientific Committee on Food), 2000d. Opinion on the Tolerable Upper Intake Level of folate.

SCF (Scientific Committee on Food), 2000e. Opinion on the Tolerable Upper Intake Level of vitamin B2.

SCF (Scientific Committee on Food), 2000f. Opinion on the Tolerable Upper Intake Level of vitamin B12.

SCF (Scientific Committee on Food), 2000g. Opinion on the Tolerable Upper Intake Level of vitamin B6.

SCF (Scientific Committee on Food), 2001a. Opinion on the Tolerable Upper Intake Level of magnesium.

SCF (Scientific Committee on Food), 2001b. Opinion on the Tolerable Upper Intake Level of biotin.

SCF (Scientific Committee on Food), 2001c. Opinion on the Tolerable Upper Intake Level of thiamin.

SCF (Scientific Committee on Food), 2001d. Statement on the use of resistant short chain carbohydrates (oligofructose and oligogalactose) in infant formulae and in follow-on formulae.

SCF (Scientific Committee on Food), 2002a. Opinion on the Tolerable Upper Intake Level of zinc.

SCF (Scientific Committee on Food), 2002b. Opinion on the Tolerable Upper Intake Level of preformed vitamin A (retinol and retinyl esters).

SCF (Scientific Committee on Food), 2002c. Opinion on the Tolerable Upper Intake Level of niacin.

SCF (Scientific Committee on Food), 2002d. Opinion on the Tolerable Upper Intake Level of iodine.

SCF (Scientific Committee on Food), 2002e. Opinion on the Tolerable Upper Intake Level of pantothenic acid.

SCF (Scientific Committee on Food), 2003a. Opinion on the Tolerable Upper Intake Level of copper.

SCF (Scientific Committee on Food), 2003c. Opinion on the Tolerable Upper Intake Level of vitamin E.

SCF (Scientific Committee on Food), 2003d. Opinion on the Tolerable Upper Intake Level of chromium.


**ABBREVIATIONS**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAP</td>
<td>American Academy of Pediatrics</td>
</tr>
<tr>
<td>AI</td>
<td>Adequate Intake</td>
</tr>
<tr>
<td>ALA</td>
<td>alpha-linolenic acid</td>
</tr>
<tr>
<td>AMP</td>
<td>adenosine 5′-monophosphate</td>
</tr>
<tr>
<td>AOS</td>
<td>acidic oligosaccharides</td>
</tr>
<tr>
<td>AR</td>
<td>Average Requirement</td>
</tr>
<tr>
<td>ARA</td>
<td>arachidonic acid</td>
</tr>
<tr>
<td>ATP</td>
<td>adenosine triphosphate</td>
</tr>
<tr>
<td>BMD</td>
<td>bone mineral density</td>
</tr>
<tr>
<td>BMI</td>
<td>body mass index</td>
</tr>
<tr>
<td>BSID</td>
<td>Bayley Scales of Infant Development</td>
</tr>
<tr>
<td>CD</td>
<td>coeliac disease</td>
</tr>
<tr>
<td>CLA</td>
<td>conjugated-linoleic acid</td>
</tr>
<tr>
<td>CMP</td>
<td>cytidine 5′-monophosphate</td>
</tr>
<tr>
<td>CoA</td>
<td>coenzyme A</td>
</tr>
<tr>
<td>DFE</td>
<td>dietary folate equivalent</td>
</tr>
<tr>
<td>DHA</td>
<td>docosahexaenoic acid</td>
</tr>
<tr>
<td>DNA</td>
<td>deoxyribonucleic acid</td>
</tr>
<tr>
<td>DPA</td>
<td>docosapentaenoic acid</td>
</tr>
<tr>
<td>DRV</td>
<td>Dietary Reference Value</td>
</tr>
<tr>
<td>DXA</td>
<td>dual-energy X-ray absorptiometry</td>
</tr>
<tr>
<td>E %</td>
<td>percentages of the total energy intakes</td>
</tr>
<tr>
<td>EPA</td>
<td>eicosapentaenoic acid</td>
</tr>
<tr>
<td>ESPGHAN</td>
<td>European Society for Paediatric Gastroenterology Hepatology and Nutrition</td>
</tr>
<tr>
<td>FA %</td>
<td>percentage of total fatty acids</td>
</tr>
<tr>
<td>FAD</td>
<td>flavin adenine dinucleotide</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>FADS</td>
<td>fatty acid desaturase</td>
</tr>
<tr>
<td>FMN</td>
<td>flavin mononucleotide</td>
</tr>
<tr>
<td>FOF</td>
<td>follow-on formulae</td>
</tr>
<tr>
<td>FOS</td>
<td>fructo-oligosaccharides</td>
</tr>
<tr>
<td>GMP</td>
<td>guanosine 5′-monophosphate</td>
</tr>
<tr>
<td>GOS</td>
<td>galacto-oligosaccharides</td>
</tr>
<tr>
<td>HDL</td>
<td>high-density lipoprotein</td>
</tr>
<tr>
<td>HLA</td>
<td>human leucocyte antigen</td>
</tr>
<tr>
<td>IDD</td>
<td>iodine deficiency disorders</td>
</tr>
<tr>
<td>IF</td>
<td>infant formula(e)</td>
</tr>
<tr>
<td>Ig</td>
<td>immunoglobulin</td>
</tr>
<tr>
<td>IGF</td>
<td>insulin-like growth factor</td>
</tr>
<tr>
<td>IGFBP</td>
<td>IGF-binding protein</td>
</tr>
<tr>
<td>IMP</td>
<td>inosine 5′-monophosphate</td>
</tr>
<tr>
<td>IQ</td>
<td>intelligence quotient</td>
</tr>
<tr>
<td>ISP</td>
<td>isolated soy protein</td>
</tr>
<tr>
<td>LA</td>
<td>linoleic acid</td>
</tr>
<tr>
<td>LC</td>
<td>long-chain</td>
</tr>
<tr>
<td>LOAEL</td>
<td>Lowest Observed Adverse Effect Level</td>
</tr>
<tr>
<td>MCFA</td>
<td>medium-chain fatty acid</td>
</tr>
<tr>
<td>MDI</td>
<td>Mental Developmental Index</td>
</tr>
<tr>
<td>MUFA</td>
<td>monounsaturated fatty acid</td>
</tr>
<tr>
<td>NAD</td>
<td>nicotinic adenine dinucleotide</td>
</tr>
<tr>
<td>NADP</td>
<td>NAD phosphate</td>
</tr>
<tr>
<td>NE</td>
<td>niacin equivalents</td>
</tr>
<tr>
<td>NEPSY</td>
<td>A Developmental NEuroPSYchological Assessment</td>
</tr>
<tr>
<td>NPN</td>
<td>non-protein nitrogen</td>
</tr>
<tr>
<td>PDI</td>
<td>Psychomotor Development Index</td>
</tr>
</tbody>
</table>
PL  phospholipid
PPVT-III Peabody Picture Vocabulary Test, 3rd edition
PPVT-R PPVT, revised
PRI Population Reference Intake
PUFA polyunsaturated fatty acid
RCT randomised controlled trial
RE retinol equivalents
RI Reference Intake range for macronutrients
RNA ribonucleic acid
SCF Scientific Committee on Food
SCFA short-chain fatty acid
SD standard deviation
SFA saturated fatty acid
SNP single-nucleotide polymorphism
T1DM type 1 diabetes mellitus
TAG triacylglycerol
TDI Tolerable Daily Intake
TE tocopherol equivalents
TFA trans-fatty acid
ToR Terms of Reference
TPN total parenteral nutrition
UDP uridinediphosphate
UL Tolerable Upper Intake Level
UMP uridine 5’-monophosphate
VELS Verzehrsstudie zur Ermittlung der Lebensmittelaufnahme von Säuglingen und Kleinkindern
WPPSI-R Wechsler Preschool and Primary Scale of Intelligence Revised
WHO World Health Organization